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Reptin is a member of the AAA+ (adenosine triphosphatase associated with diverse 
cellular activities) protein superfamily with roles in many protein complexes and 
interactions which have been indicated in cancer including transcription factors and 
chaperon proteins. An in silico screen was used to identify small molecule binders of 
the ATP binding site of Reptin. These small molecules were then investigated for 
their effect on known protein-protein interactions of Reptin, specifically the Reptin-
AGR2 interaction. Chemical optimisation of the original ‘hit’ compound lead to the 
development of Liddean, whose binding was seen to affect the Reptin-AGR2 
interaction as well as the oligomerisation of Reptin. The affect of Liddean on Reptin 
was then further investigated using a combinational peptide phage library to find 
binding motifs, this led to the discovery of the novel Reptin interaction site on the 
p53 tumour suppressor protein. Hydrogen deuterium exchange was used to gain 
further information into the changes in conformation and oligomerisation seen with 
the addition of Liddean. This revealed a novel site on Reptin, forming a inter-subunit 
bridge, responsible for stabilisation of the Reptin homo-hexamer, known as the 
‘Click-motif’. Further study identified tyrosine 340 as crucial for the formation of the 
Reptin homo-hexamer by point mutation to alanine resulting in Reptin which is 
monomeric in vitro. These data suggest that the Reptin interactome is regulated 
ligand binding and the conformational changes which occur due to this.   
 iv 
Lay Summary 
Reptin is a member of the large AAA+ (adenosine triphosphatase associated with 
diverse cellular activities) superfamily. Reptin is known to have interactions with 
several proteins important for cancer, including many involved in cell growth and cell 
death. A virtual screen was used to identify drugs which could bind directly to Reptin 
that would have an affect on its protein-protein interactions. The ‘hits’ that were 
identified were tested using a known complex, Reptin-AGR2, which has previously 
been associated with metastasis, the process in which caner spreads around the 
body. These investigations lead to the discovery of Liddean, a specific small 
molecule binder of Reptin which can alter its interaction with AGR2. To confirm that 
Liddean was able to cause changes in the protein-protein interactions of Reptin, a 
library of short peptide motifs was exposed to Reptin with and without Liddean and 
binding motifs were identified. These experiments identified p53, a protein known to 
have important roles in cancer, as another binder of Reptin. Further investigations 
looked at how Liddean and Reptin bound together and revealed a specific part of 
Reptin which is necessary for it to form a complex with itself. The precise location of 
the self-interaction was studied, and a single amino acid was found to be required. 
The data collected in this study show that the protein-protein interactions of Reptin 
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 Introduction 
1.1 The treatment of Cancer  
Cancer is the common name for a group of diseases associated with abnormal cell 
growth, which has the potential to spread to other parts of the body (Pathak et al., 
2018). There are more than 200 types of cancer that are diagnosed and treated in 
specific ways. There are two mains ways of grouping cancers. One method is 
grouping by are by the type of cell that the tumour has developed from, carcinoma, 
sarcoma, leukaemia, lymphoma and myeloma and brain and spinal cord tumours. 
The second is classification by localisation of the primary tumour such as breast and 
liver cancers, many of these classifications have existed since the 1970s (Carter 
and Salvik, 1974). These different types of cancer all have different 5-year survival 
rates, many of these survival rates have been increased in the past 20 years 
however some cancers still have a very short life expectancy after diagnosis. 
According to the WHO, in 2014 there were 8.8 million deaths due to cancer (Stewart 
and Wild, 2014), this shows that cancer is still a current problem for the medical and 
pharmacological communities.    
 Drug development in cancer  
Currently, widely used therapies are chemotherapy and radiotherapy in combination 
with surgery. For some types of cancer, these techniques are very successful but 
they also come with many adverse side effects, which, in some cases cause the 
patient to want to stop treatment early due to the reduction in quality of life (Hoelder 
et al., 2012).   
Small molecule therapies are now used more commonly in the clinic with many 
being approved in recent years. The reason for this surge in treatment type is due to 
the ability of small molecules to circulate the body and affect cancer cells at multiple 
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sites rather than focusing on the area of the primary tumour (as in many surgical 
approaches) and not treating metastatic sites (cancer cells which have broken away 
from the primary tumour and begun to proliferate), with a reduction in the side 
effects seen with chemotherapy and radiotherapy as they are more specific for the 
mutated cancer cells. However, the development and approval of new small 
molecular therapies is still a complex and lengthy process (Hoelder et al., 2012). 
Following on from the human genome project that announced in 2000 that nearly 
the whole of the human genome had been sequenced (Collins and McKusick, 
2001), new techniques have been developed in DNA sequencing making it both 
faster and more cost-effective. This means it is now possible to sequence a patient's 
tumour to discover the specific mutations which have led to its change from a 
'normal' cell to a cancerous one. This can then help with treatment plans, which are 
thought to be more specific and have a greater chance of being effective (Meldrum 
et al., 2011). This has now been developed even further to allow for DNA 
sequencing of tumour cells found in the circulatory system allowing for less invasive 
procedures as well as earlier detection (Heitzer et al., 2015).   
Proteins identified as being highly upregulated or mutated in either a specific cancer 
type or many cancer types are the focus of small molecule drug development 
(Pathak et al., 2018). There are many different families of proteins which are 
targeted including kinases, cyclins, and tumour suppressor proteins.   
1.1.1.1 Kinases as small molecule drug targets   
Protein kinases are enzymes involved in signal transduction by the transfer of 
phosphate groups from donor molecules, such as ATP, to specific substrates, this 
process is known as phosphorylation (Wang and Cole, 2014). Phosphorylation can 
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both activate and inhibit substrate proteins depending on the site of the 
phosphorylation and its relation to the rest of the protein.   
Polo-like kinases (PLK) are serine/threonine kinases. The most well-known is PLK-
1, a mitotic checkpoint regulator with roles in chromosome segregation, cytokinesis 
and centromere maturation. Overexpression of PLK-1 results in genetic instability as 
a result of the loss of checkpoint control. PLK-1 has been identified as a target for 
drug therapy due to its inhibition resulting in disruption of the cell cycle and a 
reduction in proliferation (Strebhardt and Ullrich, 2006). Several small molecules are 
at different stages of drug trials including rigosertib (Komrokji et al., 2013) which is 
currently in phase 3 for blood cancers, specifically myelodysplastic syndrome but 
could also be effective in other leukaemia types.  
Aurora kinases are also serine/threonine kinases involved in the regulation of the 
cell cycle, specifically mitosis and cytokinesis. Aurora A promotes CDK1 activation 
and mitotic entry, by phosphorylating PLK-1. Aurora A also has roles in centromere 
maturation, spindle assembly and spindle orientation (Bischoff and Plowman, 1999). 
Aurora B is part of the chromosomal passenger complex where it helps to control 
many stages of mitosis and cytokinesis (Carmena et al., 2012). Overexpression of 
both kinases has been observed in several cancer types pointing to them as a 
possible drug target, with many investigations ongoing including trials with Alisertib 
which is specific for Aurora A (Friedberg et al., 2014).   
1.1.1.2 Cell cycle regulators as small molecule drug targets   
As cancer is a disease of misregulated cell division, cell cycle regulatory proteins 
are of interest when looking for small molecule drug targets. Cyclins and Cyclin 
dependant kinases (CDKs) are proteins which enable the cell to progress through 
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the cell cycle. The cell cycle and the specific Cyclins and CDKs controlling it at each 
step can be found in figure 1.1 (Wasserman, 2020). 
CDK4 and CDK6 control the G1 phase of the cell cycle. The gene containing these 
proteins is often mutated in human cancers suggesting that their misregulation has a 
large impact on the ability of the cells to form a tumour. Some breast cancers are 
currently being treated with inhibitors of these proteins, such as Palbociclib, 
Ribociclib and Abemaciclib which block the cells in G1, halting the cell cycle before 
the replication of DNA in S-phase.   
CDK1 is activated by cyclins B2 and B-protein. Throughout the cell cycle, 
phosphorylation and dephosphorylation of CDK1 are essential for tight regulation of 
progression from G1 to M phase. When cells are blocked using the CDK1 
checkpoint, they are unable to enter M-phase. TG-02, Flavopiridol, Roscovitine, 
Dinaciclib, AT7519, Milciclib and RGB-286638 are all in clinical trials at various 
stages (Goh et al., 2012).   
1.1.1.3 Tumour suppressor proteins as small molecule drug targets   
There are a wide number of known tumour suppressor proteins which can prevent 
cancer by a variety of mechanisms.   
One such protein is BRCA1, it is involved in DNA strand break by being involved 
and repeat and prevention. There are many cellular functions which contribute to the 
tumour suppression caused by BRCA1, including apoptosis, DNA repair and 
transcription. BRCA1 and BRCA2 act together to stabilise the human genome. 
Mutations in the BRCA1 gene are found to result normally in breast and ovarian 
cancers, several drugs are currently in trials to aid those with BRCA1/2 mutations 
including Valiparib, Olaparib and Rucaparib (Kaufman et al., 2009).   
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Figure 1.1 The cell cycle and its control   
Cell cycle stages and the specific Cyclins and CDKs that control progression from one stage 
to the next. Figure adapted from (Wasserman, 2020).  
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P21 is a CDK1 inhibitor activated by p53. It helps to maintain cell growth and 
responds to DNA damage. It helps to suppress the cell cycle and DNA replication by 
its interaction with Proliferating cell nuclear antigen (PCNA). It also has roles in cell 
morphogenesis, motility, survival, apoptosis and gene transcription. HDAC inhibitors 
promote p21 activation resulting in inhibition of cancer cell growth. A p21 specific 
inhibitor is currently in development for the treatment of several cancer types and is 
known as Bortezomib.  
Human p53 is known as the 'guardian of the genome' and has roles in controlling 
cell cycle checkpoints. Around 50% of human cancers have mutations in the p53 
gene. Normally, p53 senses DNA damage and promotes G1 arrest to allow repair of 
the damage, at increased levels of damage, p53 can induce a cascade resulting in 
apoptosis. PRIMA-1 is currently in clinical trials as a drug targeted to restore the 
activity of mutant p53 proteins in cancer cells (Lewis, 2015).   
1.2 The AAA+ protein superfamily  
The AAA+ (ATPases associated with various cellular activities) superfamily of 
proteins is present within all kingdoms of life. These proteins are characterised by 
the presence of a conserved module of around 130 amino acids which contains 
Walker A and Walker B motifs, the sequence of these can be found in figure 1.2A. 
These motifs were first identified in 1982 by Walker and his co-workers as 
nucleotide-binding motifs found in several ATP binding proteins (Walker et al., 
1982). These sequences were found to create a common nucleotide binding fold 
which enables the creating of pocket for ATP binding and hydrolysis. This 
superfamily of proteins is a member of the larger superfamily of ring-shaped P-loop 
NTPases which use their activity through the energy dependant remodelling or 
translocation of macromolecules, of which most are found to hydrolyse the β-g 
phosphate bond of a bound NTP, often ATP or GTP (Snider et al., 2008).  
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Figure 1.2 Walker A and B Motifs   
A) Walker A and B motif consensus sequences B-G) Alignments of Reptin (red) with various 
other AAA+ superfamily proteins (blue) aligning to the Walker A motif highlighted in yellow. 
B) Reptin and VPS4B C) Reptin and Pontin D) Reptin and NVL E) Reptin and RIG I F) 
Reptin and Brr2 first site G) Reptin and Brr2 second site 
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AAA+ proteins are known to combine ATP hydrolysis with conformational changes 
in the protein which can then be transduced into a mechanical force which is then 
exerted on a macromolecular substrate (Hanson and Whiteheart, 2005). Often, 
these proteins form homohexamers which form a ring-shaped structure with a 
central pore, this structure helps them to carry out their function using ATP 
hydrolysis to induce conformational changes in the subunits which induce action 
upon a target substrate such as proteasomes (Vale, 2000).  
As is suggested by their name, this protein family has a diverse number of functions 
within the different cellular compartments and have key roles in numerous essential 
cellular activities. Many of the AAA+ proteins also form part of large complexes with 
non-AAA+ proteins.  Some family members can be found in figure 1.2B-G aligning 
their Walker A sites to the Walker A site of Reptin highlighting the ATP binding 
pockets of these proteins. These alignments show how the superfamily vary in the 
overall structure. VPS4B (Scott et al., 2005), Pontin (Matias et al., 2006), NVL 
(Fujiwara et al., 2011), RIG I (Kohlway et al., 2013) and Brr2 (Mozaffari-Jovin et al., 
2013) are used as examples from different clades.  
 Different clades of AAA+ proteins  
Due to their wide range of functions, more classification of the superfamily is 
required. This is done by dividing the family into several groups (Ammelburg et al., 
2006) and clades (Iyer et al., 2004), these have been identified structurally and 
computationally by clustering analysis. The HEC group containing the clamp loader 
and DnaA/OCR clade, the extended AAA clade/group, and the PACTT group 
containing the helix-2 insert clade and the Lon/CLP-D2 clade, the majority of AAA+ 
proteins fit into one of these groupings, however, some are not able to be linked with 
other AAA+ proteins. The clamp loader clade proteins contain an SR[CAT] motif 
associate with an arginine finger, proteins found in this clade include those of the 
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HolB/DNAX family and the RFC family. The DnaA/OCR clade are identified by two 
helices of approximately equal length after strand 2 and include the DnaA and 
CDC6/OCR families. The AAA clade has a small helix between strand-2 and helix2 
as well as an [GN]R motif associated with an arginine finger, this is the 'classical' 
clade and containing proteins of the FtsH, CDC48 and Proteasomal ATPase 
families. The Lon/CLP-D2 clade contains an extended loop after strand 2 and 
includes, as the name would suggest, the Lon family, the CLP family and the 
HslU/Clpx family. The helix-2 insert clade contains an a-b-a insert after helix-2 and 
the proteins in this family are from the MCM family, the chelates family, the McrB 
family and the dynein family.   
Due to their variety, a vast number of techniques have been used to characterise 
several of the AAA+ proteins, with Dynein possibly being the most well 
characterised (Kim et al., 2012). X-ray crystallography, cryo-electron microscopy 
and solution NMR have been used to look at the structure of dynein alone (Kon et 
al., 2012) and in complex with interacting proteins (Urnavicius et al., 2018, Rao et 
al., 2013). The structure of the Minichromosomal Maintenance (MCM) helicase from 
Sulfolobus solfataricus has been examined by hydrogen-deuterium exchange to 
confirm the external binding sites for DNA on MCM5 (Graham et al., 2016). Due to 
the diversity of these proteins, a multifaceted approach to understanding their 
structure, function and interaction is essential.  
 The active site of AAA+ proteins  
Due to the presence of the Walker A and B motifs, it is relatively easy to compare 
the structure of the different active sites of AAA+ proteins. In figure 1.2 the are 
several AAA+ proteins aligned to RuvBL2/Reptin. Vacuolar protein (Vps4p) is 
involved in the endosome (Xiao et al., 2007), nuclear vasolin like (NVL) is involved 
in the assembly of the telomerase holoenzyme (Her and Chung, 2012), RIG-I is 
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involved in RNA binding and can activate the inane immune machinery (Kohlway et 
al., 2013), RNA helicase (Brr2) which is a core component of the spliceosome 
(Mozaffari-Jovin et al., 2013) and Pontin is the homolog if Reptin and will be 
discussed further (Matias et al., 2015). These 6 proteins are all involved in very 
different processes within the cell. These were chosen due to their wide range of 
activities and the presence of a solved structure in the protein databank. From this is 
it clear that the Walker A and B sites allow for the creation of a binding pocket in all 
of these proteins and that the shape of this binding pocket appears to be very similar 
across the proteins.   
 The Ruv proteins  
RuvB is a member of the AAA+ protein superfamily and was discovered in E. coli 
after mutations in the ruv gene were observed, creating both ruvA and ruvB. The ruv 
gene was named as it was discovered in E. coli that have a resistance to ultraviolet 
light in 1982 (Shurvinton and Lloyd, 1982). In the study which found the mutations, 
E. coli were exposed to low doses of ultraviolet radiation and the two mutants were 
found to be about 10 to 20 times more sensitive to exposure than the wildtype strain. 
These strains were found to form multi-nucleate filamentous cells suggesting that 
the ruv gene is required for septum formation in E. coli after periods of inhibition of 
DNA synthesis. In figure 1.3 the similarity between RuvA and RuvB can be found. 
These two proteins have been found to work together in complex and, with the 
addition of ATP, can reform denatured cruciform structures in supercoiled DNA. The 
complex is known as RuvAB and is a helicase involved in mediating Holliday 
junction migration (West, 1996). RuvB has been found to possess weak ATPase 
activity, which is stimulated by the presence of its homolog RuvA and DNA 
(Tsaneva et al., 1993).   
 
  11 
 
Figure 1.3 Amino acid alignments of RuvA and RuvB yeast proteins. 
Identical amino acids are identified with *, similar amino acids are highlighted with :, weakly 
similar amino acids are highlighted with . 
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1.2.3.1 Reptin and Pontin  
Reptin and Pontin are members of the AAA+ protein superfamily and were first 
identified as putative DNA helicases due to their homology with the bacterial protein 
RuvB, described above. Duplication and the evolution of the RuvB gene occurred 
creating these two proteins. In a similar manner to RuvB, these proteins act in a 
complex with one another, as RuvB did with RuvA. Both Reptin and Pontin many 
names. Pontin is also known as RuvBL1, Tip49a and Reptin are also known as 
RuvBL2, Tip49b amongst others and this is due to their wide range of functions 
(Matias et al., 2015). In figure 1.4 a schematic of the sequences of Reptin and 
Pontin is shown, highlighting the important Walker A and B motifs which classify 
these are AAA+ proteins as well as the sensor domains which are involved in ATP 
hydrolysis and/or binding. The sequences of the two proteins also show high 
similarity between the protein sequences with the amino acid alignment.  
The oligomeric nature of these proteins both in combination and individually have 
been investigated. Crystal structures are complete for the heterododecamer 2XSZ 
(Gorynia et al., 2011) of Pontin and Reptin and the homo-hexamers of Reptin 3UK6 
(Petukhov et al., 2012) and Pontin 2C9O (Matias et al., 2006). The 
heterododecamer is a combination of the two proteins at an equimolar ratio. The 
presence of these structures shows that when not in complex with each other, both 
proteins can form stable hexameric structures like that of half of the Reptin-Pontin 
dodecamer with slight variation in conformation.  
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Figure 1.4 The similarities between Reptin and Pontin 
Schematic representation of A) Reptin and B) Pontin with structural elements highlighted. 
C) Amino acid alignment of Reptin and Pontin. Identical amino acids are identified with *, 
similaramino acids are highlighted with :, weakly similar amino acids are highlighted with . 
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Cryo-EM has also been performed on the dodecameric complex, the data from this 
study shows that the complex is likely formed of two hexameric rings which interact 
at the head (Torreira et al., 2008). A more recent cryo-EM experiment showed that it 
is likely two conformations for the dodecamer, a stretched and a relaxed form (Silva-
Martin et al., 2016). The compact form is more common when there is no ligand 
present and the percentage of stretched for increases in the presence of ADP. 
There is also a crystal structure available for this protein complex 2XSZ (Gorynia et 
al., 2011). In this crystal structure, it appears that there are two hexameric rings on 
top of one another with alternating subunits of Reptin and Pontin, found in figure 1.5. 
The similarity in the structure of the monomeric subunits of these proteins can be 
seen in complex in panels C and D, although variations are seen in the sequences 
of the two proteins, the structure of the two proteins remains very similar. Reptin can 
be seen in red and pontin in blue showing very small changes in their 3D alignment. 
The amino acid sequence and the 3D organisation of the monomeric units of Reptin 
and Pontin appear to show very high similarity as is expected with a gene 
duplication event.   
The Walker A site of many AAA+ proteins is very important, in figure 1.6 we can see 
this motif created by aligning the Walker A sites for all human AAA+ proteins. The 
localisation of the site on Reptin and Pontin monomers is also visualised.  
These two proteins act as chaperones and are involved in the assembly of many 
complexes within the cell. They are important for DNA damage repair and RNA 
metabolism. In many cases, Pontin and Reptin are found in the same complexes, 
however, they seem to have opposed functions. These proteins have also been 
observed to operate individually within the cell, sometimes with opposing effects 
such as their roles in transcriptional regulation as Pontin acts as a co-activator  
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Figure 1.5 Aligning Reptin and Pontin 
Reptin (red) and Pontin (blue) heterohexamer (2xsz) from the top (A) and side (B). 
Alignments of 
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Figure 1.6 Walker A motif and alignment  
A) Walker A motif as discovered using MEME suite in putting human Walker A sites. 
B) Alignment of single monomer of Reptin (red) (3UK6) and Pontin (blue) (2c9o) with Walker 
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whereas Reptin functions as a co-repressor, however, these interactions are far less 
characterised (Huber et al., 2008).   
1.2.3.2 The role of Reptin  
Reptin itself is 463 amino acids in length and around 51,000 Daltons in size, making 
the hexamer around 300,000 Daltons. It was discovered, in many yeast- two-hybrid 
assays and co-immunoprecipitation experiments throughout many model organisms 
(Qiu et al., 1998). This makes it a good target for biochemical analysis as there is a 
large difference between the oligomeric forms of Reptin making them easily 
distinguishable from one another. Although the Reptin homohexamer has been 
characterised in vitro and can be seen in the crystal structure (Petukhov et al., 
2012), there is little evidence for its role in vivo. More investigation is also required to 
see if this homo-hexamer is present in vivo.  
As previously stated, the main binding partner of Reptin is its homolog Pontin. 
These proteins in combination are found in many larger protein complexes within the 
cell including INO80, Swrl1 and TIP60 complex which are all involved in chromatin 
remodelling (Nano and Houry, 2013, Kim et al., 2006, Jonsson et al., 2001). They 
have also been observed to have roles in stimulation and repression of transcription 
factors such and Myc (Wood et al., 2000) and β-catenin (Kim et al., 2005). These 
proteins have also been observed in the assembly of ribonucleoprotein complexes 
like snoRNPs and telomerase (Venteicher et al., 2008, Nano and Houry, 2013). 
These proteins have roles in binding to heat shock proteins, such as HSP90 as part 
of the R2TP complex (Muñoz-Hernández et al., 2019).  These interactions are 
summarised in figure 1.7. 
The R2TP complex is made up of four proteins. This complex is highly conserved 
from yeast to humans. The R2TP complex was discovered in 2005 and classified as  
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Figure 1.7 Various functions of the RuvB/RuvB-like proteins  
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having roles apoptosis, PIKK signalling, RNA Pol II assembly and snoRNP 
assembly (Kakihara and Houry, 2012). Pontin and Reptin are two of the components 
of the complex, and they interact with Pih1 (PIH1D1) and Tah1 (RPAP3) to form 
R2TP. Both Pih1 and Tah1 are Hsp90 interacting proteins, and this was thought to 
be the initial role of the complex. Further investigation resulted in the discovery of 
many cellular interactions. 
The complex itself is formed by a hexameric ring of Reptin and Pontin, the Pih1-
Tah1 dimer than binds to the ring via the IRD II domain of Pih1. This structural make 
up was discovered using a combination of cryo-electron microscopy, hydrogen-
deuterium exchange, analytical ultracentrifugation, and chemical crosslinking 
(Rivera-Calzada et al., 2017).  
TIP60 complex contains many proteins as its subunits and has a range of activities. 
It is characterised as tumour suppressor chromatin-remodelling complex (Ikura et 
al., 2000). Its activities include a well-established role in transcription, through 
binding and acetylation of multiple substrates including histones H2AX, H3 and H4 
(Ikura et al., 2015, Sun et al., 2009, Matias et al., 2015, Sanchez-Molina et al., 
2014), the Androgen Receptor (AR) (Gaughan et al., 2002) or p53 (Tang et al., 
2006). The TIP60-p53 interaction is critically important for the decision between cell 
cycle arrest and apoptosis, a vital role of p53 with regards to cancer. TIP60 is critical 
for ATM acetylation and this modification precedes ATM activation. Additionally, 
functional human TIP60 complex is required for the recruitment of Rad51, a protein 
catalysing homologous recombination in the repair of DNA, to the sites of DNA 
damage. The presence of the Ruv proteins in the TIP60 complex is required for the 
assembly of a functional complex, here Reptin and Pontin act as molecular adaptors 
for the assembly and stability of this large multiprotein complex however the ATPase 
activity of these proteins is not required for this role (Jha et al., 2013).   
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The role of Reptin in activation or repression of transcription is mediated by the 
interaction of Reptin with the specific transcription factors, such as TBP, Myc, E2F1 
and ATF2 (Shen et al., 2000). Reptin has also been found to bind directly to the 
promoters of the genes targeted by the transcription factors stated, this often 
involves the TIP60 complex. Reptin potentiates c-Myc mediated repression of p21 
gene, hence impedes cell cycle arrest (Wood et al., 2000). Further, Reptin 
represses b-catenin-dependent reporters. This may indirectly point to Reptin playing 
a role in cellular transformation, as deregulation of β-catenin signalling, due to an 
activating mutation of β-catenin or its interacting partners, was observed in several 
cancers (Kim et al., 2005).   
The important physiological function of Reptin in the chromatin remodelling 
complexes is linked to the DNA damage response. The DNA damage response 
checkpoints involve three members of the phosphatidylinositol 3-kinase-related 
protein kinase (PIKK) family: ATM, ATR, and DNA-dependent protein kinase 
catalytic subunit (DNA-PKCs) and clamp loader/polymerase clamp (RFC/PCNA)- 
related Rad17-RFC/9-1-1 complex (this is a complex which contains another AAA+ 
protein) (Izumi et al., 2010). Upon DNA damage ATM kinase autophosphorylates at 
Ser1981. This converts an inactive dimer into an active monomer that can bind to 
chromatin and phosphorylate its substrates. Activated ATM phosphorylates histones 
to "mark" damaged sites and this triggers recruitment of amplifying or repairing 
proteins, like MDC1, MRN complex, 53BP1, and BRCA1 (Izumi et al., 2012). Also, 
chromatin remodelling machines have to be recruited to facilitate opening and 
repairing of the altered chromatin structure. Interestingly, the Reptin containing 
chromatin remodelling complexes such as TIP60 and INO80 are also recruited to 
DNA damage sites.   
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As Reptin is incorporated in these complexes and is believed to be essential for their 
assembly, these findings suggest that Reptin may be involved in DNA repair 
pathway due to the requirement for chromatin remodelling at the DNA damage sites.   
snoRNPs are RNA processing enzymes and were found to modify small nuclear 
RNA (snRNA), ribosomal RNA (rRNA), and tRNAs. Reptin protein was found to 
associate with small nucleolar RNPs (snoRNPs) in different species and be involved 
in their biogenesis and assembly in the process involving a chaperone multicomplex 
of Tah1 (Rpap3), Pih1 (Nop17), Pontin and Hsp90 (Rosenbaum et al., 2013). In 
addition to snoRNP, Reptin is involved in the assembly of the telomerase complex. 
Telomerase complex consists of the telomerase reverse transcriptase (TERT), 
telomerase RNA component (TERC) and the TERC-binding protein dyskerin (Her 
and Chung, 2012). Reptin together with Pontin interact with dyskerin and this is 
important for the assembly and stability of the TERC RNP. Moreover, both these 
proteins interact with TERT. Interestingly this PPI is regulated by the cell cycle and 
is increased in the S phase. The TERT-Reptin-Pontin complex displays reduced 
telomerase activity and precede the formation of the active telomerase complex 
which coincides with Reptin/Pontin dissociation. Also, the transiency of this 
interaction is consistent with the chaperoning activity of these proteins (Mao and 
Houry, 2017).  
Due to this wide range of interacting proteins, the roles of Reptin include, but are not 
limited to, cell transformation, metastasis, response to DNA damage, apoptosis, and 
mitosis.  
1.3 Reptin and Cancer  
Reptin has been discovered to be up-regulated in some human cancers, 
such as prostate and hepatocellular carcinoma, making it a desirable drug 
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target. The interactions between Reptin and several other proteins such as 
Pontin (Matias et al., 2015), p53 (Tang et al., 2006), ARG2 (Maslon et al., 
2010), c-Myc (Wood et al., 2000) and ARF (Xie et al., 2012), have been 
characterised. Many of these interactions relate to the role of Reptin in 
transcription and could set a starting point for the discussion on the roles of 
Reptin overexpression in the pathogenesis of the disease. Due to its role in 
both proliferative and apoptotic pathways, this protein is a favourable drug 
target. As there is still uncertainty of the cell signalling network surrounding 
this protein in the absence of its homolog Pontin, further investigation is 
required.   
 
The role of Pontin and Reptin in the development of hepatocellular 
carcinoma (HCC) is well-established (Grigoletto et al., 2013). Not only are 
they both overexpressed in HCC tissues, where their overexpression was 
associated with poor prognosis, they both also showed stronger 
cytoplasmic staining in tumour cells compared to normal hepatocytes. In 
colorectal cancer, Reptin cooperates with Ets2 to transcriptionally regulate 
hTERT (Flavin et al., 2011).  
 
The discovery of Reptin and Pontin as having roles in both HCC and 
colorectal cancer lead to more work being carried out on them in other 
cancer types. Reptin and/or Pontin have been seen to be overexpressed in 
oesophageal squamous cell carcinoma, gastric cancer, pancreatic ductal 
adenocarcinoma, renal cell carcinoma, micropapillary carcinoma, non-small 
cell lung cancer, small cell lung cancer, early-stage breast cancer and 
ductal carcinoma, ovarian cancer, acute myeloid leukaemia and lymphoma 
(Mao and Houry, 2017). For example, Reptin expression has also been 
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seen to be positively regulated by MLL-fusion proteins in acute myeloid 
leukaemia (Osaki et al., 2013). Mis-localisation of Reptin and/or Pontin 
have also been shown to be correlated with metastasis and unfavourable 
outcomes (Rousseau et al., 2007).   
The large number of cancers which these proteins are overexpressed in 
suggest that they could have a role in cancer development, either alone or 
in partnership. The investigation into whether the contribution or regulation 
of tumour progression is specific to each type of cancer or can be more 
generalised would be of great help to understand why these proteins, which 
have toles in so many DNA related complexes, are found to be 
overexpressed in such a wide variety of cancer types.   
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1.4 Hypothesis 
The members of the AAA+ protein superfamily have roles which are known to be 
highly regulated, some of which are dependent on ATP binding and ATP hydrolysis. 
These proteins are known to be involved in many protein complexes with both AAA+ 
proteins and others. The role of Reptin when combined with Pontin is well 
established and investigated (Mao and Houry, 2017, Rosenbaum et al., 2013) but its 
role alone is less clear. It is known that Reptin can form a homohexamer (Petukhov 
et al., 2012) but the purpose of this protein complex within cells is not understood. 
The work in this thesis is focused on the role of Reptin in the absence of Pontin, 
looking at changes in protein interactions and oligomerisation that are caused by the 
binding of ligands. Following on from previous work with AAA+ proteins it is likely 
that binding of ligands will cause a change in oligomerisation and its protein 
interactions.  
1.5 Aims 
 The purpose of the investigations in this thesis is to discover more about the 
allosteric nature of the AAA+ protein Reptin. 
We want to investigate: 
• If an ATP mimetic can be created to enable tighter control of the oligomeric 
state of Reptin 
• If the protein interactions of Reptin are dependant on ligand binding 
• If Reptin can form stable interactions with other proteins in the absence of 
Pontin 
• How the Reptin hexamer is formed and the differences between it and the 
Reptin-Pontin com
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 Materials and Methods 
2.1 Reagents, chemicals and plasmids 
Chemicals and reagents were purchased from Sigma unless otherwise indicated. 
Plasmid for Reptin WT pDEST15 was a gift from Dr Magdalena Maslon, University 
of Edinburgh. pCDNA- 3xHA-Reptin and pCDNA-3xFLAG-Pontin were obtained 
from addgene. The wild type AGR2 protein was a gift from Dr Terry Gray and the 
wild type p53 protein was a gift from Kathrin Luise. Peptides (see table below) were 
purchased from Chiron Mimotopes and were synthesised with an N- terminal biotin 
tag and Ser-Gly-Ser-Gly spacer. 
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Table of peptides used in protein-peptide binding assays 
Protein  Identifier  Sequence  
Reptin  1  SGSGMATVTATTKVPEIRD  
Reptin  2  SGSGPEIRDVTRIERIGAH  
Reptin  3  SGSGRIGAHSHIRGLGLDD  
Reptin  4  SGSGLGLDDALEPRQASQG  
Reptin  5  SGSSQASQGMVGQLAARRA  
Reptin  6  SGSGAAARRAGVVLEMIRE  
Reptin  7  SGSGEMIREGKIAGRAVLI  
Reptin  8  SGSGRAVLIAGQPGTGKTA  
Reptin  9  SGSGTGKTAIAMGMAQALG  
Reptin  10  SGSGAQALGPDTPFTAIAG  
Reptin  11  SGSGTAIAGSEIFSLEMSK  
Reptin  12  SGSGLEMSKTEALTQAFRR  
Reptin  13  SGSGQAFRRSIGVRIKEET  
Reptin  14  SGSGIKEETEIIEGEVVEI  
Reptin  15  SGSGEVVEIQIDRPATGTG  
Reptin  16  SGSGATGTGSKVGKLTLKT  
Reptin  17  SGSGLTLKTTEMETIYDLG  
Reptin  18  SGSGIYDLGTLMIESLTKD  
Reptin  19  SGSGSLTKDKVQAGDVITI  
Reptin  20  SGSGDVITIDKATGKISKL  
Reptin  21  SGSGKISKLGRSFTRARDY  
Reptin  22  SGSGRARDYDAMGSQTKFV  
Reptin  23  SGSGAEWREEGKAEIIPGV  
Reptin  24  SGSGIIPGVLFIDEVHMLD  
Reptin  25  SGSGVHMLDIESFSFLNRA  
Reptin  26  SGSGFLNRALESDMAPVLI  
Reptin  27  SGSGAPVLIMATNRGITRI  
Reptin  28  SGSGGITRIRGTSYQSPHG  
Reptin  29  SGSGQSPHGIPIDLLDRLL  
Reptin  30  SGSGLDRLLIVSTTPYSEK  
Reptin  31  SGSGPYSEKDTKQILRIRC  
Reptin  32  SGSGLRIRCEEEDVEMSED  
Reptin  33  SGSGEMSEDAYTVLTRIGL  
Reptin  34  SGSGTRIGLETSLRYAIQL  
Reptin  35  SGSGYAIQLITAASLVCRK  
Reptin  36  SGSGLVCRKRKGTEVQVDD  
Reptin  37  SGSGVQVDDIKRVYSLFLD  
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Reptin  38  SGSGSLFLDESRSTQYMKE  
Reptin  39  SGSGQYMKEYQDAFLFNEL  
Reptin  40  SGSGLFNELKGETMDTS  
p53 peptide 38  1  SGSGYFTLQIRGRERFEMF  
p53 peptide 38  2  SGSGYATLQIRGRERFEMF  
p53 peptide 38  3  SGSGYFALQIRGRERFEMF  
p53 peptide 38  4  SGSGYFTAQIRGRERFEMF  
p53 peptide 38  5  SGSGYFTLAIRGRERFEMF  
p53 peptide 38  6  SGSGYFTLQARGRERFEMF  
p53 peptide 38  7  SGSGYFTLQIAGRERFEMF  
p53 peptide 38  8  SGSGYFTLQIRARERFEMF  
p53 peptide 38  9  SGSGYFTLQIRGAERFEMF  
p53 peptide 38  10  SGSGYFTLQIRGRARFEMF  
p53 peptide 38  11  SGSGYFTLQIRGREAFEMF  
p53 peptide 38  12  SGSGYFTLQIRGRERAEMF  
p53 peptide 38  13  SGSGYFTLQIRGRERFAMF  
p53 peptide 38  14  SGSGYFTLQIRGRERFEAF  
p53 peptide 38  15  SGSGYFTLQIRGRERFEMA  
p53 peptide 38  16  SGSGFTLQIRGRERFEMF  
p53 peptide 38  17  SGSGTLQIRGRERFEMF  
p53 peptide 38  18  SGSGLQIRGRERFEMF  
p53 peptide 38  19  SGSGQIRGRERFEMF  
p53 peptide 38  20  SGSGIRGRERFEMF  
p53 peptide 38  21  SGSGYFTLQIRGRERFEM  
p53 peptide 38  22  SGSGYFTLQIRGRERFE  
p53 peptide 38  23  SGSGYFTLQIRGRERF  
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2.2 Equipment 
A Fluroskan Ascent FL (Thermo Scientific) and Victor3 1420 Multilabel Counter 
(Perkin Elmer) were used to read 96-well plates. DNA concentrations were 
measured using a Nanodrop(R) spectrophotometer. SDS-PAGE was carried out 
using Bio-Rad Protean II mini-gel system. Radioactivity-containing plates were 
visualised with the use of Phosphoimager. X-ray films were developed using a 
Konica Medical Film Processor (Model SRX-101A). Sorvall RC-5C Plus, Eppendorf 
5810 R and Eppendorf 5415R were used for all centrifugations. PCR was performed 
using the DNA Engine Dyad Peltier cycler (Bio-Rad). 
2.3 Microbial techniques 
 Growing bacterial cultures 
Bacterial cultures were grown in Luria-Bertani (LB) media, at 37°C, with shaking 200 
rpm, and in the presence of a selective antibiotic when required, at the following final 
concentrations: 100 µg/ml ampicillin, 50 µg/ml kanamycin, 30 µg/ml 
chloramphenicol. Cultures were inoculated from a single colony or glycerol stocks, 
and grown in sterile flasks with a capacity of at least four times the culture volume, 
to allow appropriate aeration. 
LB media 
1 % (w/v) bacto-tryptone 
0.5 % (w/v) bacto-yeast extract 
1 % (w/v) NaCl 
Dissolve in distilled water and autoclave at 121°C for 20 minutes. 
LB agar plates were prepared using LB media with the addition of 1.5 % (w/v) bacto-
agar. LB agar was first melted by heating in the microwave and then cooled to 
around 45°C. Subsequently, the appropriate antibiotic was added and LB agar was 
poured into 90 mm Petri dishes (Sterilin), and allowed to cool. The culture plates 
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were stored at 4°C for no longer than 2 weeks and were warmed to 37°C for 1 hour 
before use.  
 Glycerol stocks 
Glycerol stocks were prepared to allow long term storage of bacteria containing 
plasmids or phage. 800 µl of an overnight culture was mixed with 200 µl of 80 % 
sterile glycerol and stored in a cryotube (Nunc), this was snap-frozen in liquid 
nitrogen and stored at -80°C.  
 Preparation of competent cells  
Bacterial cells were inoculated into 5 ml of LB and incubated overnight at 37°C with 
shaking at 200 rpm. The overnight culture was diluted 1:200 in 100 ml of LB and 
incubated at 37°C until the OD600 reached 0.6. Cultures were centrifuged for 20 
minutes at 4000 rcf, 4°C with the resulting pellets resuspended in 15 ml of ice-cold 
buffer I. This was then incubated on ice for 1 hour before centrifugation as described 
above. The pellet was resuspended in 4 ml of ice-cold buffer II and incubated for 15 
minutes on ice. Subsequently, the cells were aliquoted (50 µl) into pre-chilled sterile 
Eppendorf tubes, snap-frozen in liquid nitrogen and stored at -80°C. 
Buffer I 
60 mM CH3COOK 
10 mM RbCl 
10 mM CaCl2 
40 mM MgCl 
15 % (v/v) Glycerol 
Adjust to pH 5.8 with CH3COOH and filter sterilise. 
 
Buffer II 
10 mM MOPS 
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10 mM RbCl 
75 mM CaCl2 
15 % (v/v) Glycerol 
Adjust to pH 6.5 with NaOH and filter sterilise. 
 Transformation of bacterial cells 
100 ng of plasmid DNA was added to 50 µl of freshly thawed competent cells and 
incubated on ice for 30 minutes. The cells were heat-shocked at 42°C for 1 minute 
and placed straight on ice for 2 minutes to cool. 500 µl of LB was added, and the 
culture was incubated at 37°C for 45 minutes, with shaking 200 rpm. 100 µl was 
then plated into LB-agar plate containing appropriate selective antibiotic and 
incubated at 37°C overnight. 
2.4 Molecular Biology Techniques 
 Amplification, purification, and quantification of plasmid 
DNA 
A single bacterial colony was picked from an LB-agar plate and inoculated into 5 ml 
of LB broth containing selective antibiotic when required and grown for several 
hours at 37°C with shaking 200 rpm. The starter culture was diluted into 500 ml on 
LB containing selective antibiotic, if required, and grown overnight at 37°C with 
shaking 200 rpm. The culture was then centrifuged at 4°C for 15 minutes at 6000 
rcf. Plasmid DNA was extracted from pellet using plasmid Maxi kit (Qiagen) 
according to the manufacturer’s instructions. If lower yield was required starter 
cultured was subjected to DNA Mini kit (Qiagen). Plasmid DNA was eluted in 
nuclease-free water and stored at -20°C. The concentration of obtained DNA was 
measured using Nanodrop ND-1000 (absorbance at 260 nm). 
 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was used to separate and analyse DNA. Agarose gels 
were prepared by adding electrophoresis-grade agarose (Invitrogen)to 1x TAE 
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buffer to a final concentration of 1 % and melted by heating in the microwave. The 
agarose solution was then cooled to around 60oC before the addition of SybrSafe 
DNA gel stain (Thermo Fisher) to a concentration of 1x. The solution was then 
poured into a casting tank and allowed to sit at room temperature before being 
submerged in 1x TAE buffer. DNA samples were mixed with 6x DNA loading buffer. 
Once samples were loaded alongside either Quick-load 100 bp DNA ladder (NEB) 
and/ or 1 kb DNA ladder (NEB) the gel was run at 100 V for approximately 1 hour 
with the bands being visualised under UV transilluminator Syngene (Genesnap). 
1x TAE 
40mM Tris 
1mM EDTA pH 8.0 Adjust pH to 8.0 
 
6x DNA loading buffer 
0.25 % bromophenol blue  
0.25 % xylene cyanol FF  
15 % Ficoll 
 DNA sequencing 
All Sanger DNA sequencing was carried out by Source Bioscience (LifeSciences). 
Plasmids were sequenced using stock primers from Source Bioscience. 
Next-generation sequencing was carried out by Otogenetics. 
 Cloning 
2.4.4.1 Gateway cloning 
Sequences of interest were cloned into the Gateway system (Invitrogen) following 
the manufacture's protocol. Initially, an insert flanked by the attB recombination sites 
were generated. This was followed by the production of an entry clone using the BP 
reaction. Finally, a destination clone was created using the LR reaction. 
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2.4.4.1.1 Producing attB-PCR Products 
An insert flanked by the attB recombination sites were generated, this was 
performed by the creation of primers (Sigma) containing the N or C termini of the 
protein of interest and the corresponding attB site. The PCR reaction was carried 
out as is described in the PCR methodology. The PCR product was purified using 
gel electrophoresis and gel extraction. 
2.4.4.1.2 BP and LR reactions to create entry and destination clones 
BP reaction was carried out as manufactures instructions to create an entry clone 
using pDONR221. LR reactions were then carried out as manufactures instructions 
to insert Reptin and pontin into desired destination vectors. 
2.4.4.2 Conventional cloning 
Conventional cloning is performed using restriction enzymes (RE) and is carried out 
in three steps, amplification, digestion and ligation. 
2.4.4.2.1 PCR amplification of the desired insert, with the addition of the 
required restriction sites.  
Suitable plasmid DNA for the insert was used as a template. Primers were designed 
that incorporated different RE sites into the 3’ and 5’ end. Nucleotide bases are 
added alongside the RE sites to allow for efficient binding. These nucleotides are 
random and are manipulated to get good G/C content and a suitable melting 
temperature. In it important to note that that primers used must result in an insert 
which will be in frame with the destination vector. 
PCR reaction mix 
25 µl 2x Pfu master mix 
5 µl Band doctor (Rovalab) 
5 ng template DNA 
1 µl forward primer (20 µM stock)  
1 µl reverse primer (20 µM stock)  
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Nuclease free water up to 50 µl 
 
Thermal cycling conditions  
Incubate at 95°C for 2 minutes  
Incubate at 95°C for 20 seconds  
Incubate at 68°C for 40 seconds  
Incubate at 72°C for 1 minute  
Cycle to step 2 for 30 cycles  
Incubate at 72°C for 1 minute  
Hold at 4°C forever 
2.4.4.2.2 Restriction enzyme double digests of insert and vector.  
All restriction digests were carried out using restriction enzymes (RE) and buffers 
from New England Biolabs and digest conditions recommended by the supplier. 
Insert digest 
40 µl PCR product 
5 µl NEB buffer 
0.5 µl BSA (10 mg/ml) 
1 µl Enzyme 1 
1 µl Enzyme 2 
Nuclease free water up to 50 µl 
 
Vector digest 
5 µg destination vector 
5 µl enzyme buffer 
0.5 µl BSA (10 mg/ml) 
1 µl Enzyme 1 
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1 µl Enzyme 2 
Nuclease free water up to 50 µl 
Double digests were incubated at 37°C for 60 minutes as recommended. If 
inactivation of the enzymes is possible, the RE was inactivated by incubating at 
65°C for 10 minutes. Following the double digestion, the digest mix was loaded onto 
a 1 % agarose gel. The gel was viewed under UV light and the bands corresponding 
to digested insert and vector cut out and purified using the Qiagen Gel extraction kit. 
Purified DNA was eluted in 50 µl nuclease-free water. 
2.4.4.2.3 Ligation of digested vector and insert. 
Ligation of vector and insert was carried out using T4 DNA ligase (Promega), 
following the protocol from the supplier. 100 ng vector was used and the amount of 
insert required was calculated using the following formula: Insert(ng) = (Vector(ng) x 
Insert size(kb)) x Molar ratio of insert Vector size(kb) vector ratio of insert to vector 
was always tested by ligation. 1:1, 2:1 and 3:1 molar 
Ligation reactions 
1 µl ligase buffer (10x) 100 ng vector 
X ng insert 
1 µl T4 DNA ligase 
Nuclease free water to 10 µl water 
Ligation reactions were carried out at room temperature for 1 hour and 
overnight. 
2.5 µl of the mix was transformed into DH5α competent cells and plated onto LB 
agar plates containing antibiotic matching that of the destination vector. Colonies 
were selected and plasmid DNA obtained using the Qiagen Mini-prep kit. 
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2.4.4.3 Site-directed mutagenesis 
Site-directed mutagenesis was carried out by preparing primers specific to the 
mutation of interest and then performing a PCR reaction.  The resulting solution was 
exposed to Dpn1 before transformation into DH5 αcompetent cells. 
Reptin D299N mutant 
forward primer 5′-GAGTGCTGTTCATCAACGAGGTCCACATGC-3′ 
reverse primer 5′-GCATGTGGACCTCGTTGATGAACAGCACTC-3′ 
Reptin Y340A mutant  
forward 5′- GAATCCGGGGCACCAGCGCCCAGAGCCCTCACGGCA-3′  
reverse 5′- GCCGTGAGGGCTCTGGGCGCTGGTGCCCCGGATTC-3′ 
PCR reaction mix 
25 µl 2x Pfu master mix 
5 µl Band doctor (Rovalab) 
5 ng template DNA 
1 µl forward primer (20 µM stock)  
1 µl reverse primer (20 µM stock)  
Nuclease free water up to 50 µl 
 
Thermal cycling conditions  
Incubate at 95 °C for 2 minutes  
Incubate at 95 °C for 1 minute  
Incubate at 60 °C for 1 minute  
Incubate at 72 °C for 5 minutes  
Cycle to step 2 for 19 cycles  
Incubate at 72 °C for 5 minutes  
Hold at 4 °C forever 
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Once PCR was completed, 1µl Dpn1 (20000 U/ml, NEB) used to digest methylated 
DNA. The incubation was carried out at 37°C for 1 hour. Dpn1 was inactivated after 
this by incubation at 65oC for 10 minutes. 
2.5 µl of the mix was transformed into DH5α competent cells and plated onto LB 
agar plates containing antibiotic matching that of the destination vector. Colonies 
were selected and plasmid DNA obtained using the Qiagen Mini-prep kit. 
2.5 Biochemical techniques 
 SDS-PAGE for protein separation 
Polyacrylamide gels were prepared as described by Laemmli, using the recipes 
listed below and the Biorad Mini-PROTEAN 3 Cell. The appropriate separating gel 
was cast and overlaid with isopropanol. The isopropanol acts in two ways, it levels 
out the top of the separating gel and prevents oxygen from reaching the gel, 
allowing the even polymerisation of the acrylamide. Once the separating gel had 
polymerised the isopropanol was removed and the stacking gel cast. Samples to be 
loaded were first mixed with sample buffer (2x) in a 1:1 ratio and heated for 3-5 
minutes at 90 °C. Prestained protein markers (Fermentas) were loaded and used as 
size markers. Gels were run at 150 V for 1 hour in running buffer (1x) and 
terminated once the dye front had reached the end of the gel. 
10 % Resolving gel 
30 % acrylamide mix 10 % (v/v) 
1.5 M TRIS (pH 8.8) 0.39 M 
10 % (w/v) SDS 0.1 % (v/v) 
10 % (w/v) APS 0.1 % (v/v) 
TEMED 0.04 % (v//v) 
H2O to final volume 
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(Other percentage resolving gels, 8 %, 12 % and 15 % were assembled in 
the same manner adjusting the amount of acrylamide mix and water.) 
 
Stacking gel 
30 % acrylamide mix 5 % (v/v)  
1 M TRIS (pH 6.8) 0.13 M 
10 % (w/v) SDS 0.1 % (v/v)  
10 % (w/v) APS 0.1 % (v/v)  
TEMED 0.1 % (v//v) 
H2O to final volume 
Sample buffer 
300mM Tris (pH 6.8) 
5 % (w/v) SDS 
25 % (v/v) glycerol 
400mM DTT 
bromophenol blue to desired colour 
 
Running Buffer  
192 mM glycine  
25 mM Tris 
0.1 % (w/v) SDS 
 Coomassie staining 
After SDS-PAGE, to detect all proteins in the gels, coomassie staining was 
performed. Gels were submerged in Coomassie blue stain for 20 minutes and then 
destained to the desired colour by submerging in destain for 10 minutes before 
removal and addition of clean destain for the rest of the incubation (2 hours-
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overnight). Once destained, the gels were rinsed in water and dried using a heated 
vacuum gel drier (Gel master model 1426, Welche Rietschle Thomas). 
Stain 
50 % (v/v) methanol 
10 % (v/v) glacial acetic acid 
0.2 % (w/v) coomassie brilliant blue R-250 
 
Destain 
7.5 % (v/v) methanol 
10 % (v/v) glacial acetic acid 
 Western blotting 
For analysis of specific proteins, western blotting was performed. Proteins were 
transferred from SDS-PAGE gels and onto 0.2 µM nitrocellulose membrane 
(Protran). The transfer was carried out in tanks containing transfer buffer and an ice 
pack, to prevent overheating, at 100 V for 1 hour or 30 mAmps overnight. Transfer 
apparatus supplied by Biorad. 
Post transfer the membrane was washed in Phosphate Buffered Saline (PBS) 
containing 0.1 % (v/v) TWEEN-20 (PBST), 3 washes for 5 minutes. The membrane 
was blocked with blocking buffer (3 % (w/v) (skimmed milk powder in PBST) for 30 
minutes. The membrane was incubated with the primary antibody in blocking buffer 
for 1 hour at room temperature, or overnight at 4 oC, and then washed with PBST, 3 
washes for 5 minutes. The membrane was incubated with horseradish peroxidase-
conjugated secondary antibody (1:1000, Dako) in blocking buffer for 1 hour at room 
temperature and washed as above. 
Antibody signal was detected using enhanced chemiluminescence (ECL). Blots 
were overlaid with a fresh mix of ECL 1 and ECL 2 (1:1) for 1 minute, blotted to dry 
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and exposed to Hyperfilm ECL (Amersham) for the desired period. The film was 
developed using a Konica medical film processor (model SRX-101A). 
Transfer Buffer  
192 mM glycine  
25 mM TRIS  
20 % methanol 
 
ECL 1 
100mM Tris (pH 8.5) 
2.5 mM luminol 
0.4 mM p-Coumaric acid 
 
ECL 2 
100mM Tris (pH 8.5)  
0.02 % hydrogen peroxide 
 Stripping nitrocellulose blots 
When probing with multiple antibodies was required, blots were stripped by 
incubation with stripping buffer for 30 minutes at room temperature with gentle 




62.5 mM TRIS (pH 6.8) 2 % (w/v) SDS 
0.6 % (v/v) BME 
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2.6 Cell culture 
 Cell lines and media 
All cell lines were incubated at 37oC with 5 % CO2 (except A375 which require 10 % 
CO2) in a humidified incubator. Media (Gibco) was supplemented with 10 % (v/v) 
FBS and 1 % (v/v) penicillin/streptomycin (Gibco). 
 Cell number and viability 
To assess cell number and viability, cells were counted using a haemocytometer. 
First cells were diluted 1:5 with Trypan blue solution to allow differentiation between 
live and dead cells. To calculate the number of viable cells/ml the average cell count 
from each of the sets of 16 corner squares is taken and then multiplied by 10,000. 
To correct for the dilution with trypan blue, multiply by 5. This gives the number of 
viable cells/ml. 
 Sub-culturing of cells 
Cells were maintained in sterile 10 cm diameter dishes and cultured to 70-80% 
confluence. When the cells reached this point, culture media was removed, and the 
cell monolayer was washed twice with 10 ml of sterile PBS. 2 ml of 0.05% 
Trypsin/EDTA was added to the dish and incubated at 37oC until the cells detached 
from the plastic surface. Next, 8 ml of fresh culture media was added, and the cell 
suspension was added to a 15 ml falcon tube. After appropriate dilution, cells were 
seeded into a new cell culture plate, as required. 
 Freezing and recovery of cells     
At 90-100% confluence, cells were trypsinised from flasks for 5 minutes. 10 ml new 
media was added before centrifugation. Centrifugation of the 15 ml falcon occurred 
at 200 rcf for 5 minutes and the supernatant was removed. Cells were resuspended 
in 3 ml of freezing media. The cell was aliquoted into cryotubes (Nunc) and stored in 
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Nalgene TM Cryo 1oC freezing container at -80oC overnight before permanent 
storage in liquid nitrogen. 
To thaw and recover cells from liquid nitrogen, a cryovial containing the cells was 
rapidly thawed at 37°C in a water bath. The cells were transferred into a 10 cm 
culture dish containing 10 ml of fresh culture media. The next day, media was 
discarded, and new media was put in its place. The cells were then incubated at 
37°C until confluent. 
 Transient transfection of DNA 
Transfection of DNA was carried out at around 50 % confluence. All transfections 
were carried out using Attractene (Qiagen). The amounts of DNA transfected were 
normalised using appropriate empty vector DNA. 
For 6 well transfection, the appropriate amount of DNA was incubated with 4.5 µl 
Attractene in a total volume of 100 µl, made up with serum and antibiotic-free media 
for 20 minutes at room temperature. During this incubation 1900 µl of fresh media 
was added to each well of the 6-well plate. After incubation, the transfection reaction 
is added to the wells and incubated at 37°C for 24 or 48 hours or as is sown in 
figure legends. Cells were either treated or harvested as described in figure legends. 
 Drug and small molecule treatment 
For these experiments, cells were treated with drugs and small molecules following 
the transfection protocol above.  
 Harvesting cells 
Cells were placed on ice to chill and the culture media was discarded. Cells were 
then washed three times with ice-cold PBS (2 ml for 6-well plate and 10 ml for 10 cm 
plate). Cells were scraped into 1 ml of ice-cold PBS and transferred into a microfuge 
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tube and centrifuged for 5 minutes at 3000 rpm. The supernatant was discarded, 
and the cell pellets were snap-frozen in liquid nitrogen and stored at -80oC. 
 Cell lysis 
Cells were lysed using Urea lysis buffer, between 2 and 4 volumes (depending on 
the size of cell pellet). Cells were resuspended in lysis buffer by pipetting and 
incubated on ice for 30 minutes. The cells were centrifuged for 15 minutes at 
maximum speed. The supernatant was transferred to a fresh tube and protein 
concentration was calculated using a Bradford assay.  
Urea lysis buffer 
8 M Urea 
50 mM Tris (pH 8) 1 % (w/v) DTT  
2 % (w/v) SDS 
1 x cOmpleteTM, Mini, EDTA-free Protease Inhibitor Cocktail (Roche)  
 Protein quantification 
Protein concentration was determined using the Bradford assay use Bradford’s 
reagent (Bio-rad), following manufacturer’s instructions. Absorbance at 595 nm was 
measured using the Victor3 plate reader with BSA concentration standards.  
2.7 Protein expression and purification from E. coli 
 Protein expression in E. coli 
Wild type or mutant Reptin and Pontin expression vectors were transformed into 
BL21-AI cells. A single colony was inoculated into 200 ml LB containing 100 µg/ml 
ampicillin, and incubated overnight at 37°C with shaking at 200 rpm. 20 ml of starter 
culture was diluted into 1000 ml of LB containing 100 µg/ml ampicillin and incubated 
at 37°C, shaking until the OD600 reached 0.6. Protein expression was induced with 
the addition of 0.2 % (w/v) arabinose, this was incubated at 30°C for 3 hours with 
shaking at 200 rpm. Cultures were centrifuged at 6000 rcf for 15 minutes at 4°C. 
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Resulting pellets were resuspended in 30 ml of storage buffer and snap-frozen for 
storage in -80°C.  
Storage buffer 
10 % (w/v) sucrose 
50 mM HEPES pH 7.5  
 Purification of GST-tagged protein 
The cell pellet in storage buffer was defrosted in warm water for 5 minutes before 
being transferred into ice for the rest of its defrosting. The components of the lysis 
buffer were added to the storage buffer to create the lysis buffer. Cell pellet in lysis 
buffer was incubated on ice for 30 minutes and then sonicated 3 times for 15 
seconds at an amplitude of 10 with 10-second incubations on ice between each 
sonication. The lysate was then centrifuged for 15 minutes at 4°C at 13000 rpm. The 
supernatant was then transferred to a tube containing 500 µl of glutathione-
sepharose 4B beads (Amersham GE) (washed 3 times in PBS to remove storage 
solution) and incubated for 1.5 hours at 4°C rotating. The lysate and beads were 
centrifuged for 5 minutes at 4000 rpm and the supernatant removed. Next, 5 ml of 
high salt wash buffer was used to add beads onto a 5 ml disposable column 
(MoBiTec) and left to empty by gravity. Beads were washed twice with 5 ml of high 
salt wash buffer with triton and then twice with high salt wash buffer (without triton). 
Low salt washes were then performed twice with triton, twice without triton. Next, the 
beads were washed with 5 ml elution buffer before the column was closed and 500 
µl of elution buffer was added to the column. Finally, 30 µl of PreScission protease 
(GE Healthcare) was added to the beads and incubated overnight rotating at 4oC. In 
the morning, this was centrifuged at 2000 rpm for 5 minutes and the supernatant 
containing cleaved protein was collected and transferred to the new tube before 
being stored at 4°C for short term storage or aliquoted into 100 µl and stored at -
20°C. 
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Lysis buffer 
10 % Sucrose (already present) 
50 mM HEPES pH 7.5 (already present)  
400 mM NaCl 
0.1% Triton-X 100 
1mM DTT 
1mM benzamidine 
0.5 mg/ml lysozyme 
1x cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail 
2.8 Biochemical Assays 
 In vitro peptide binding assay 
Streptavidin beads were saturated with the biotinylated peptide of interested. The 
beads were first incubated with peptide diluted in Pierce Protein-Free Blocking 
Buffer (Thermo Scientific) rotating for 1 hour at room temperature. The beads were 
then washed to remove any residual non-binding peptide with PBST (3x 1ml) 
Whole-cell lysate or purified protein was then incubated with the beads, rotating at 
room temperature for 1 hour. Beads were washed with PBST (5x 1ml) before the 
proteins were eluted into SDS-PAGE sample buffer by boiling for 10 minutes 95°C. 
Eluted proteins were subjected to SDS-PAGE for analysis.  
 Peptide-protein binding assay 
Streptavidin (1 µg per well) was coated onto a CostarTM white 96 well plate (Fisher) 
in water (50 µl) overnight at 37 °C. The following day wells were washed with PBST 
(5x 200 µl, 0.1 % (v/v) TWEEN-20) and then incubated with biotin tagged peptide, to 
saturate the streptavidin (500 ng per well), in water (50 µl). The wells were washed 
as above and blocked with either Pierce Protein-Free Blocking Buffer (200 µl, 
Thermo Scientific) or blocking buffer ((PBS (200 µl) containing 3 % (w/v) BSA (BSA-
PBS)), for 1 hour at room temperature, with shaking. The wells were then washed 
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with PBST as described above. A titration of the protein of interest was added to 
wells (the wells preincubated with peptide) in Pierce Protein-Free Blocking Buffer or 
blocking buffer ((PBS (200 µl) containing 3 % (w/v) BSA (BSA-PBS)) (50µl) and 
incubated for 1 hour at room temperature, with shaking. The wells were then 
washed as described above and incubated with primary antibody diluted in Pierce 
Protein-Free Blocking Buffer or blocking buffer ((PBS (200 µl) containing 3 % (w/v) 
BSA (BSA-PBS)) (50µl) for 1 hour at room temperature, with shaking. The wells 
were washed as above then incubated with HRP-conjugated secondary antibody 
diluted in Pierce Protein- Free Blocking Buffer or blocking buffer ((PBS (200 µl) 
containing 3 % (w/v) BSA (BSA-PBS)) (50 µl) for 1 hour at room temperature, with 
shaking. The wells were washed for a final time, as described above, and peptide-
protein binding was detected by electrochemical luminescence (50 µl ECL per well) 
and quantified using a luminometer (Labsystems Fluroscan Ascent FL).  
 Protein-protein binding assay 
Protein 1 (100 ng per well) was coated onto a CostarTM white 96 well plate (Fisher) 
in 0.1 M NaHCO3 (50 μl) overnight at 4°C. The wells were washed with PBST (5x 
200 µl, 0.1 % (v/v) TWEEN-20) before the addition of blocking buffer ((PBS (200 μl) 
containing 3 % (w/v) BSA), for 1 hour at room temperature, with shaking. The wells 
were then washed with PBST as described above. A titration of protein 2 was added 
to wells (the wells preincubated with protein 1) in BSA-PBS (50 µl) and incubated for 
1 hour at room temperature, with shaking. The wells were then washed as described 
above and incubated with primary antibody (to protein 2) diluted in 3% BSA-PBS (50 
µl) for 1 hour at room temperature, with shaking. The wells were washed as above 
then incubated with HRP-conjugated secondary antibody diluted in 3% BSA-PBS 
(50 µl) for 1 hour at room temperature, with shaking. The wells were washed for a 
final time, as described above, and protein-protein binding was detected by 
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electrochemical luminescence (50 µl ECL per well) and quantified using a 
luminometer (Labsystems Fluroscan Ascent FL).  
 ATPase assay 
ATPase assay was carried out in Mass spec grade H2O using ATPase Activity 
Assay Kit (Colorimetric) (Biovision) following manufactures protocol. Purified 
proteins were added directly or incubated with each other overnight to allow for 
oligomerisation to occur. Detection was carried out at OD 650 nm.  
 ATP filter binding assay 
Reptin, wildtype or mutant, is incubated with ATP-gamma32P in solution (PBS). The 
solutions are then filtered through a disc to capture the protein. If the ATP is binding 
to the protein it will be captured with the protein on the disc. These discs are then 
placed on a phosphor screen to expose the amount of radioactivity in each sample. 
The phosphor screen is then imaged using a Phosphoimager. This creates a digital 
image, like a western blot, which can be used for quantitation.  
 Crosslinking of protein using glutaraldehyde 
Reptin WT was incubated with and without 100µM Liddean for 1 hour. To perform 
the crosslinking, increasing concentrations of glutaraldehyde were added and 
incubated for 15 minutes. The protein complexes found were then analysed using 
SDS PAGE and Western blotting.  
 Peptide phage display 
Peptide phage display was performed using a commercial library phage expressing 
different 7mer or 12mer peptides on their surface. This is exposed to the protein of 
interest and the peptides which bind are identified using next-generation 
sequencing.  
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Round 1 This experiment is set up in duplicate on two separate plates to analyse the 
data when comparing fast washes and slow washes. The first steps are 
simultaneous.  
The purified protein (100 ng per well) was coated onto a CostarTM white 96 well 
plate (Fisher) in 0.1 M NaHCO3 (50 µl) overnight at 4oC. The following day wells 
were washed with Tris-buffered saline containing (3x, 0.1 % (v/v) TWEEN-20 
(TBST) and then blocked with Tris-buffered saline (TBS, 200 µl) containing 3 % 
(w/v) BSA. The phage (Ph.D-12 phage display library, New England Biolabs) was 
added to wells (4 μl in 96 µl TBST), to those wells containing the protein. For the 
fast wash data, the wells of one plate were washed with TBST (10x 200 µl). The 
phage was eluted with 0.2 M glycine-HCl pH2.2 (100 µl) containing BSA (1 mg/mg) 
for 15 minutes at room temperature with rocking. This step must not be allowed to 
progress past 15 minutes. The eluted phage was transferred to a fresh Eppendorf 
and 1M Tris-HCl (15 µl) was added to neutralise the phage solution. This 
neutralisation must be carried out immediately. The eluted phage was then stored at 
4°C. For the slow data wells were washed with TBST (6x 200 µl), 5 minutes per 
wash. Following the washes, the phage was eluted and neutralised as before. An 
overnight was set up with ER2738 cells (New England Biolabs) in LB (10 ml) 
containing tetracycline (1 µg/µl) at 37°C, 220 rpm. The overnight culture was diluted 
1:200 in LB (20 ml) and grown for 1 hour at 37°C, 220 rpm. It was then inoculated 
with the eluted phage (100 μl) and incubated for 4.5 hours at 37°C, 220 rpm. The 
culture was centrifuged for 10 minutes, 12000g, 4oC and the supernatant transferred 
to a fresh tube and centrifuged for 10 minutes, 12000g, 4°C. The top 80 % of 
supernatant was transferred to a fresh tube and 20 % (w/v) PEG/2.5 M NaCl was 
added (1/6 of the supernatant volume) to precipitate the phage, the phage was 
precipitated overnight at 4°C. In preparation of the second round the following day, 
purified protein (100 ng per well) was coated onto a CostarTM white 96 well plate 
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(Fisher) in 0.1 M NaHCO3 (50 µl) overnight at 4°C. As above the plates were set up 
in duplicate. The following day the PEG solution was spun for 15 minutes, 12000g, 
4°C and the supernatant discarded, the tube was left upside down to drain for 10 
minutes. The pellet was resuspended in TBS 200 µl, transferred to an Eppendorf 
and centrifuged for 5 minutes, 13000 rpm, 4°C. The supernatant was transferred to 
a new tube, and the amplified phage from round one was stored at 4°C.  
Round 2 was carried out following the method for round one, except, instead of 
adding phage library to the wells, amplified phage (10 µl in 100 µl total volume in 
TBST) was added at this point in the method.  
PCR step. The eluted and amplified phage were subjected to PCR before being run 
on agarose gels before next-generation sequencing by Otogenetics.  
PCR mix 
5 µl 5 M betaine 
10 µl 5x herculase II buffer 5 µl 132 mM trehalose 
2.5 µl 10 mM dNTP 
1 µl 100 mM reverse primer  
1 µl herculase II enzyme 
1 µl forward primer 
10 µl phage 
Nuclease free water to 50 µl  
 
Thermal cycling conditions  
Incubate at 95 °C for 60 seconds  
Incubate at 95 °C for 15 seconds  
Incubate at 55 °C for 20 seconds  
Incubate at 70 °C for 60 seconds  
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Cycle to step 2 for 30 cycles  
Incubate at 70 °C for 210 seconds  
Hold at 4 °C forever  
 Antibody phage display 
Antibody phage display was performed using an in lab-made library of phage 
expressing different nanobodies on their surface. This is exposed to the protein of 
interest and the nanobodies which bind are then amplified and identified using 
sequencing. 
Round 1 This experiment is set up in duplicate on two separate plates to analyse the 
data when comparing fast washes and slow washes. The first steps are 
simultaneous.  
The purified protein (100 ng per well) was coated onto a CostarTM white 96 well 
plate (Fisher) in 0.1 M NaHCO3 (50 µl) overnight at 4 °C. The following day wells 
were washed with Tris-buffered saline containing (3x, 0.1 % (v/v) TWEEN-20 
(TBST) and then blocked with Tris-buffered saline (TBS, 200 µl) containing 3 % 
(w/v) BSA. The phage was added to wells (4 μl in 96 µl TBST). For the fast wash 
data, the wells of one plate were washed with TBST (10x 200 µl). The phage was 
eluted with 0.2 M glycine- HCl pH2.2 (100 µl) containing BSA (1 mg/mg) for 15 
minutes at room temperature with rocking. This step must not be allowed to 
progress past 15 minutes. The eluted phage was transferred to a fresh Eppendorf 
and 1M Tris-HCl (15 µl) was added to neutralise the phage solution. This 
neutralisation must be carried out immediately. The eluted phage was then stored at 
4 °C. For the slow data wells were washed with TBST (6x 200 µl), 5 minutes per 
wash. Following the washes, the phage was eluted and neutralised as before. An 
overnight was set up with ER2738 cells (New England Biolabs) in LB (10 ml) 
containing tetracycline (1 µg/µl) at 37oC, 220 rpm. The overnight culture was diluted 
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1:200 in LB (20 ml) and grown for 1 hour at 37°C, 220 rpm. It was then inoculated 
with the eluted phage (100 µl) and incubated for 4.5 hours at 37°C, 220 rpm. The 
culture was centrifuged for 10 minutes, 12000g, 4°C and the supernatant transferred 
to a fresh tube and centrifuged for 10 minutes, 12000g, 4°C. The top 80 % of 
supernatant was transferred to a fresh tube and 20 % (w/v) PEG/2.5 M NaCl was 
added (1/6 of the supernatant volume) to precipitate the phage, the phage was 
precipitated overnight at 4°C. In preparation of the second round the following day, 
purified protein (100 ng per well) was coated onto a CostarTM white 96 well plate 
(Fisher) in 0.1 M NaHCO3 (50 µl) overnight at 4°C. As above the plates were set up 
in duplicate. The following day the PEG solution was spun for 15 minutes, 12000g, 
4°C and the supernatant discarded, the tube was left upside down to drain for 10 
minutes. The pellet was resuspended in TBS 200 µl, transferred to an Eppendorf 
and centrifuged for 5 minutes, 13000 rpm, 4°C. The supernatant was transferred to 
a new tube, and the amplified phage from round one was stored at 4°C.  
Subsequent rounds were carried out following the method for round one, except, 
instead of adding phage library to the wells, amplified phage (10 µl in 100 µl total 
volume in TBST) from the previous round was added at this point in the method.  
Nanobody pools were tested against the protein of interest by coating purified 
protein (100 ng per well) onto a CostarTM white 96 well plate (Fisher) in 0.1 M 
NaHCO3 (50 µl) overnight at 4°C. The amplified phage was then incubated in the 
well for 1 hour (concentrated and dilution 1:10, 1:100 used). Phage was detected 
using an anti-phage antibody to allow for determination of the efficiency of the 
nanobody pool.  
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2.9 Biophysical Assays 
 Gel filtration 
Reptin, WT and mutants, were incubated with and without ligands in 100µl HEPES 
buffer (pH 7.6) containing PBS. Samples were injected onto a 25 ml Superose-12 
gel filtration column in the same buffer and fractions were collected at a flow rate of 
0.5 ml/min. In the ligand-bound state, the column was pre-incubated in the same 
buffer with the addition of ligand. Gel filtration markers were used to calibrate the 
column.  
50µl was taken from each of the fractions eluted from the column and bound to an 
ELISA plate before identification with anti-Reptin antibody as with standard protein-
protein interaction protocol.  
 Hydrogen-deuterium exchange 
Reptin (6 µM) was prepared in H2O (control) and D2O for set time intervals (1, 2, 5, 
10, 30, 60 and 180 minutes) before the exchange was terminated by quenching with 
Trifluoroacetic acid.  
Reptin was prepared in the presence of Liddean and incubated at room temperature 
(60 minutes) to allow for complex formation. The samples were then prepared for 
exchange as for Reptin.  
The samples were measured on the Orbitrap Elite mass spectrometer connected to 
HD robot and liquid chromatography. HD exchange analysis was done in MS mode 
in orbitrap analyser with 120 000 resolution. Two different fragmentation methods 
were applied, collision-induced dissociation (CID) and higher-energy collisional 
dissociation (HCD) and peptide mapping were measured in MSMS mode with data 
dependant analysis (TOP3).  
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 The discovery and characterization 
of a first-in-class drug lead that 
binds Reptin 
Some of the work in this chapter was published in 2015 in Chemical 
Science as a collaboration between the laboratories of Prof. Ted Hupp and 
Prof. Nicholas Westwood (Healy et al., 2015).  Other work in the chapter 
was published in 2019 in Journal of Proteomics as a collaboration between 
the laboratories of Prof. Ted Hupp, Prof. Borek Vojtesek and Dr Douglas 
Houston (Remnant et al., 2019).  
 
3.1 Introduction 
 Reptin and Pontin, members of the AAA+ protein 
superfamily 
The AAA+ (ATPases associated with various cellular activities) protein superfamily 
is present in all kingdoms of life (Snider et al., 2008). The members of this protein 
superfamily exist as oligomers and are particularly interesting due to their ligand 
binding ability and allosteric regulation of protein function (Stinson et al., 2013).  
Reptin and Pontin are paralogs and members of this protein superfamily, they are 
usually found in complex with each other forming a heterododecamer.  These 
proteins have high sequence identity and similarity (Nano and Houry, 2013) and are 
known to be involved in many cellular complexes, a large number of which many are 
involved in interacting with DNA. The heterohexameric complex of Reptin and 
Pontin was crystallised in the presence of ligand in 2011 by the Carrondo lab with a 
resolution of 3A (Gorynia et al., 2011). This structure shows alternating subunits of 
Pontin and Reptin forming two heterohexameric rings which lie on top of one 
another in a head-head formation. 
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In contrast to the well-characterised interactions of Reptin in the presence of Pontin, 
there is little information on the function and interactions of Reptin alone. The crystal 
structure of a Pontin hexamer was published in 2006 by the Carrondo lab (Matias et 
al., 2006), this was followed by the structure of the heterohexamer, as previously 
mentioned. Finally, a crystal structure of Reptin was first published in 2012 by 
Grigoriev lab (Petukhov et al., 2012). This shows that Reptin and Pontin can form 
stable complexes without each other in vitro, however, both require the presence of 
ligand. Previous research in the lab has shown that Reptin binds to Anterior-
Gradient-2 (AGR2) (Maslon et al., 2010) in the absence of Pontin and other ligands, 
this lead to the belief that the Reptin homohexamer must have protein-protein 
interactions independent of Pontin. 
Although Reptin is a member of the AAA+ protein family which are known to bind 
ATP, this is a highly transient interaction, Reptin alone has a very low affinity for 
ATP. It has been observed previously in the AAA+ protein family that conformational 
changes occur when a protein binds to its ligand or when the ligands are 
enzymatically broken-down releasing energy. One of the most well-characterised 
members of the AAA+ family is dynein which uses its AAA+ domain to provide the 
energy required for its role as a motor protein. The protein uses ATP driven 
conformational changes in the AAA+ ring to induce movement in the adjacent motor 
domain (Gleave et al., 2014).  
 Mutations in AAA+ proteins 
In previous studies, following common mutations used to study AAA+ proteins 
(Hanson and Whiteheart, 2005), two mutant versions of Reptin were characterised, 
K83A which is a mutation in the Walker A binding site resulting in a loss-of-function 
mutant, and D299N which is a mutation in the Walker B site resulting in a loss of 
ATP hydrolysis.  Further studies showed that contrary to its loss of ATP hydrolysis, 
 
  54 
the D299N mutant protein has a higher affinity for ATP that the wildtype. In the same 
experiment, the K83A mutant showed a reduction in ATP binding compared to the 
wildtype (Maslon et al., 2010). 
 Known Reptin protein-protein interactions 
Reptin was identified as a possible cancer therapeutic target due to its binding to 
Anterior-Gradient2 (AGR2) and its role in the interaction between AGR2 and p53. 
The binding interaction between AGR2 and Reptin is thought to have a role as part 
of a signalling complex involved in the development of pro-metastatic cancer 
(Maslon et al., 2010). This could be related to the role of Reptin in complexes such 
as TIP60 and its interaction with c-Myc. AGR2 has a wide range of cellular 
functions, including cell migration, cellular transformation and metastasis (Zhang et 
al., 2005, Reiner et al., 2009) but it is its role as in inhibitor of p53 which is most 
interesting (Pohler et al., 2004). As a therapeutic target, it was found that there were 
significant associations between levels of AGR2 expression in a tumour and either 
oestrogen receptor-α positivity or tamoxifen resistance (Fritzsche et al., 2007, 
Hrstka et al., 2010). AGR2 is found to be overexpressed in many cancer types, 
including oesophagus, pancreas, breast, prostate, and lung (Fritzsche et al., 2006, 
Zhang et al., 2005, Reiner et al., 2009, Liu et al., 2005). P53 is the most well-studied 
tumour suppressor protein with roles in transcriptional activation and DNA binding 
(Hupp et al., 1992, Raycroft et al., 1990, Pietenpol et al., 1994). P53 responds to 
cellular stress resulting in the induction of cell cycle arrest and apoptosis or 
senescence (Fridman and Lowe, 2003). Many cancers, especially those that are 
hereditary, are a result of mutations in the p53 gene (Perri et al., 2016). It is the role 
of Reptin binding to AGR2 and the effect of this interaction in pro-metastatic cancer, 
in the absence of Pontin, which leads to an investigation into ligands which bind 
Reptin.  
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 The importance of protein-protein interactions in 
therapeutics  
Understanding the network of protein-protein interactions (PPIs) is crucial in the 
development of novel therapeutics but the discovery of new PPIs is still a major 
challenge scientifically (Jubb et al., 2012). The creation of a comprehensive list of 
interactors for a protein of interest allows a greater understanding of how to 
manipulate specific cellular pathways, whilst attempting to reduce off-target effects 
within the cell. Using these complex networks to identify novel targets for diagnostic 
and therapeutic purposes remains an unexploited avenue in drug discovery (Healy 
et al., 2015). 
Here computational biology, chemical synthesis and biochemistry were used to 
develop small molecule binders of the Reptin protein. The resulting ligands were 
then tested with a range of biochemical and cell biology approaches to characterise 
the changes seen in protein-protein interactions and the wider cell environment. 
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3.2 Aims 
The experiments in this chapter aim to develop a small molecule ATP mimetic which 
can bind specifically to Reptin. This ATP mimetic should result in changes of binding 
of Reptin to its known binders in the same manner as ATP (Maslon et al., 2010).  
We want to investigate: 
• If an ATP mimetic can be created to enable tighter control of the allosteric 
nature of Reptin 
• If the binding of this ATP mimetic results in changes of the protein 
interactions of in the same way as the binding of ATP 
• If this ATP mimetic causes Reptin to change its oligomeric state  
• If this small molecule can be used within cells and if there are any resulting 
phenotypes 
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3.3 The creation of Liddean 
An in-silico screen was carried out using a library of commercially available small 
molecules to identify those which might bind to the Walker A site of Reptin. This 
method takes the binding site of a protein and combines it with a library of small 
molecules to see the likelihood of interaction occurring. The rigid-body docking 
program LIDAEUS (Taylor et al., 2008) was used to dock a virtual conformer library 
of 4.4 million compounds. The results were ranked based on their LIDAEUS score 
and the top 49971 compounds were tested again using Vina and Autodock, this 
work was carried out by Douglas Houston, the University of Edinburgh (flowchart of 
methodology can be seen in figure 3.1A). This led to the selection of 30 small 
molecules which had been predicted to bind to Reptin, these small molecules were 
all commercially available. To analyse their effect on Reptin, a peptide-binding 
assay was carried out against the AGR2 peptide, FVLLNLVY, which has previously 
been described to bind Reptin (Maslon et al., 2010). This characterisation was 
performed as previous work in the laboratory has shown that the presence of ATP 
had a direct effect on the binding interaction of Reptin and AGR2 (Maslon et al., 
2010). The hits were ranked equally by a significant increase or decrease in binding 
of the protein to the peptide compared to the control, Reptin alone. Compound 1 
(figure 3.1B)  was identified as inducing the greatest response and was ranked 
highest for further investigation. Compound 1 contains a biphenyl substituent that is 
predicted to sit deep in the Walker A pocket where the adenine of ADP/ATP binds 
and a pyridine–oxazolo ring system which is predicted to extend out of the pocket 
(Healy et al., 2015). 
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Figure 3.1 Creation of small molecule Liddean using a combinatorial approach.  
A) Flowchart showing process used to combine data from the surface potential of proteins 
with a library of conformers of commercially available small molecules to create a list of likely 
binding candidates. B) Structure of ‘Compound 1’ C) Comparison between the binding 
contacts of Liddean (stick) and ATP (space fill and stick) created in the active site of Reptin. 
D) Locations of modification sites of Compound 1 used in development of Liddean. E) 
Structure of ‘Liddean’  (Healy et al., 2015) 
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A comparison of the binding contacts in the pocket shared between ATP/ADP and 
Compound 1 can be seen in figure 3.1C (Autodock software). The interactions deep 
within the binding pocket appear to be the same for Compound 1 and ATP/ADP, 
however, the orientation of tail of the small molecules as they exit the binding pocket 
are likely to have very different conformations. 
A structure-activity-relationship study (SAR) was then carried out on Compound 1 by 
Alan Healy, The University of St Andrews. The sites for modification can be seen in 
figure 3.1D showing sites of the” A”,” B” and” C” rings as well as the linker region. All 
of these sites were modified to create a library of Compound 1 derivatives. Modified 
analogues of Compound 1 were either synthesised (Alan Healy) or purchased (if 
available) for in vitro analysis using protein-protein and protein-peptide assays.  
 Expression of Reptin 
The DNA sequence for the Reptin protein was cloned into pDEST15 using the 
Gateway cloning methodology (figure 3.2A) (Katzen, 2007). The vector containing 
the original Reptin sequence was a gift from a previous lab member, Magdalena 
Maslon. Primers containing either attR1, a Precission protease cleavage site and 
the N-terminal nucleotides of Reptin or the C- terminal nucleotides of Reptin and the 
attR2 site were designed and then synthesised by Sigma. These were used to copy 
the Reptin sequence into a Gateway entry vector pDNR221 using the LR reaction. 
The sequence of the entry plasmids was then checked using Sanger sequencing by 
Source Bioscience against the predicted sequence of the insert, combining the 
cleavage site and the cDNA sequence of Reptin. Once the sequence of the entry 
vector was confirmed, the BP reaction was carried out using the pDNR221 
containing the Reptin sequence and the pDEST15 vector. The pDEST15 was 
selected due to it containing GST upstream of the attR1 site so that both the GST 
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and the attR1 site could be cleaved from the final protein once it has been Figure 3.2 Expressing Reptin in bacteria  
A) Map of the expression vector created to enable to expression and purification of human 
Reptin in E. coli. B) Purification of Reptin protein from bacteria showing various 
concentrations of BSA as standard to aid in quantification of the concentration of and purity 
of purified Reptin, the proteins removed directly from the beads are also shown.   
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expressed.  
The new pDEST15 plasmid containing the Reptin sequence, from now on known as 
pDEST15 Reptin, was transformed into BL21-AI cells (Saida et al., 2006). These are 
a modified form of E. coli specifically for expression of toxic proteins which require 
tight regulation, expression of a protein with these cells requires induction with the 
sugar arabinose. Once transfected, the cells were grown at 37oC overnight before 
being diluted the following morning and grown until the cells reached an OD of 0.8-
1. The cultures were moved to 25oC and protein expression was induced with the 
addition of arabinose. After induction of protein expression for 3 hours the cultures 
were pelleted ready for purification of the expressed protein. 
For purification of the protein, the BL21-AI cells were lysed, the supernatant 
collected, and the expressed fusion protein was captured using Glutathione beads. 
The beads were washed repeatedly to remove contaminant host cell proteins bound 
to GST-Reptin. Finally, Precission protease is added to the beads and left to 
incubate overnight, the protease itself also has a GST tag meaning it is removed 
from the supernatant during this step. The concentration of the protein expressed is 
measured using the combination of a Bradford assay and a coomassie stained gel 
containing BSA standards, this combination allows correct quantification of the 
protein concentration and checks the purity of the expressed protein. An example of 
coomassie stained gel can be found in figure 3.2B. It is also visible in the gel that the 
cleaved beads still have a large amount of Reptin protein which is not eluted but has 
been cleaved from the GST. A smaller band is visible below 25kDa which is likely to 
be a combination of the GST itself and the protease used to cleave as they are both 
similar in weight. This method was further optimised to allow recovery of more of the 
purified protein by increasing both the volume of elution buffer and amount of 
Precission protease used to cleave the fusion protein. 
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 Testing Compound 1 analogues in vitro 
3.3.2.1 Changes in protein and peptide binding with the addition of ligands 
A combination of peptide-protein and protein-protein binding assays were used to 
look at the effect different small molecules had on the binding affinity of Reptin to 
known binding proteins and itself. To keep the experimentation as comprehensive 
as possible, the analogues were given numbers. This allowed testing to occur ‘blind’ 
whilst still retaining the ability to look at the specific modifications which have 
created the greatest effect. 
3.3.2.1.1 Protein-protein assays 
In protein-protein assays, a polystyrene plate is coated with protein 1 (solid phase) 
by incubation overnight in a mildly denaturing buffer (0.1 M NaHCO3), blocking 
solution is added for 1 hour (3% BSA in PBST), protein 2 is then added to the well in 
blocking solution. A primary antibody against protein 2 is used to detect the protein. 
A secondary antibody raised against the primary antibody (swine anti-rabbit or rabbit 
anti-mouse) conjugated to HRP (horseradish peroxidase) is then added. The 
amount of protein was quantified using the ECL reaction measuring the 
luminescence in relative light units. A schematic of these experiments can be found 
in figure 3.3A. 
Reptin binding to p53 and AGR2 was used to look at the changes in protein-protein 
interactions. The interaction between Reptin and AGR2 peptide had been used to 
study the effects of the original 30 ligands, the next step was looking at protein-
protein interactions. Figures 3.3C and 3.3D show representative assay results, 
observing the effect small molecule binders on these interactions. The binding of 
Reptin in solution phase is shown to change when Reptin has been incubated with 
the small molecule library for 1 hour before combining with the protein in the solid 
phase, either AGR2 or p53. 
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Figure 3.3 Protein-protein binding assays to measure changes in protein interactions  
A) Schematic of protein-protein binding assay. The solid phase protein is shown in orange, 
the solution phase protein is shown in green. The primary antibody used against the solution 
phase protein is shown in blue and the secondary antibody conjugated to HRP is shown in 
orange with a pink HRP and a star representing the ECL reaction. B) Chemical structure of 
27 (Liddean). C) Protein-protein binding assay showing changes in the ability of Reptin 
(solution phase) to bind p53 (solid phase) in the presence of a range of small molecules. D) 
Protein-protein binding assay showing changes in the ability of Reptin (solution phase) to 
bind AGR2 (solid phase) in the presence of a range of small molecules.  
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All the compounds used here are derivatives of Compound 1, with variations in the 
molecular structure of the molecule, as explained earlier (figure 3.1E). Compound 
27 can be seen to have both the biggest increase in the amount of Reptin protein 
binding to p53 compared to the Reptin alone, and the compound which can be seen 
to have the greatest reduction in the amount of Reptin protein bound to AGR2 
compared to Reptin alone. This was the first indication that this adaptation of 
Compound 1 could be of interest. When the results of these experiments were 
communicated with the collaborators it was clear that the composition of the “B” ring 
of Compound 1 was very important. It was variations here in the “B” ring which 
appear to have the biggest effect on the affinity of Reptin to binding its partners. 
From these experiments, it was clear that a single modification was the most 
effective. The structure of this compound can be seen 3.3B, this molecule different 
from Compound 1 as the halogen in the ‘B’ ring has been changed from chlorine to 
bromine. This small molecule from now on will be referred to as Liddean (Healy et 
al., 2015). 
3.3.2.1.2 Peptide-protein assays 
Peptide-protein assays are like protein-protein assays but here we are utilising 
overlapping peptide libraries to look at changes in the interactions between Reptin 
and short linear motifs. A schematic of this assay can be found in figure 3.4A. In 
brief, a polystyrene plate is coated overnight with streptavidin to allow binding of 
commercially synthesised biotinylated peptides (Biotin-SGSG-XXX…) to the well. 
Reptin was added to the wells and the protein was detected using a rabbit 
polyclonal antibody against Reptin, and a secondary antibody, swine anti-rabbit, 
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conjugated to HRP (horseradish peroxidase). The amount of protein was quantified 
Figure 3.4 Binding of Reptin protein to peptides from p53 and itself 
A) Schematic of peptide-protein binding assay. The streptavidin coated plate is shown in 
blue with the biotinylated peptide in orange. The solution phase protein is shown in green. 
The primary antibody used against the solution phase protein is shown in blue and the 
secondary antibody conjugated to HRP is shown in orange with a pink HRP and a star 
representing the ECL reaction. B) Peptide-protein binding assay using overlapping p53 
peptides in the solid phase binding to solution phase Reptin protein. The blank well 
contains a mixture of all peptides showing background level binding of the Reptin 
antibody against the peptides. (Healy et al., 2015) C) Peptide-protein binding assay using 
overlapping Reptin peptides in the solid phase binding to solution phase Reptin protein. 
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using the ECL reaction measuring the luminescence in relative light units. 
As the interaction between Reptin and p53 protein had previously been investigated 
in the lab (Healy et al., 2015), it was decided to look and see if there was specific 
peptide showing a high binding indicating a binding site for Reptin. The results of the 
experiment can be found in figure 3.4B. Here we can see two peptides showing a 
high binding to full-length Reptin protein, these are peptides 31 
(SGSGRNSFEVRVCACPGRD) and 38 (SGSGYFTLQIRGRERFEMF). Peptide 31 
can be mapped to the BOX-V domain of p53 and peptide 38 is mapped to its 
tetramerization domain.  
As the only reliable commercially available antibody to Reptin is a rabbit polyclonal 
antibody, it is not possible to use this to investigate Reptin self-binding. To enable 
testing of this aspect of the behaviour of Reptin, a library of overlapping Reptin 
peptides was purchased which contain a 5 amino acid overlap at both N and C 
termini, creating a peptide of 15 amino acids in length. The initial experiment looked 
at how Reptin itself bound to these peptides and see which peptide or peptides had 
the greatest affinity of the Reptin peptide library. The largest signal is produced 
when Reptin is bound to peptides 3, 27 and 28. On inspection of the sequences of 
these peptides, it was decided that peptides 27-29 would be the most interesting to 
use for further experiments. This is due to their overlapping peptide sequences, 
which show very different binding strengths. The sequence of these peptides is as 
follows APVLIMATNRGITRI, GITRIRGTSYQSPHG and QSPHGIPIDLLDRLL (p27-
29 respectively, also seen in figure 3.5A). 
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Following on from this, peptides 27-29 were used to look at how exposure to small 
Figure 3.5 Measuring changes in self peptide binding on the addition of ligands 
A) specific peptide sequences of Reptin self-peptides p27, p28 and p29. B) Peptide-
protein binding assay using specific overlapping Reptin peptides in the solid phase 
binding to solution phase Reptin protein. In the first four conditions Reptin and small 
molecules were added at the same time to the peptides on the well, whereas the second 
four colours show Reptin which has been with small molecules described for 30 minutes 
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molecules affects the binding of Reptin to these peptides. As all of the small 
molecules are dissolved in DMSO it is a requirement to test whether the addition of 
the DMSO affects the binding affinity, which it appears to. The changes observed in 
Reptin exposed to small molecules in addition to DMSO are much more significant 
than those seen with Reptin and DMSO compared to Reptin alone (figure 3.5B). The 
first 4 sections show Reptin which has been added to the well at the same time as 
being exposed to the ligand, comparatively, in the second 4 sections the Reptin was 
incubated with the small molecules at 25oC for 30 minutes before adding to the well. 
This shows the time required for the complex of protein and ligand to form and to 
see if there is. A requirement for any conformational changes to occur. Both 
datasets show very similar binding, this means that incubation is not required for 
complex formation, the binding between Reptin and the small molecules must occur 
very quickly, inducing conformational or oligomeric changes in Reptin. This assay 
also shows that the novel synthesised ligand, Liddean, acts very similarly in this 
assay to ADP, the molecule on which it was based. 
3.3.2.2 Testing SDS resistance of Reptin oligomers 
From the previous experiment, we saw changes induced by the presence of Liddean 
appear to be similar to those induced by ADP. As we know from other AAA+ 
proteins this is likely to be a result of oligomerisation. Here we are testing whether 
Liddean can affect the oligomeric state of Reptin. To achieve this, Reptin, apo and in 
the presence of ligands, was subjected to incubation with increasing percentages of 
SDS before being run on an SDS-PAGE gel, proteins were visualised using silver 
staining. 
In the SDS incubation assay, increasing amounts of SDS are used to attempt to 
collapse the Reptin oligomer back to a monomer, the more stable the oligomeric 
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structure is, the greater the percentage of SDS required to collapse it. SDS is a 
molecule known to reduce proteins to their monomeric state by coating the 
polypeptide in SDS allowing it to flow easier through the polyacrylamide gel. Here 
the gel is stained using the silver stain protocol to detect the very low amount of 
protein in all lanes of the gel. In figure 3.6A we can see that, in lanes where Liddean 
in present, but not ADP, there are large higher-order structures which can are stable 
in the presence of SDS, due to both their different sizes and discrete banding they 
may represent different confirmations of the hexametric Reptin. In all lanes a band is 
visible around 130kDa, this could be a dimeric form of Reptin.  
3.3.2.3 Crosslinking of Reptin oligomers 
Crosslinking of Reptin in the absence and presence of Liddean with increasing 
amounts of glutaraldehyde should give more detail about the higher-order oligomers 
visualised in the SDS experiment. In figure 3.6B much less monomeric Reptin is 
present in the samples containing Liddean even at the lowest concentration of 
glutaraldehyde. This likely means that Liddean binding to Reptin induces its 
oligomerisation and creates a more stable form of the oligomer than its ligand. 
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Figure 3.6 Examining changes in oligomeric state induced by small molecule 
binding 
A) SDS PAGE silver stained gel showing Reptin incubated in presence of small 
molecules in increasing concentrations of SDS. (Healy et al., 2015) B) Western 
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 Testing Compound 1 analogues in cells 
To measure changes in cells caused by the addition of ligand, these must be 
introduced into cells in a reproducible manner. Due to the insolubility of Liddean in 
aqueous solution, it was required that Liddean must remain in dissolved in DMSO, 
as with the previous experiments. Previous work has shown that it is possible to 
introduce small molecules into cells using transfection reagents which would 
normally be used for DNA and RNA (Rena et al., 2004). 
3.3.3.1 Measuring changes in cell impedance on the addition of ligand 
The use of non-invasive electrical impedance monitoring systems allows for the 
quantitative observation of cell proliferation and changes in cell morphology with 
high temporal control, in real-time. Cell impedance is as a measure of cell 
adherence and proliferation. The RTCA iCELLigence is designed to do just that. 
Cells are grown in wells on top of electrodes, a small electrical current is passed 
across and changes in this current are measured and plotted against time. 
Here an RTCA iCELLigence instrument was used to measure changes in cells 
caused by the addition of Liddean. For these experiments, the HCT116 cell lines 
were chosen. These are a human colon cancer cell line which is available as p53 
positive and negative. Due to the known binding of Reptin, AGR2 and p53, these 
interactions and the changes seen as a result of the presence of Liddean in vitro, it 
was thought these cell lines might show differences in impedance due to the 
presence of active of p53 in the cell. The cells were incubated in the chambers for 
24 hours, allowing for normalisation between experiments and checking the number 
of cells in each well same in all. After 24 hours, Liddean was added to cells at 
different concentrations (or DMSO alone) after incubation with Attractene as a 
carrier for the small molecules. The cells were monitored for a further 72 hours.  
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The results of this experiment can be found in figure 3.7 showing cell impedance 
Figure 3.7 iCELLigence analysis of HCT116 cells exposed to Liddean 
Time course of cell culture impedance values. Cells were incubated for 24 hours in 
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once exposed 4 μM Liddean. The dose of 4 μM Liddean shows a dramatic increase 
in impedance on the addition of the small molecule. Due to the speed of this 
increase, it is unlikely that this is due to cell division as the cells are not 
synchronised and therefore not ready to enter mitosis. This increase is likely due to 
cells adhering to the surface of the well and changing their morphology after 
exposure to Liddean. At this stage, it was not possible to confirm this hypothesis and 
further testing will be required.  
3.3.3.2 Testing cell cycle changes due to the addition of ligand 
Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry 
which counts the number of cells in a population that contain a particular amount of 
DNA, thus enabling identification of the percentage of the cell population is at 
particular stages in the cell cycle or apoptosis. FACS can be used to ascertain 
whether the observed increase in cell impedance was due to the addition of Liddean 
causing cells to synchronously enter mitosis. The test was carried out 6 and 48 
hours after the addition of different concentrations of Liddean. The 6-hour time point 
was chosen as in the iCELLigence experiment this is the time after addition of 
Liddean where I saw the greatest increase in cell impedance value. The 48-hour 
time points should allow the cells to go through two cell cycles. 
The results of these experiments can be found in figure 3.8. Here, we can see there 
is no observable difference between treated and untreated cells at any of the 
timepoints observed, all data here is not significant. The total number of cells in 
each gate is seen to be similar, independent of the condition they come from, this 
shows that it is also unlikely that the addition of Liddean is inducing an increase in 
apoptosis in these cells. 
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Figure 3.8 FACS analysis of cells exposed to Liddean  
6 and 48-hour time points looking specifically at cell cycle stage in HCT116 WT 
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3.4 Discussion 
The AAA+ protein family are characterised by their nucleotide-binding that 
induced formation of oligomeric complexes. This investigation exploited this 
ability of Reptin to develop a small molecule binder of Reptin which can be 
used to explore the conformational and oligomeric changes in Reptin further. 
As ATP is highly abundant and required for a vast number of cellular 
functions it is very difficult to examine the changes of a specific protein-
ATP/ADP interaction in vivo. The specificity of this new small molecule might 
mean it is unable to bind into the ATP binding sites of some other AAA+ 
proteins due to steric hindrance from amino acids outside of the pocket, 
although further investigation is required.  
The ability to add a specific amount of ligand which is not able to undergo hydrolysis 
enables us to study the ligand-bound form of Reptin without the conformational 
changes which occur as a direct result of the ATPase activity of the protein. The 
information gained with the use of the mimetic can be compared to that found when 
using either ADP or ATP. This will allow for further dissection of the complex nature 
of this protein. 
The initial protein-protein interaction studies show how ligand binding, and therefore 
likely conformation or oligomeric change in the protein of interest, have a direct, and 
specific influence on the binding affinity of the protein of interest. The experiments 
show that the binding of p53 and AGR2 must occur via different mechanisms as the 
binding of one is increased with ligand addition whilst the other is decreased. The 
same trend is seen with some of the other ATP mimetic small molecules. These 
observed changes were similar to those from the peptide-protein Reptin peptide 
library assay. Here we observe an increase in binding of specific self-peptides, 
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including a specific small linear motif, which is directly affected by the addition of 
small molecules.  
The studies looking for higher-order oligomers of Reptin in the presence of ligands 
both show the existence of a stable high molecular weight protein. The SDS assay 
shows that it is possible the binding of Liddean to Reptin is more stable than the 
binding of Reptin to ADP as the high molecular weight proteins are only SDS 
resistant in this condition. The crosslinking with glutaraldehyde shows that wildtype 
Reptin can be crosslinked into higher molecular weight oligomers in the absence of 
ligand, however, the presence of ligand appears to reduce the amount of monomer 
visualised to a greater extent showing similarly that the higher-order oligomer 
formed with the addition of Liddean is stable.  
As we were able to discount changes in impedance due to the cell cycle with the 
FACS data, we can conclude that that increase in impedance seen in the 
iCELLigence experiment is due to a change in cellular adherence or morphology 
with the addition of Liddean. In this instance, this may show the off-target effects of 
Liddean. As Liddean is an ATP mimetic designed to bind to a Walker A motif other 
proteins within the cell are likely able to bind it if they contain this motif. Liddean 
could bind to any of the P-loop NTPases which also contain Walker A sites, many 
motor proteins are found in this superfamily (Berg et al., 2002). The members of the 
AAA+ superfamily also fall into the P-loop NTPases superfamily. P-loop NTPases 
include myosin and kinesins (Leipe et al., 2002). Dynein is a likely candidate as an 
off-target binder as it is a member of the AAA+ superfamily and has roles in 
cytoskeletal regulation (Kim et al., 2012) although there are several others also 
(Vale, 2000, Hanson and Whiteheart, 2005, Snider et al., 2008). As bioelectrical 
impedance cell-based biosensors are so sensitive, they can be used to screen 
bioactive agents. They easily translate changed in cell growth into a measurable 
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figure and can be used to determine the efficacy of a specific compound 
(Ramasamy et al., 2014). There is also evidence that binding of small molecules to 
protein targets in vitro can cause changes in the measured electrical impedance of a 
solution, this could mean that the change in impedance measured is a direct result 
of Reptin and Liddean binding to one another although this would need further 
investigation (Pisa et al., 2019). Although the reason for the change in impedance 
value in still unknown in this case, this result still gives us additional information into 
the action of Liddean within the cell. The results in the iCELLigence experiment are 
like what would be expected during attachment of cells on to the plate so is it 
possible that Liddean is affecting the adherence of the cells. 
The use of Liddean may enable discovery of the complete protein-protein interaction 
network of Reptin. Small molecule stabilisation or destabilisation of specific 
interactions is underused used in the clinic, especially those which act on small 
linear motifs in protein interactions. Currently drug leads with similar are emerging 
for use in the clinic, one if which targets the linear peptide motif binding groove of 
MDM2 oncoprotein (Ray-Coquard et al., 2012). Linear peptide motifs are interesting 
due to their combination of specificity and lack of study. This aspect of protein-
protein interaction could be used in new pathways of drug discovery as currently, 
this dynamic system is yet to explore. 
Several other ATP mimetic molecules have been developed with the hope that they 
are highly specific for their target. As ATP is so ubiquitous in the cell, it is complex to 
ensure that the small molecules designed to bind into the binding sites on these 
proteins are specific and do not have several off-target effects. Many kinase 
inhibitors have been developed as ATP mimetics, in the past, these were designed 
and then discovered to target multiple enzymes, although this was through to be 
positive. However, more recently an increase in specificity has been required as the 
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understanding of protein interaction pathways is revealed (Knight and Shokat, 
2005). There have been many ATP competitive small molecules developed as 
phosphatidylinositol-3-kinase (PI3K) inhibitors, this is due to PI3K having a 
prominent role in many cancers due to the Akt/mTOR pathway. Currently, eight 
PI3Ks that have been identified and these small molecules have varying binding to 
each of the proteins (Liu et al., 2017). This is an important example in drug 
development as the ‘off-target’ binding to proteins which are highly similar to the 
protein of interest can cause unwanted effects. The methodology used here, with 
the use of in silico screening, enables comparison of binding between a single small 
molecule and many binding pockets could help in the future for more specific drug 
targeting. Recently, an ATP mimetic called Sorafenib has been developed as an 
inhibitor of Reptin (Nano et al., 2020), however, this small molecule does not appear 
to have an affect on the overall conformation of Reptin as we see with Liddean. This 
inhibitor is known to reduce ATPase activity. It would be interesting to compare the 
affects of the two small molecules. 
Other AAA proteins have also had small molecules developed with Walker A and B 
binding in mind. Using the previously published crystal structures, in a similar way to 
which LIDAEUS does, small molecules have been developed which should have 
able to avoid resistance by looking at possible mutations which could occur in the 
binding pocket of proteins, specifically spastin (Mitchell and Matsumoto, 2011).  
The ability to target small molecules to specific protein-protein interactions has been 
further advanced by the use of tools like LIDAEUS. As we are now able to use 
virtual screening to test whether a particular small molecule is likely to bind to a 
specific interface, it is possible to look at the interfaces between two proteins in the 
same complex which would normally be thought of as being inaccessible and design 
small molecules which will bind directly, blocking interaction (Wu et al., 2019). This 
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use of super-computing as part of drug development is increasing in popularity due 
to its speed and reduction in costs (Mitchell and Matsumoto, 2011). Focusing on a 
specific protein-protein interaction gives a greater standing of the likely side effects 
and possible efficacy of blocking a particular stage in the pathway (Fotis et al., 
2018). These larger screening mythologies also allow for drugs which have already 
been developed and have gained approval to be tested in silico for use with other 
interactions and diseases.  
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 Developing antibodies to 
distinguish between different 
oligomeric states of Reptin 
Some of the work in this chapter was published in 2015 in Chemical Science as a 
collaboration between the laboratories of Ted Hupp and Nicholas Westwood (Healy 
et al., 2015).   
4.1 Introduction 
Antibodies are often used to identify proteins in vivo and in vitro, in both research 
and medicine. There are many biochemical assays which use antibodies to identify 
the presence of a protein of interest, such as in ELISAs assays (Engvall, 1980), or 
localisation of a protein of interest, such as immunofluorescence (Donaldson, 2015). 
Antibodies are also used in a clinical setting for both diagnostic and treatment 
purposes. For diagnostic purposes, antibodies can be used to detect particular 
proteins within bodily fluids, for example, human chorionic gonadotropin is usually 
present in the urine of pregnant women during the first trimester (Butler et al., 2001). 
Another use of antibodies in a diagnostic setting can be to detect a patients’ 
immunoglobulins which can be indicators of specific illnesses and diseases. The 
therapeutic use of antibodies is also widespread, they can be used to treat several 
diseases including arthritis, chon’s disease and cancers (Scott et al., 2012) (figure 
4.1).  
Development of many of these biological techniques and therapeutic uses is made 
is easier when there are multiple antibodies for a single protein of interest. 
Monoclonal antibodies have defined single epitopes on an antigen, therefore these 
can be used to look at changes in conformation or protein interaction if their binding 
site is masked in these different situations. Polyclonal antibodies bind to several 
epitopes on a single antigen, this can be very helpful in protein interaction studies if 
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a monoclonal epitope is blocked, a polyclonal antibody pool is likely to still be able to 
Figure 4.1 Different uses of antibodies.  
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bind due to the vast number of epitopes, allowing for constant detection of the 
protein of interest. These are visualised in figure 4.2A. 
 The molecular structure of antibodies and their 
derivatives 
Antibodies are large proteins, around 150 kDa in total. They are composed of 4 
polypeptide chains, two heavy and two light chains, each containing variable and 
constant regions, creating the ’Y’ shaped molecule (figure 4.2B). More recently, the 
development of alternatives to antibodies has been carried out, these include the 
production of Fab fragments, single-chain variable-fragments (ScFv) and VH/VHH 
(figure 4.2C). Fab fragments are the largest of these derivatives and contain the 
variable regions as well as constant regions as a linker. ScFv is smaller, normally 
between 25 kDa and 35 kDa, and contain just the variable regions. VH/VHH contain 
just a single variable region (Bird and Webb Walker, 1991). These smaller 
derivatives have several advantages over full-sized antibodies including being able 
to be synthesised in bacterial rather than animal systems. Another advantage of 
ScFv and VH/VHH is that they lack the constant regions which tend to be specific to 
the animal in which the antibodies are made in, and therefore are more likely to be 
identified as foreign by the immune system.  
ScFv can be used in a form of phage display where the variable fragments are 
expressed on the protein coat of bacteriophage. In phage display, a library of these 
bacteriophages, each expressing different ScFv on its protein coat, can be used to 
determine the number of ScFv that have an affinity for a protein of interest. Once the 
selection has occurred, the ScFv can be sequenced and then developed for use in 
other protocols, such as immunofluorescence, ELISA and PLA (Jain et al., 2016). 
 
  83 
 Use of antibodies in a therapeutic setting 
Figure 4.2 Schematics of antibodies  
A) Difference between a monoclonal and polyclonal antibody. B) Schematic of full-
length antibody containing a heavy and light chain. C) Difference between Fab 
fragments, ScFv and VHH/VH 
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The first monoclonal antibody therapy was licenced in 1986 (Liu, 2014),m since then 
many more have come to the market, currently, there are over 80 (Bates and Power, 
2019) in use, many of which have roles in cancer for diagnostics and therapeutic 
purposes (Scott et al., 2012). However, there are several commonly occurring 
problems with these including clearance times from the bloodstream, non-specific 
binding to normal organs and tissues and low efficacy. Due to their much smaller 
size, ScFv exhibits unique properties which mean they are not subjected to the 
same issues which affect larger antibody fragments and whole antibodies. ScFv is 
much less likely to be recognised and removed by the immune system (Kholodenko 
et al., 2017). Also, they are much easier to produce due to their ability to be 
expressed and purified from bacteria in high volumes at lower costs (Fernandes, 
2018).  
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4.2 Aims  
The experiments in this chapter aim to develop tools to help measure a change in 
oligomeric state. In Chapter 3, Liddean was developed and it was shown that this 
small molecule was able to induce an oligomeric change in the Reptin protein. We 
know that Reptin and Pontin form complexes in cells and this is well documented, 
but it is currently not possible to visualise oligomeric Reptin.  
We want to investigate: 
• If it is possible to create antibodies able to distinguish between the 
oligomeric forms of Reptin 
• If we can develop single chain antibodies which are specific to Reptin when 
bound to specific partners, either small molecules or other proteins 
• If we can use these single-chain antibodies in current methodologies, such 
as proximity ligation assays, to determine the oligomeric state of Reptin 
inside cells and whether this is localisation specific  
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4.3 Visualising Reptin and its binding partners in 
cells 
In the previous chapter, we looked in detail into the interactions of Reptin and its 
known binding partners in vitro. Using a combination of immunofluorescence and 
proximity ligation assays we can observe the same interactions in cells. 
Visualization of Reptin and its known binding partners has previously been studied 
in the lab (Healy et al., 2015).  
 Localising protein interactions with Proximity ligation 
assays 
To confirm the interaction between Reptin and its binding partners' proximity 
ligations assays were utilised. In this experiment, a signal is only observed when the 
two proteins of interest are in very close proximity with each other either directly 
interacting or as part of the same complex (Clausson et al., 2011, Gullberg et al., 
2004). The interactions between Reptin and Pontin and Reptin and p53 can all be 
confirmed in vivo using this technique.  
In brief, a cell was grown on coverslips and then transfected with either DMSO or 
Liddean with the Attractene carrier (Rena et al., 2004) (as seen in Chapter 3, figure 
3.7) and incubated for 24 hours. Cells were fixed with 4% paraformaldehyde. The 
samples are permeabilised before unspecific antibody binding is blocked with the 
addition of 3% BSA in PBS. Primary antibodies raised against your target antigens 
are incubated with the samples, one polyclonal and one monoclonal raised in 
different animals.  PLA probes were added to cells and incubated to 1 hour at 37°C. 
The ligation mix was added for 30 minutes at 37°C followed by the polymerase 
amplification mix for 2 hours at 37°C. Coverslips are then mounted onto slides 
before imaging using a BX51 (Olympus) Fluorescent microscope. 
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We can visualise foci which are a result of the interaction between Reptin and p53 
(figure 4.3B, control seen in 4.3A), here we can see that the foci are almost 
exclusively present in the nucleus of the cell, this correlates with previously 
published data on the localisation of these two proteins. We could not visualise 
Reptin and AGR2 at the same time due to the antibodies available, for three-
channel imaging, the primary antibodies must be raised in different animals.  
When investigating the effect the presence of Liddean has on the protein-protein 
interactions of Liddean we looked specifically at the Reptin-Pontin interaction. Here 
we can see that in the absence of Liddean, Reptin-Pontin foci are found in the 
nucleus of the cell but after 24 hours exposure to 2mM Liddean results in the 
shuttling of these foci into the cytoplasm of the cell (figure 4.3C). The quantification 
of this experiment is seen in figure 4.3D (grey bars – cytoplasmic, white bars - 
nuclear), here we can also see that 2mM Liddean appears to reduce the total 
number of Reptin-Pontin foci but in 1mM Liddean they remain at a similar level to 
the control; however, we still see the shift of the foci into the cytoplasm of the cell. 
The number of foci was counted by hand, using the DAPI staining to qualify whether 
a spot was nuclear or cytoplasmic.    
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Figure 4.3 Proximity ligation assays (PLA) between Reptin and various 
binding partners in HCT116 cell line. 
A) Control PLA using no primary antibodies. B) PLA of Reptin-p53 interaction, PLA foci in 
green channel with DAPI used to localise nuclei. C) The effect of Liddean on Reptin-Pontin 
interaction. DAPI used to localise foci as nuclear or cytoplasmic in either DMSO or 2mM 
Liddean treated cells. D) Quantification of number of Reptin foci localised as either 
cytoplasmic (grey bar) or nuclear (white bar). (Healy et al., 2015) 
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4.4 Antibody phage display to produce single chain 
antibodies for Reptin analysis 
Development of a single-chain variable-fragment (ScFv) library specific to Reptin will 
allow for more robust investigation of Reptin in vivo and in vitro. Due to a 
combination of epitopes, it should be possible to determine different oligomeric 
states of Reptin. 
 Development of Reptin specific ScFv 
A single-chain variable-fragment (ScFv) library expressed on the coat of 
bacteriophage was created previously in the lab (Jain et al., 2016). A novel library of 
ScFv was extracted from naive canine spleens using extracted RNA. PCR was used 
to amplify the heavy and light variable regions before being ligated into phage 
display vectors. The Phagemid vectors were then transformed into E. coli for the 
production of the bacteriophage expressing the ScFv on its protein coat. The 
resulting ScFv bacteriophage library was used to aid the creation of a Reptin 
specific ScFv library. 
A schematic of the panning process can be seen in figure 4.4. In brief, Reptin and 
AGR2 were bound to wells overnight. The library was precleared against the 
opposite condition, to remove ScFv which had a high binding affinity to protein in 
general, this was incubated for 1 hour. Here I did not use Liddean as I wanted to 
create a library of ScFv able to recognise all oligomeric forms of Reptin, not just the 
form induced by Liddean binding. The precleared library of phage was added to the 
well containing the protein of interest and incubated for 1 hour. Unbound phage was 
washed away and then the bound phage is eluted. The eluted phage was amplified 
and then used for a second round of panning in the place of the library. A third-
round was also carried out, in the same manner, using the amplified phage from the 
second round as the input. 
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Figure 4.4 Panning process for antibody phage display.  
Cycle of panning showing rounds of amplification and elution used to develop 
ScFv. Different expressing ScFv on the protein coat can be seen as different 
coloured circles. The protein of interest is seen as a red ball, bound to different 
ligands (yellow hexagon and green star) resulting in different conformations of the 
protein of interest.  
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Once three rounds had been carried out, the affinity of the bacteriophage for Reptin 
was carried out using AGR2 as a negative control to check the specificity of the 
phage pools (figure 4.5). Here we can see the specificity of the pools increased over 
the rounds and that there is a reduction in the amount of phage able to bind Reptin 
in the presence of Liddean compared with Reptin only. This was encouraging and 
could mean that there is conformation-specific ScFv in the polyclonal pools. 
To develop ’monoclonal’ ScFv, the round 3 polyclonal pool for Reptin was used to 
infect bacteria before being plated out to hopefully form colonies expressing a single 
ScFv. 96 colonies were picked and grown-up similarly to the polyclonal pools before 
being tested for binding against Reptin and Reptin + Liddean. The results of these 
experiments can be seen in figure 4.6 showing the three graphs containing the 
binding of all 96 ‘monoclonal ScFv’, 1-32, 33-64 and 65-96. 
The ‘12 top binders’ were then tested in a protein-protein binding experiment using 
the ScFv to detect Reptin bound to AGR2 (figure 4.7). This allowed observation of 
whether these ScFv could be used in established protocols. Many of the ScFv was 
seen to be able to detect the presence of Reptin in this protein-protein binding 
assay. 
Previously designed primers were to extract the ScFv sequences for sequencing by 
Source Bioscience. From the 12 available ScFv, 6 produced PCR products that 
gave readable sequences, these can be seen in figure 4.8. From these 6 
sequences, we can see that we had purified 5 different ScFv, 21 and 59 have 
identical sequences in both the heavy and light chains but all others have different 
sequences. The FR regions are framework regions that do not have variation, but 
the CDR regions are the variable regions which are responsible for binding. There is 
also a linker which combines the heavy and light chain variable fragments, this is  
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Figure 4.5 Testing Polyclonal Phage Pools for Specific Binding 
Testing ScFv Polyclonal phage pools from multiple rounds against Reptin and AGR2 (used 
as control protein) in presence and absence of Liddean. 
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Figure 4.6 Testing Monoclonal Phage Pools for Specific Binding 
Monoclonal phage developed from pools binding to Reptin in presence and absence of 
Liddean 
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Figure 4.7 Using monoclonal phage against Reptin to identify Reptin bound to AGR2. 
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Figure 4.8 Sequences of monoclonal phage aligned showing CDR domains which are 
responsible for binding affinity of ScFv 
Identical amino acids are identified with *, similar amino acids are highlighted with :, weakly 
similar amino acids are highlighted with . 
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required as they would not be found in the same polypeptide chain in the full-length 
antibody. 
 Mapping and testing binding of ScFv to Reptin in 
different states 
These monoclonal ScFv were then tested to see where they were binding to the 
Reptin sequence. The peptide mapping combined overlapping Reptin self-peptides 
in groups of 5 to create ‘regions’ of Reptin. The ScFv was then tested to see which 
region they bound to (figure 4.9A). Here we can see that some of the ScFv do not 
appear to bind to any of the peptides, their epitope is likely to not be a linear epitope 
but a structural one, these ScFv could be useful when investigating conformational 
change. Their epitopes could be mapped using other techniques such as hydrogen-
deuterium exchange mass spectrometry. 
Several ScFv can be seen to bind to peptides 1-5, this could be due to the sticky 
nature of peptide 3, as seen in Chapter 3 figure 3.4C. This experiment should be 
repeated omitting peptide 3 from the 1-5 well and a peptide 3 only well would 
confirm this. ScFvs 4 and 25 can be seen to bind to different regions of Reptin, 
peptides 21-25 and peptides 31-35 respectively, the level of binding here is much 
higher than the background seen with the other ScFv. As these two were found to 
have different binding sites with a strong affinity it was decided to map these binding 
sites onto the crystal structure of Reptin (figure 4.9B).  
Following this, these ScFv were selected for mammalian cell expression in addition 
to ScFv 21. To achieve this, these sequences were ordered for synthesis, with the 
addition of a CD20 tag to allow easier identification and purification. The sequences 
were restriction cloned into pSF-CMV vector for mammalian expression (figure 
4.10A). The result of this expression can be seen in figure 4.10B, with ScFvs 21 and 
25 expressing well. It was not possible to express ScFv 4 under these conditions 
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Figure 4.9 Mapping ScFv binding sites on to Reptin. 
A) Mapping ELISA to gain information on the epitopes which each ScFv recognize. B) Sites 
mapped on to 3UK6 structure. The chain in green is a single monomer. ScFv 4 binding site 
in orange, ScFv 25 binding site in blue and several ScFv binding site in red. Adjacent 
monomers can be seen in beige and pale blue. 
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Figure 4.10 Expressing ScFv in Bacteria.  
A) Map of plasmid used to express ScFv in bacteria B) Western blot of purified ScFv grown 
in bacteria. 
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and more optimisation is required however the sequence of the ScFv 4 vector was 
seen to have no mutations.  
Unfortunately, due to time constraints and techniques still being developed in the 
Hupp laboratory, it was not possible at the time to carry on with this work, however, 
the results seen here are very promising that the ScFv developed using this assay 
would be able to bind different oligomeric forms of Reptin.  
 
  100 
4.5 Discussion 
Visualisation of the Reptin protein and its binding partners has been achieved in 
cells using immunofluorescence, from this we can see that both Reptin and its 
binding partners localise to the same regions of the cell.  
To confirm the interaction between Reptin and its binding partners' proximity 
ligations assays were utilised. In this signal is only observed when the two proteins 
of interest are in very close proximity with each other either directly interacting or as 
part of the same complex. The interactions between Reptin and p53 and Reptin and 
Pontin could both be confirmed in vivo using this technique. Here we can see that 
the addition of Liddean had an effect of the localisation of the interaction between 
Reptin and Pontin.  
Here, the development of 5 individual single-chain variable-fragments (ScFv) which 
bind Reptin protein has been achieved. Starting with these 5, it would now be 
possible to create a new Reptin specific library which can be expressed in bacteria, 
without the need for the bacteriophage or the use of mammals. This library could be 
further expanded by using the sequences of the 5 ScFv, the different heavy and light 
chains could be rearranged and reordered. For example, the heavy chain from ScFv 
4 could be partners with the light chain from ScFv 21 creating a new single chain. 
This could then also be reordered so that when it is expressed instead of the fusion 
protein being heavy-chain – linker – light-chain, we could have light-chain – linker – 
heavy-chain. This small difference has been observed to change the binding affinity 
of an ScFv. This would mean we could have a library of up to 50 single-chain 
variable fragments able to bind Reptin. This Reptin specific library could then 
undergo testing to look at changes in binding epitopes and affinities. The ability to 
have several antibodies which can recognise different conformations of Reptin 
would be very beneficial.  
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The epitopes were mapped using a peptide binding assay, this showed that there 
was variation in binding sites. The ScFv which bound to peptides 1-5 could be 
further investigated for specificity to Reptin, measuring their binding to peptide 3 and 
peptides 1, 2, 4, and 5 separately. To investigate the further these epitopes were 
mapped onto the 3D structure of oligomeric Reptin showing that although the 
epitopes for several ScFv (peptides 1-5, red) and ScFv 25 (peptide 31-35, blue) are 
both exposed on the surface of hexameric Reptin, the epitope for ScFv 4 (peptides 
21-25, orange) is hidden in the hexamer. This then means that this single chain 
could be used to identify monomeric forms of Reptin in vivo and in vitro.  
In the future, these single-chain variable fragments could be the first specifically 
designed to look at changes in oligomeric state of a protein. The ability to recognise 
and localise the monomeric form of Reptin would be very beneficial as it may be this 
form of Reptin which is oncogenic. Hexameric Reptin is well characterised due to its 
high stability within the cell, especially its interactions with Pontin, however, as we 
have previously seen different binding affinities with Reptin for p53 and AGR2 in the 
presence of ligand, this too could be the state in cells. Combining the Reptin specific 
ScFv library and proximity ligation assays may give an insight into the amount of the 
Reptin pool which is involved in each protein-protein interaction. It would also allow 
an investigation into changes due to drug treatments, stress and stages of the cell 
cycle.  
Due to the size and easy expression of ScFv, they are much more suited for use in 
a clinical setting that full-length antibodies. The lack of constant regions makes them 
less immunogenic, as does their expression in bacteria. Nanobodies can also be 
developed from a single-chain variable fragment by taking either the heavy or light 
chains. These tend to be much less stable but are more applicable for use in the 
clinic due to their smaller size and lack of a linker region. It is possible to develop an 
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immunity against the linker region, targeting the ScFv for destruction by the immune 
system. Thus, in a clinical setting, ScFv is probably superior to full-length antibodies, 
however, nanobodies are likely to be the future of this type of therapy due to their 
smaller size and lack of immunogenic regions. 
The use of antibody phage libraries to discover novel biologics is still in 
development. This technique has revolutionised the field of immunovirology. It is 
both robust and versatile, as is shown here by being able to develop multiple single 
chains to a single protein in one experiment. There is an increasing amount of work 
occurring veterinary field with regards to the use of antibody phage display as, for 
disease in animals, antibodies made in animals are thought to be considered 
economically impractical. With the development of phage display techniques, this 
financial burden is reduced (Bashir and Paeshuyse, 2020). The primary focus has 
tended to be on use as diagnostics but their potential use in therapeutics exceeds 
this usefulness. The work carried out here shows the ability of this technique to 
distinguish between two versions of the same protein. This could be used to 
distinguish mutations, changes in conformation or oligomerisation or protein 
interactions which are crucial to disease.  Due to being recombinantly expressed 
they are highly modifiable and could also be used in drug delivery systems with 
advanced in Click Chemistry (Pisa et al., 2019).   
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 The impact and significance of 
ligands on the linear peptide 
binding activity of Reptin using 
combinatorial peptide libraries 
Some of the work in this chapter was published in 2015 in Chemical Science as a 
collaboration between the laboratories of Ted Hupp and Nicholas Westwood (Healy 
et al., 2015).   
5.1 Introduction 
In Chapters 3 and 4, it has been shown that there are specific changes in protein-
protein interactions with the addition of ligands, for example, figure 3.3C and 3.3D 
where we were examining changes in Reptin binding to p53 and AGR2 respectively 
when Reptin had previously been incubated with a variety of small molecules.  
 Combining Peptide Phage Display (PPhD) and Next-
Generation Sequencing 
Using Peptide Phage Display (PPhD) and Next-Generation Sequencing this change 
in binding affinity can be investigated further by looking specifically at short peptide 
motifs (Matochko et al., 2012, Dias-Neto et al., 2009). The PPhD technique uses a 
commercially available library of peptides which are expressed on the protein coat of 
bacteriophage, this is available with 7mer and 12mer peptides from NEB. The 
peptide expressing bacteriophage are exposed to protein bound to a well or tube in 
the same manner as other interaction assays, this is known as the panning steps. 
The bound bacteriophage is collected and amplified for subsequent rounds of 
panning to enrich for strongest binding peptides. In traditional experiments, the 
specific bacteriophage is selected by plating of eluted phage and sequenced to give 
a comparatively low number of binding peptides, normally between 100 and 1000 
peptides are sequenced from the third round of panning, with less than 100 being 
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unique (Scott and Smith, 1990). In our protocol we extract the DNA from the whole 
pool of eluted phage, amplifying the fragments which correspond to the peptide 
expressed on the protein coat, allowing for millions of sequences to be obtained.  
 The importance of short linear motifs in protein-protein 
interactions 
Discovery of new protein-protein interactions is a complex process as many of these 
interactions are highly transient. Many protein-protein interactions appear to use 
motifs to allow one protein to have many binding partners. These specific, short 
motifs are linear and do not require a three-dimensional organisation for their 
recognition. These short motif sequences allow some level of variability between the 
sequence in the different proteins but the overall pattern to remain the same, these 
are known as consensus sequences. This means that several proteins can contain 
the same short, conserved motif, which is used by their binding partner to recognise 
and target the protein interaction, this is very common for phosphorylation where 
each kinase is thought to have a specific sequence on its target which pinpoints the 
location of the addition of a phosphate group (Aitken, 1999).  
The importance of these short linear motifs and their flanking amino acids was 
observed in Chapter 3 with regards to Reptin protein binding to the overlapping 
peptide library created from the amino acid sequence of Reptin. In figure 3.4B we 
saw that although peptides 27, 28 and 29 (APVLIMATNRGITRI, 
GITRIRGTSYQSPHG and QSPHGIPIDLLDRLL) were all overlapping there was a 
large difference in the binding. There was a large increase in binding between 
peptide 27 and 28, showing the effect of accessibility of a particular sequence of 
amino acids. This high binding was completely abolished with peptide 29 showing 
that a motif of interest must have been contained within the overlap between 
peptides 27 and 28. During this Chapter, we also saw, in figure 3.5 that even very 
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strong binding can be attenuated when the protein of interest is incubated with a 
ligand.  
 Peptide Phage Display 
The concept of peptide phage display was first published in 1985, looking at 
expressing specific amino acid sequences on the protein coat of the phage, P3 
(Smith, 1985). From this initial idea, there were several groups which showed that it 
was possible to express random peptides on the protein coat on P3 creating the first 
peptide phage display libraries (Scott and Smith, 1990, Devlin et al., 1990, Cwirla et 
al., 1990). In the following years, many developments were using different phages 
as the carrier for the library. As mentioned above it is now possible to obtain ready-
made libraries commercially.  
Using the peptide phage display technology, I performed and experimented 
comparing apo Reptin, Reptin with ADP and Reptin with Liddean. I then used next-
generation sequencing to identify peptides which were bound to the different 
conditions. The computational analysis allowed in-depth investigation into the large 
datasets. From this, it was clear the particular motifs were conformationally 
dependant whereas others are not and show strong binding independent of ligand 
presence. 
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5.2 Aims 
The experiments in this chapter aim to focus on changes in protein interactions and 
linear peptide-binding motifs of Reptin when it is exposed to ligands.  
We want to investigate: 
• The impact of ligand binding on linear peptide-binding motifs 
• If peptide phage display can be sued to find or confirm protein-protein 
interactions 
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5.3 Carrying out peptide phage display 
A schematic of the panning process can be seen in figure 5.1A. In brief, Reptin has 
bound to the well overnight either alone, or in the presence of ligands. The library of 
phage was added to the well containing the protein of interest and incubated for 1 
hour. Unbound phage was washed away and then the bound phage is eluted. The 
eluted phage is amplified and then used for a second round of panning in the place 
of the library. Once completed, the sequenced of the phage are extracted and bar-
coded by PCR to each round and condition, a schematic for the location within the 
phage genome of the expressed peptide in the protein sequence and the primers 
used can be found in figure 5.1B. The PCR fragments, which can be seen in figure 
5.1C, were extracted from the gel and sent for Next-Generation Sequencing. The 
library was also sequenced to ensure diversity from the offset.  
The experiment was carried out twice as the sequencing of the library itself showed 
a lack of diversity on the first screen. The library in the second screen was seen to 
have a might higher diversity and the data from this screen was examined in much 
more detail. 
 Analysis of the first peptide screen 
Even though the library was seen to have a lack of diversity it was decided that 
there still may be the opportunity to find linear binding motifs from this screen. As 
next-generation sequencing was used, a large number of peptides were still 
obtained despite the reduction in the variety of peptides expressed on the coat of 
the phage. Previously published data used libraries that were not subjected to next-
generation sequencing and therefore their diversity was not unknow, due to this it 
was decided to still probe this data for possible linear peptide motifs. 
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Using MEME SUITE (Bailey et al., 2009), the peptide lists were subjected to 
Figure 5.1 Peptide phage display methodology 
A) Cycle of panning showing rounds of amplification and elution used to get specific binding 
peptides. Different expressing peptides on the protein coat is shown as different coloured 
circles. The protein of interest is seen as a red ball, bound to different ligands (yellow 
hexagon and green star) resulting in different conformations of the protein of interest. B) 
Schematic for the location within the phage genome (N-terminal of gene III protein) of the 
expressed peptide in the protein sequence, XXXXXXX represent the 7-mer peptide library.  
Amplification of the phage pool DNA ready for next generation sequencing, the primers used 
are shown here with the barcodes for different samples shown as NNN. C) Representative 
DNA gel visualising the bands cut for DNA extraction before being sent for next generation 
sequences. The band of interest can be seen between the 50bp and 200bp markers. With 
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analysis and a selection of motifs found can be seen in figure 5.2, all these motifs 
have a p-value greater than 0.05. We could use this list of motifs to obtain possible 
binding proteins which could be further investigated. All of the motifs shown here are 
found to be in peptides found in the Reptin + Liddean samples compared to Reptin 
only samples. 
One motif of particular interest, found from the peptides obtained in the Reptin 
bound to Ligand samples, is an RER motif (figure 5.3A). This motif is found within 
the sequence of p53, and more importantly than that, can be found one of the 
peptides of p53 which had high levels of binding to Reptin (Chapter 3, figure 3.4B). 
As previously described, the addition of ligand results in an increase in Reptin to 
binding to p53 protein (Chapter 3, figure 3.3C), so the appearance of this motif is 
especially encouraging. This p53 peptide of interest is known as peptide 38 
(YFTLQIRGRERFEMF) which can be seen in figure 5.3B with the location of RER 
highlighted. To investigate the importance of this linear motif in the binding of Reptin 
and p53, a peptide screen was obtained containing variants of peptide 38, firstly an 
alanine scan of the whole peptide and secondly, truncations and both the N and C 
termini to observe how binding was affected, this library of peptides can be seen in 
figure 5.3C. 
The protein-peptide assay, seen in figure 5.3D shows the importance of the 
presence of the RER motif and how important the accessibility of the motif is. The 
changes in the length of the peptide showed how its location is so important. The 
peptide with the highest binding, peptide 24 (YFTLQIRGRER), is the one which 
contains the motif at the C-terminus making it the most freely accessible. We can 
also see how disruption of motif or its adjacent amino acids can affect levels of 
binding. Peptides 6 (YFTLQARGRERFEMF), 7 (YFTLQIAGRERFEMF), 9 
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(YFTLQIRGAERFEMF), 11 (YFTLQIRGREAFEMF), and 12 
Figure 5.2 Top 15 motifs discovered using first Peptide Ph.D screen 
Motifs discovered by subjecting the peptides found in the Reptin + Liddean samples 
compared to Reptin only samples. All these motifs have a p value greater than 0.05. The 
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(YFTLQIRGRERAEMF) all show an abolition in Reptin protein binding. Here we can 
Figure 5.3 RER motif discovered in p53 
A) RER motif as given by MEME SUITE (Bailey et al., 2009).  B) Amino acid 
sequence of Peptide 38 of p53 with RER motif highlighted. C) Library of peptides 
developed from peptides 38 including alanine scan and truncations. D) Peptide-
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see the disruption of either arginine residues (peptides 9 and 11), as well as 
changes in the amino acids flanking the motif, tend to result in loss of binding. 
Peptide 8 (YFTLQIRARERFEMF), whose mutation is directly before the RER motif, 
appears to be unaffected in its binding level. Conversely, peptides 10 
(YFTLQIRGRARFEMF) and 13 (YFTLQIRGRERFAMF) both appear to have a large 
increase in binding affinity, this is noteworthy because this shows that this 
consensus sequence is more likely to be an R-X-R motif as the mutation of the 
central amino acid resulted in an increased in binding.  
The screen shows how changes in a single peptide, either with an alanine scan or 
shortening of the peptide, can have a drastic effect on the strength of an interaction. 
These short motifs are often highly specific and are not very flexible with regards to 
mutation. There are several diseases which are the result of point mutations, for 
example, sickle cell anaemia is caused by a single nucleotide change resulting in 
the peptide chain containing valine rather than a glutamic acid, this changes the 
charge of the amino acid causing a conformational change in the result of the 
peptide chain (Elion et al., 1992).  
 Analysis of second peptide screen 
The sequencing for the library used in this screen was found to be much more 
diverse than that of the first screen. This allowed for bioinformatic analysis of the 
next-generation sequencing data from the second screen was carried by Stuart 
Aitken (IGMM Bioinformatics Core Facility).  
Figures 5.4 and 5.5 show the results of this analysis and were created by Stuart 
Aitken. Figure 5.4A shows the percentage of sequences which were obtained for 
each of the conditions relative to one another, AAA is the library itself. From this 
data, it is possible to see that the number of peptides sequences in each condition is 
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skewed away from the Reptin-Liddean samples. We can see that there is an 
Figure 5.4 Bioinformatic analysis of second peptide phage display screen. 
A) Pie chart showing the percentage of sequences which were obtained for each of 
the conditions relative to one another, AAA is the library, Reptin, Reptin-ADP and 
Reptin-L(iddean). B) Comparison of the depth of sequence between samples. C) 
The Number of unique peptides in each of the samples across the rounds, the 
average of the library is also shown. D) Total number of unique peptides across 
the different rounds for Reptin-ADP. Peptides which only appear in one round or 
just the library (blue), peptides found in the subsequent round (green) peptides 
seen in the previous round (red), peptides found in both earlier and later rounds 
(orange). E) Normalised read counts for the six most highly expressed peptides in 
Reptin-ADP. SYQSHYY, VSYQSSR, FTSYQAS, NERALTL, WSYQSPS, 
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equality between the number of sequences sequenced in each sample, for each 
Figure 5.5 Volcano plots comparing peptides seen under different 
conditions.  
A) Library with Reptin-ADP round 3. B) Reptin round 3 with Reptin-ADP round 3. 
C) Library with Reptin-Liddean round 3. C) Reptin round 3 with Reptin-Liddean 
round 3. Diagonal lines represent the average correlation between the two 
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round of panning, except the Reptin-Liddean sample from round 2 (Figure 5.4B), the 
reduction in the size of this sample explains the reduction in the number of 
sequences overall for all rounds, seen in the pie chart in figure 5.4A, in comparison 
to the other experimental conditions. 
The number of unique peptides in each of the samples is probed in figures 5.4C and 
5.4D. In figure 5.4C we see the Reptin-Liddean samples (yellow cross) appear to 
have many more unique peptides than the others, this is opposing with the other 
ligand-bound form of Reptin, Reptin-ADP, which appears to have the least number 
of unique hits. The large number of unique peptides seen in all conditions means 
that there are specific binding profiles for each of the forms of Reptin. The bar chart 
in figure 5.4D shows the total number of unique peptides across the different 
rounds, this time looking specifically at Reptin-ADP. In blue we have highlighted 
those which only appear in one round (or just the library), those that are found in the 
subsequent round in green, those that have been seen in the previous round in red 
and those that are found in both earlier and later rounds in orange. Here we can 
observe that many of the peptides are only sequenced in a single round, however, 
the number of unique peptides decreases over the rounds, showing an increase in 
specificity as we perform the rounds of panning. This analysis was not possible for 
the Reptin-Liddean samples due to the lack of data from the second round of 
panning. 
Normalised read counts for the six most highly expressed peptides in Reptin-ADP 
are found in figure 5.4E and are shown by crosses. The circles show the number of 
reading counts from the Reptin only samples for the same peptides and the parallel 
lines represent the levels observed for these particular peptides in the library. Their 
sequences are as follows - SYQSHYY, VSYQSSR, FTSYQAS, NERALTL, 
WSYQSPS, GLSYQSP. We can see follows how the read counts are amplified for 
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each peptide throughout the rounds showing the increase in specificity if these are 
true binding peptides of Reptin.  
The volcano plots in figure 5.5 compare the results from the different conditions to 
the library itself and the Reptin conditions. The conditions compared were the library 
and the Reptin-ADP round 3 sample (figure 5.5A), the Reptin sample with the 
Reptin-ADP sample, both from round 3 (figure 5.5B), the library and the Reptin-
Liddean round 3 sample (figure 5.5C), the Reptin sample with the Reptin-Liddean 
sample, both from round 3 (figure 5.5D). Due to the shape of these plots, it is 
possible to suggest that we do see a combination of peptides which are binding 
under all conditions in addition to those which are specific to each condition (outlying 
points). The diagonal lines represent the average correlation between the two 
samples. 
Peptides were ordered for commercial synthesis to see if the amino acid sequences 
observed to have variation in their binding to the different forms of Reptin in the 
screen could also do so in peptide-protein binding assays, in a similar manner to 
those performed in Chapter 3, figure 3.4. Figure 5.6 shows many different peptides 
binding to Reptin in the absence and presence of Liddean. H6, a peptide from AGR2 
which shows the reduction in binding on the addition of Liddean, is used as a control 
on both sets of samples (peptide 1). Figure 5.6A shows peptides selected as binding 
to Reptin in the absence of ligand, these do a variation, some are seen to have a 
reduction in binding in the presence of ligand whereas others can be seen to have 
increased binding. In contrast, those peptides selected as Reptin-Liddean binders, 
in figure 5.6B, do consistently show an increased affinity for Reptin in the presence 
of ligand. 
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Figure 5.6 Reptin binding to synthesized peptide phage display peptides in the 
absence and presence of Reptin.  
A) Peptides designated Reptin only binders. B) Peptides designated as Reptin-Liddean 
binders. 
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5.4 Discussion 
Combining peptide phage display and next-generation sequencing allowed for a 
much deeper screen of peptides which can bind to Reptin than would have been 
possible with the traditional method of sequencing individual bacterial colonies 
infected with phage.  
In the first screen, we were able to identify several binding motifs, one of which, 
RER (figure 5.3A), was then used to identify a possible binding interface between 
Reptin and p53. Following on from the studies in Chapter 3, I already knew that 
these two proteins were able to bind one another in both the protein-protein and 
peptide-protein interaction assays. Using an overlapping peptide library from the p53 
sequence we identified two peptides from p53, peptide 31 (RNSFEVRVCACPGRD) 
and peptide 38 (YFTLQIRGRERFEMF) which had a high binding affinity for Reptin. 
When comparing these two peptides to the results of this screen we identified the 
presence of the RER motif in peptide 38 (YFTLQIRGRERFEMF).  
To enable confirmation of the importance of this peptide and motif a peptide library 
was created for peptide 38 containing an alanine scan and truncated peptides 
(figure 5.3C). This assay showed the importance of this site in the binding interface 
between Reptin and peptide 38. Also, it revealed the possibility of a more complex 
binding motif at this site.  
Due to the greater diversity in the library used in the second screen, it was possible 
to perform a more complex bioinformatic analysis of the data. This analysis enabled 
confirmation of specific pools of peptides which can bind to Reptin under different 
conditions (figure 5.4). We can also observe how specific peptides are enriched for 
binding throughout the experiment.  
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From the bioinformatic analysis, several peptides were selected as binding to Reptin 
in a single condition. These peptides were then synthesized for testing in the same 
manner as is chapter 3. From this assay, there is a diversity of results from the 
different peptides showing a landscape of Reptin binding affinities.  
In this chapter novel binding peptides have been identified for their ability to bind 
Reptin. It has also been possible to map a possible binding interface between 
Reptin and p53. The next step for this investigation would be to the first model and 
then mutate the residues IRGRERFE on the binding of Reptin protein to peptide 38 
in the full length p53 protein and observe the changes in protein-protein interaction. 
If the results seen in the protein-protein assays mirrored the results from the 
peptide-protein assays, then it is likely that these residues on p53 are the binding 
site for Reptin. 
Reptin is known for interacting with many chromatin and chaperonin signalling 
proteins. The techniques used here provided novel insights into the protein-protein 
interactions of Reptin. With further, more detailed analysis, it may be possible to 
create an entire Reptin protein-protein interaction network, using the motifs 
discovered to identify novel binding partners, this has previously been done using 
phosphorylation dependant signalling (Miller et al., 2008). The small linear peptide 
motifs can form dynamic and highly specific docking sites on one protein for another 
protein (Van Roey et al., 2014, Tompa et al., 2014). Small molecule stabilisation and 
destabilisation, as we see here, provides a promising approach towards the 
modulation of protein functions on a much larger scale (Jubb et al., 2012). An 
example of this is a linear peptide motif which binds into a groove on the surface of 
MDM2 has been developed for use in the clinic as an MDM2 inhibitor, allowing 
activation of the p53 pathway to decrease proliferation in tumours (Ramasamy et al., 
2014).  
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Small linear peptide motifs form a vast and largely untapped landscape in both 
scientific research and the clinic (Basse et al., 2013). Approaches focusing of the 
importance of these small linear peptide motifs provide new possibilities for drug 
discovery (Ramasamy et al., 2014, Kumar et al., 2020) and there is emerging 
information that proteins, such as Reptin, which have a large number of binding 
partners, may exhibit features making them linear motif binding hub proteins able to 
help regulate the large protein complexes which they form part of (Jespersen and 
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 Examining changes in protein 
oligomerisation and conformation 
with the addition of ligands 
Much of the work in this chapter was published in 2019 in Journal of Proteomics as 
a collaboration between the laboratories of Ted Hupp, Borek Vojtesek and Douglas 
Houston (Remnant et al., 2019). Some of the work in this chapter was published in 
2015 in Chemical Science as a collaboration between the laboratories of Ted Hupp 
and Nicholas Westwood (Healy et al., 2015).   
6.1 Introduction  
The super-family of ATPases associated with various cellular activities (AAA+) are 
proteins which all contain a nucleotide-binding domain, the AAA domain, which 
facilitates ligand binding (Snider et al., 2008). It is well documented that members of 
the AAA+ protein family can change conformation when bound to their ligand. This 
change in conformation could mean a change in the protein-protein interactions a 
particular protein takes part in. This could result in changes in the role a particular 
protein plays within the cell and the pathways it is involved in (Weikl and Paul, 2014, 
Keskin, 2007). 
 3D structure of Reptin and Pontin 
Reptin and its homolog Pontin form a heterododecamer. This complex was 
examined using cryo-EM (Lopez-Perrote et al., 2012), in the presence and absence 
of ligand, in this case, ADP and two derivatives. Two conformations have been 
observed in both the apo and ligand-bound complexes. These two conformations of 
the human proteins, a compact and a stretched conformation, are thought to coexist 
to allow regulation of the accessibility of the DNA binding domains. The appearance 
of compact and stretched conformations has previously been observed in yeast 
proteins, and therefore, as Reptin and Pontin are derivatives of yeast RuvB, these 
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conformations can likely be found in vivo as they show so much similarity with RuvB 
itself. These two conformations are thought to be caused by a change in domain II 
of the proteins, the domain which has previously been removed to allow the 
formation of crystals for X-ray crystallography experiments, therefore, removing the 
flexibility of the proteins. If it is this domain is causing two conformations of the 
protein then removal of this domain can allow for a single conformation and 
therefore the creation of crystals with proteins of identical conformation as opposed 
to a mix of two conformations which would not be compatible with the X-ray 
crystallography technique. The conformational change observed in this experiment 
is thought to be due to the need for regulation of DNA or RNA binding. Domain II 
which is thought to contain the nucleotide-binding domain, however, this has not 
been experimentally proven and it only assumed due to the presence of the binding 
motif (Lopez-Perrote et al., 2012). 
 Techniques for measuring conformational change 
It is possible to observe of changes in conformation through many different 
biophysical techniques such as hydrogen-deuterium exchange mass spectrometry 
(Katta and Chait, 1993), ion mobility mass spectrometry (McCullough et al., 2008), 
partial digestion with proteases and native gels. 
6.1.2.1 Hydrogen-deuterium exchange mass spectrometry 
Hydrogen-deuterium (HDX) mass spectrometry (MS) (HDX-MS) (Katta and Chait, 
1993) is a biophysical technique which allows observation of conformational 
changes of a protein or proteins by comparing the amount of deuterium present in a 
peptide before and after specific treatment or interaction. The way this works is that 
the hydrogens exposed to the outside of the proteins exchange rapidly for deuterium 
(“heavy hydrogen”) when they are. Immersed in deuterated/heavy water. The longer 
the protein or proteins of interest are immersed in deuterated water the more 
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deuterated the protein becomes with hydrogen atoms found to be less exposed 
slowly changing over time. This means that use of a time course of exposure can 
give some idea on the overall globular structure of a protein and if this is changing 
with the addition of a binding partner or ligand. A schematic for this process can be 
found in figure 6.1B, here the hydrogen is shown in blue with deuterium marked in 
blue. To stop the exchange both the pH of the solution and the temperature must be 
dropped, this locks the deuterium into the peptide backbone of the protein. For mass 
spectrometry analysis of these proteins of interest, the samples are then digested 
with trypsin (or another well-characterised protease) before being loaded on to the 
mass spectrometer. With peptide sequence in the mass spectrometer, it is possible 
to follow the amount of deuteration on a specific peptide throughout the experiment 
without the need for further labelling with SILAC (Stable Isotope Labelling by Amino 
Acids in Cell Culture (Ong et al., 2002)) or TMT (Tandem Mass Tag (Thompson et 
al., 2003)) however for complex mixtures (such as multiple proteins) the addition of 
these steps can be beneficial. 
 Methods for observing changes in oligomeric state  
There are many methods for observation of the oligomeric state of a protein.  As 
spoken about above, hydrogen-deuterium exchange mass spectrometry (Katta and 
Chait, 1993) can give information on transitions between monomer and multimers as 
well as an idea of the binding site, (McCullough et al., 2008). Size-exclusion 
chromatography coupled with multi-angle light scattering (SEC-MALs) (Tarazona 
and Saiz, 2003) gives information about the exact molecular weight of a complex 
allowing for interpretation of its oligomeric state.  
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Figure 6.1 Hydrogen-deuterium exchange mass spectrometry (HDX-MS). 
A) Flowchart showing protocol for HDX-MS performed here. B) Schematic for how 
the exchanges of hydrogen atoms for deuterium atoms along the peptide 
backbone occur over time followed by how this is quenched to lock the deuterium 
into the peptide backbone before digestion and then analysis by mass 
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Gel filtration chromatography is used commonly to separate proteins and protein 
complexes of different sizes. Larger complexes are eluted from the column first 
while smaller complexes take longer, this is due to the matrix which is contained 
within the column. This matrix contains pores of varying size meaning that the 
largest proteins/complexes travel the quickest as they have a much shorter distance 
to travel compared to smaller proteins/complexes which can enter many channels 
within the matrix taking longer for them to elute from the column (Gai et al., 2004). 
This technique is commonly used to separate complex mixtures of proteins and is 
the first step in many mass spectrometry techniques and is the ‘SEC’ in SEC-MALS.   
Analytical ultracentrifugation functions in a similar manner to gel filtration, separating 
protein/complexes based on their physical attributes (Cole et al., 2008). Larger 
proteins/complexes will be found lower in the column whilst smaller 
proteins/complexes will be found more towards the top. The column is made by 
preparing a gradient, usually sucrose, and then spinning the sample at high speed in 
a vacuum for serval hours. This results in a distribution of the proteins/complexes 
after equilibrium is reached, that is directly related to the size of the protein/complex. 
This is an equilibrium sedimentation experiment. 
 Methods for examining the ATP potential of a protein 
As Reptin is a member of the AAA+ protein family with a known ATP binding site it 
seems logical that Reptin would be able to bind to ATP and hydrolyse it to ADP. 
There are several techniques which are commonly used to look at ATP binding and 
ATPase activity including measuring the amount of radioactively labelled ATP bound 
to a protein of interest and measuring levels of hydrolysis of ATP. 
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6.2 Aims 
The experiments in this chapter aim to observe small ligand binding using hydrogen-
deuterium exchange and the impact of this binding on the conformation and 
oligomerisation of the Reptin protein.  
We want to investigate: 
• The ability of Liddean to bind into the ATP binding pocket of Reptin 
• Sites of importance in changes in oligomerisation of Reptin 
• The effect of point mutations on the conformation and oligomerisation of 
Reptin 
• The role of oligomerisation in ATP binding and ATPase activity of Reptin 
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6.3 Hydrogen-deuterium mass spectrometry of 
Reptin in the absence and presence of Liddean 
Initially, Reptin was taken in the absence and presence of Liddean, a small molecule 
ATP mimetic, and exposed to deuterium for various time points between 1 second 
and 60 minutes to observe the exposed peptides in Reptin and if these changed 
after addition of a ligand. After the reactions were quenched using 1M HCl with 1M 
glycine in the case of the deuterated samples, all samples were quickly frozen. 
These samples were loaded onto an immobilized pepsin column. Peptides were 
then trapped and desalted on-line on a peptide microtrap and finally eluted onto an 
analytical column and separated by a linear gradient. These peptides entered the 
Orbitrap Elite (schematic available in figure 6.1C) using electrospray ionisation. 
Tandem mass spectrometry was used to obtain identification of specific peptides 
and then the heights of the peaks lacking deuteration and corresponding deuterated 
peaks for each peptide were compared to obtain information of the fold change in 
deuteration in the two peptides. A workflow can be found in figure 6.1A. 
The results from the injections of the different samples into the analytical column 
can be seen in figure 6.2. Here we can see the changes in retention times of the 
peptides of Reptin, relative to the time they are incubated in deuterated water. In 
panel A, the Reptin only samples, we see the introduction of several peaks in the 1 
second to 5-minute incubated samples compared to the protein lacking deuteration. 
These peaks are lost in the longer incubations with an introduction in peaks with a 
longer retention time at around 29 to 31 minutes which are not seen in the samples 
which have not been exposed to deuterated water. However, panel B, Reptin with 
Liddean, lacks the large number of peaks found to elute from the column between 4 
and 5 minutes but the peaks seen around 29 to 31 minutes are present in all 
samples except the sample which were not exposed to deuterated water. 
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Figure 6.2 Elution profiles of Reptin in the absence and presence of Liddean 
showing changes in profiles over the deuterium time course, 1s. 
A) Profiles from Reptin alone incubated for 1 hour at room temperature before expose to 
deuterium. B) Profiles from Reptin after incubation with Liddean for 1 hour at room 
temperature before expose to deuterium 
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Due to the techniques used in mass spectrometry of ionising the peptides to allow 
them to be visualised by the mass spectrometer, it is not possible to ’see’ all the 
peptides of a protein, in most cases around 60 % of the protein is seen, with regards 
to Reptin we can see around 90% of the protein, this is much higher than with the 
majority of proteins making it perfect for this type of analysis. A visualisation of the 
coverage can be seen in figure 6.3A, showing that only the N-terminus and a section 
of the C-terminus is lacking in coverage. The changes in deuteration of the peptides 
of WT Reptin after 30 minutes incubation can be found in figure 6.3B showing that, 
at this time point, a large amount of the protein has undergone hydrogen-deuterium 
exchange compared to the undeuterated sample, the higher the deuteration (in red) 
shows peptides which are exposed on the surface of Reptin whereas the blue/green 
peptides are those which tend to be more internalised, those peptides which show 
crossover with colours can show more specificity for the sites of deuteration as the 
values are averaged across the whole of the peptide. 
We can look at changes in specific peptides by observing the spectra from the mass 
spectrometer which has been given by a single peptide. The mass shifts to the right 
of the graph show a heavier peptide thus a deuterated peptide. As an example, the 
spectra for the peptide AQALGPDTPFTAIAGSE can be seen in figure 6.4A with the 
undeuterated peptide in red with the deuterated peptide (30-minute incubation) in 
blue. You can see the deuterated peak is shallower and broader and this is due to 
variation in the amount of deuterium in the peptide. The specific changes observed 
in the levels of deuteration at 30 minutes comparing apo Reptin to Reptin with 
Liddean can be seen in figure 6.4B, here a reduction in deuteration is seen in 
blue/green, this corresponds to the peptide having less exposure to the outside 
aqueous environment, an increase in deuteration can be seen in yellow, this is  
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Figure 6.3 Peptide coverage of Reptin. 
A) The peptide coverage of Reptin observed by the mass spectrometer, around 90% of the 
protein is able to be visualised. B) Changes in the deuteriation of WT Reptin peptides 
observed after 30 minutes incubation with deuterated water, colours range from blue to red 
showing low to high levels of deuterium. 
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Figure 6.4 Deuteration levels on specific peptides of Reptin 
A) Mass spectra for the peptide AQALGPDTPFTAIAGSE showing undeuterated peptide in 
red with the deuterated peptide (30-minute incubation) in blue. B) Changes in the levels of 
deuteration at 30 minutes comparing apo Reptin to Reptin incubated with Liddean for 1 hour 
prior to incubation with deuterated water. C) Changes in the levels of deuteration at 30 
minutes comparing apo Reptin to Reptin of specific peptides.   
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the externalisation of a peptide into the aqueous environment. As very few changes 
are observed this is likely due to a conformational change occurring on ligand 
binding. Two peptides can be seen in figure 6.4C showing the percentage of 
deuteration observed in the same peptide in the absence (red) and presence (blue) 
of Liddean, both of these peptides show a reduction in deuteration levels showing 
that they are more internalised in the protein in the presence of Liddean.  
These results of the peptides showing the greatest changes in the level of 
deuteration on the addition of Liddean to Reptin were then modelled onto 3UK6 
(figure 6.5A). Here we can see that the dimer interface has a reduction in the levels 
on deuteration, indicating that Reptin is forming a higher-order oligomer. We can 
also see that there is a reduction in deuteration levels on one side of the ATP/ADP 
binding pocket while the other side appears to have an increase in deuteration. This 
indicates that Liddean can be seen to be binding into the ATP/ADP pocket, blocking 
deuterium exchange. When looking specifically at the pocket (in space fill, figure 
6.5B) we can see, with the help of the placement of the ADP molecule that deep in 
the pocket there is a reduction in deuteration, however, the increase in deuteration 
can be seen along the ‘tail’ of ADP. When comparing this to the modelling of how 
Compound 1 would bind into the pocket (Chapter 3, figure 3.1D) we can see that 
this correlates with the predicted orientation of the molecule.  
 Finding the ‘CLICK’ motif 
Further mapping of the increases in deuteration was performed on the amino acid 
and crystal structure of Reptin, these can be seen in figure 6.6. The changes 
visualised here represent a 60-second exposure to deuterium. Several peptides can 
be seen in yellow showing around a 2-fold increase in the levels of deuteration with 
the peptide showing the greatest increase (10-fold) shown in red (panels A and C).  
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Figure 6.5 Mapping changes in deuteration due to Liddean binding. 
The Reptin protein (PDB 3UK6 (Petukhov et al., 2012)) is displayed as a cartoon in green. 
ADP is black (sticks). Increases in deuteration on Liddean binding are red and decreases 
are in blue. A) Reptin monomer with dimer interface and ATP/ADP pocket highlighted. B) 
Surface rendering of 3UK6. Zoom of ATP/ADP pocket. (Healy et al., 2015).   
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Figure 6.6 Mapping the increase in deuteration on Reptin 
A) Amino acid sequence of Reptin showing greatest increases in levels of 
deuteration at 2-fold (yellow) and 10-fold (red) after 60 seconds of exposed to 
deuterated water. B) Fold changes deuteration of ligand bound Reptin compared to 
apo Reptin at the same time points observed for several peptides. C) Changes in A 
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The table shown in figure 6.6B shows how some of these changes are dynamic, 
peptide 333-345, whereas the others are more stable. Even though the change seen 
in deuteration levels of peptide 333-345 are dynamic, at 300 seconds the levels are 
still 5-fold higher compared to around 2-fold with the other peptides. On the 3D 
mapping of the observed changes (figure 6.6C), it is clear that the part of the protein 
showing the greatest changes in deuteration levels could be interesting due to its 
placement on the edge of the Reptin structure.  
As mentioned above, the peptide which was seen to have the greatest change in 
deuteration on the addition of Liddean, peptide 333-345. Due to the location of the 
peptide on the monomer, it was decided to look at its location in the full hexameric 
structure and be seen in figure 6.7. Here you can see this peptide marked in red or 
blue with the rest of the same monomer coloured paler on the 3D structure (3UK6). 
The peptide on monomer appears to lock into the same peptide adjacent monomer. 
In both the ribbon (figure 6.7A) and space fill (figure 6.7B) models the adjacent 
nature of these peptides is clear. The peptides appear to ’click’ into the next subunit, 
as seen in panel C, thus coining the term ’CLICK motif’ for this small peptide 333-
345 which can be seen in red using stick modelling with the rest of the monomer 
observed using cartoon in beige, the adjacent monomer can be seen in blue in 
space fill mode highlighting the CLICK motif in a darker blue with the rest of the 
monomer in pale blue. On closer inspection it is possible to deduce that it is the 
tyrosine found at amino acid 340 which fits exactly into the pocket in the next 
monomer formed by the same peptide, panel C has this residue highlighted in 
yellow. The peptide 333-345 itself can be seen in panel D with an overlay of Reptin 
(red) and the corresponding Pontin (blue) peptide is found in panel E. What is most 
evident is that the tyrosine observed in the Reptin peptide (TRIRGTSQYSPHG) is 
absent from the Pontin peptide (CVIRGTEDITSPGH) and the central amino acids on  
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Figure 6.7 Modelling the CLICK motif  
A) Cartoon of 3UK6 (Petukhov et al., 2012) hexamer with the CLICK motif 
highlighted in darker tones. B) Space fill of 3UK6 hexamer with the CLICK motif 
highlighted in darker tones. C) Zoom of CLICK motif seen in red using stick 
modelling with the rest of the monomer observed using cartoon in beige, adjacent 
monomer can be seen in blue in space fill, Tyrosine 340 residue highlighted in 
yellow. D) The peptide 333-345 of Reptin in stick mode. E) Overlay of the peptide 
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the Pontin peptide is very different although both contain a single hydrophobic 
residue. This could mean that the Reptin-Pontin heterododecamer likely forms in a 
similar, but not identical, way to the Reptin homohexamer. 
Further investigation and modelling allowed for a greater understanding of the 
make-up of the click motif. The CLICK motif is localised within the ‘ring’ of the 
hexamer (figure 6.7A/B) and on an exposed surface of the monomer (figure 6.8A). 
The motif on one monomer appears to click into the adjacent monomer (figures 6.7B 
and zoom 6.8B). The peptide 333-345, TRIRGTSYQSPHG, can be found in figure 
6.8C with several residues highlighted in a different colour; tyrosine (orange) in the 
pocket of histidine (blue), methionine (pink), arginine (red) and threonine-arginine-
isoleucine-arginine (green).  
Due to this interesting peptide, it was decided to create a point mutation in the 
wildtype protein by site-directed mutagenesis at the site of the tyrosine 340, 
mutating it to an alanine, this was simulated by modelling (figure 6.8D) showing the 
reduction in contacts between the two adjacent monomers. Primers were designed 
to bind to the pDEST15-Reptin plasmid to introduce the point mutation. After PCR 
with these primers, the product was digested with Dpn1 and then transformed into 
DH5α cells for purification. Sequencing was performed by Source bioscience to 
confirm the presence of the required mutation. Alongside this site-directed 
mutagenesis to have the D299N mutant in the same vector was also performed. 
D299N is a well characterised, catalytically dead form of Reptin that is known to 
form stable hexamers. The new mutant plasmids were transformed into BL21-AI 
cells and expressed as per the standard protocol. Purified protein was obtained for 
both mutants to allow for ongoing experiments. The characterisation of this new  
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Figure 6.8 Make-up of the CLICK motif  
A) Monomer of Reptin (3UK6 (Petukhov et al., 2012)) with the CLICK motif, 
peptide 333-345, highlighted in red. B) Space fill of 2 adjacent monomers of Reptin 
with the CLICK motif highlighted in darker tones. C) Tyrosine (orange) in pocket of 
histidine (blue), methionine (pink), arginine (red) and threonine-arginine-isoleucine-
arginine (green). D) Tyrosine 340 in stick mode mutated to alanine. (Remnant et 
al., 2019)  
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protein will be done along with site the wildtype protein and the well characterised 
D299N mutant. 
6.4 Separating oligomeric forms of Reptin  
Due to now having three analogues of Reptin, the wildtype, the well-characterised 
D299N which results in a reduction in ATP hydrolysis and the new Y340A mutant, a 
wide variety of assays was needed to help characterise what these mutations might 
induce compared to with wildtype.  
 Gel filtration 
Gel filtration was performed to see if we could observe changes in the oligomeric 
state of these proteins. A column of Sephadex was used and the proteins were 
added to the top of the column. Over time fractions were taken from the column and 
then analysed for the presence of protein by ELISA. This was performed in the 
presence and absence of 1mM ADP (large excess) to try and induce different 
oligomeric forms of Reptin. The results of these experiments can be found in figure 
6.9 Panels A) wildtype, B) Y340A and C) D299N. The quicker a protein elutes on the 
column the larger it is as the smaller proteins take a long journey through the 
column. Molecular weight markers eluted as follows 440kDa in 11ml fraction, 
158kDa in 14.5ml fraction, 43kDa in 14ml fraction and 13kDa in 18ml fraction. In the 
wildtype protein we can see two oligomeric forms of the protein with the addition of 
ADP, but only a single peak with the protein only, due to its elution size we can 
conclude that the peak seen in both is the monomeric peak. Comparing this to the 
Y340A and D299N mutants we can see that it would appear that the Y340A mutant 
is a single monomeric species, comparatively the D299N mutant appears to be able 
to form higher-order oligomers without the need for the ligand to be present.  
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Figure 6.9 Gel filtration on Reptin in absence and presence of 100µM ADP. 
Molecular weight markers eluted as follows 440kDa 11ml, 158kDa 14.5ml, 43kDa 
14ml, 13kDa 18ml. A) Wildtype Reptin B) Reptin Y340A mutant C) Reptin D299N 
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If this is the case that the Y340A CLICK motif mutant cannot form oligomers, then 
this gives us a much greater understanding of the importance of the CLICK motif to 
the structure of the protein. 
6.5 Measuring changes in the activity of Reptin with 
the addition of point mutations 
The ATP binding and ATPase activity of Reptin alone is chronicled as being very 
low. It is important to see if the changed in the Y340A mutant result in changes in 
these abilities. The increased affinity of D299N with ATP has been previously seen 
so this allows this protein to be used as a positive control for ATP binding compared 
to the wildtype protein.  
As it is known that many AAA+ proteins only exhibit their ATPase activity when they 
are bound in complex, Pontin was now required for investigation. Using the Pontin 
sequence from the pCDNA-3xFLAG-Pontin (a kind gift from the Artandi lab 
(Venteicher et al., 2008)), Pontin was added to pDEST15 in the same manner as 
Reptin. The expression of Pontin was carried out in the same manner as Reptin this 
time with induction occurring at 30oC for a greater yield of Pontin.  
 Measuring the binding affinity of Reptin and its variants 
for ATP 
To perform this assay, Reptin, wildtype or mutant, is incubated with ATP-gamma32P 
in solution. The solutions are then filtered through a disc to capture the protein. If the 
ATP is binding to the protein it will be captured with the protein on the disc. These 
discs are then placed on a phosphor screen to expose the amount of radioactivity in 
each sample. The phosphor screen is then imaged using a Phosphoimager. This 
creates a digital image, similar to a western blot, which can be used for quantitation. 
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We can see in figure 6.10A can see that wildtype Reptin has a very low affinity of 
ATP, not much higher than background and the D299N has a much higher affinity, 
as expected. The Y340A mutant can be seen to have an affinity similar to that of the 
wild-type protein. 
 Measuring the ATPase activity of Reptin and its variants  
The enzymatic ability of Reptin alone is known to be very low, it is thought that the 
enzymatic activity of Reptin and Pontin can only be observed when they are in the 
complex. Using a colourimetric assay for the amount of free phosphate we can 
examine the ability of the protein to break down ATP into ADP and phosphate. Here 
the protein was incubated for an hour before the experiment to ensure protein 
complexes had time to form, this was especially important for the Reptin/Y340A and 
Pontin. 
We can see in figure 6.10B that the amount of free phosphate produced by Reptin 
wildtype and Pontin in the complex is 4-fold higher than Reptin or Pontin alone. The 
combination of Pontin with the Y340A mutant does not seem to have an increase or 
decrease in the amount of free phosphate available compared to the proteins alone. 
Figure 6.10C shows us that changing the amount of free ATP used in the 
experiment does not affect the results seen, the amount of free phosphate produced 
by the complexes increases with the amount of ATP input but the Y340A and Pontin 
proteins together do not create an amount of free phosphate similar to that of the 
wildtype protein with Pontin. 
 Measuring Reptin and mutant binding affinity for AGR2 
A protein-protein interaction assay was carried out by coating AGR2 onto a 
polystyrene plate (as seen in Chapter 3). Here we titrated increasing amounts of 
wildtype and mutant Reptin to observe the changed in binding affinity. In figure 6.11  
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Figure 6.10 ATP binding affinity of Reptin. 
 ATP-gamma32P was incubated with different forms of Reptin before being 
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Figure 6.11 Measuring Reptin and mutant binding affinity for AGR2. 
 Wild-type Reptin and the indicated mutants were analysed in AGR2 protein 
binding assays. AGR2 (1μg) was pre-coated onto ELISA wells. Reptin was titrated, 
and anti-Reptin and HRP-conjugated secondary antibodies were used to measure 
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it is evident here that the Y340A mutation increases the affinity of Reptin for AGR2 
whereas the D299N mutant acts similarly to the wildtype protein.  
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6.6 Discussion 
This chapter has shown how a combinatorial approach can lead to a much better 
understanding of the molecular conformation and oligomerisation of the protein of 
interest. Hydrogen deuterium exchange, in combination with the binding of the novel 
ligand Liddean, has led to the discovery of a novel site on Reptin that has been 
further investigated. The Reptin peptide 333-345 TRIRGTSYQSPHG showed the 
most dramatic increase in deuteration, 10-fold at 60 seconds, compared to all other 
peptides in the protein. This means that this peptide is likely to be more enclosed in 
the monomeric form of Reptin. Apparently, during oligomerisation, this peptide was 
released from the monomeric conformation to aid in the formation of a stable 
oligomer. 
Modelling of this peptide, TRIRGTSYQSPHG, revealed that it might help form a 
pocket for the same peptide in the adjacent monomer to bind into. Thus, leading to 
the ‘CLICK’ motif, designated as this due to the clicking together of the peptide into 
the same peptide on the adjacent monomer. The tyrosine in the peptide 
(TRIRGTSYQSPHG) appeared to be crucial for the formation of the hexameric 
Reptin ring. Further investigations allowed for confirmation me to confirm the 
importance of this amino acid in the oligomeric structure of Reptin.  
In Chapter 3, I showed that a specific self-peptide, peptide 28, of Reptin have a very 
high affinity for Reptin protein binding. The sequence of peptide 28 is 
GITRIRGTSYQSPHG. If we compare this to the CLICK motif, TRIRGTSYQSPHG, 
we can see that they are near identical, with peptide 28 containing two additional 
amino acids at its N-terminus. As this peptide was seen to have such a high level of 
binding to Reptin protein (self-binding). This observation further helps to confirm the 
importance of this motif. This peptide also shows the greatest reduction in binding 
when Reptin has previously been incubated with ligands (ADP and Liddean) 
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suggesting it may be important for the oligomerisation on the protein (Chapter 3, 
figure 3.5).  
I have found that different oligomeric forms of Reptin can be visualised by gel 
filtration. The wildtype protein can form higher-order oligomers with the addition of 
the endogenous ligand, however, the Y340A mutant is not able to form a larger 
stable oligomer. The D299N mutant was able to form a higher-order oligomer 
without the need for ligand binding which was expected, based on previously 
published data (Maslon et al., 2010). 
Reptin is a member of the AAA+ superfamily (Rosenbaum et al., 2013). These are 
known for their oligomerisation on ATP binding and ATPase ability (Hanson and 
Whiteheart, 2005)]. I have tested the wildtype and mutant proteins for both. The 
experiment looking at the binding affinity of the Reptin mutants for ATP justified the 
hypothesis that it is the oligomeric form that is required for higher binding to ATP. 
Thus, the D299N mutant has a higher affinity for ATP compared to WT and Y340A 
Reptin (figure 6.9). The ATPase experiment also showed that in the presence of 
equimolar amounts of Pontin, wildtype Reptin is able to convert ATP into ADP + Pi. 
This was not the case for the Y340A mutant and is likely due to its inability to form 
an oligomer with Pontin, although this was not tested. 
My data reveal that residue Y340 of Reptin is required for oligomerisation to occur. 
Without oligomerisation, Reptin is unable to bind and hydrolyse ATP. We have 
previously seen that the binding partners of Reptin, AGR2 and p53, have different 
binding profiles with wildtype Reptin in chapter 3. The binding of Y340A Reptin to 
AGR2 is much higher than the binding of either wildtype or D299N Reptin. As my 
data suggested that Reptin Y340A is the monomeric form of Reptin, this also agrees 
with the reduction in binding between wildtype Reptin and AGR2 seen in the 
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presence of ligand. This possibility could be further investigated in the future using 
the monomeric Reptin specific ScFv discovered in Chapter 4. This antibody would 
allow investigation of monomeric Reptin in cells and its localisation and 
colocalization with AGR2 and p53. This could be achieved a combination of imaging 
techniques including immunofluorescence (Odell and Cook, 2013), FRET/FLIM 
(Wallrabe and Periasamy, 2005) and proximity ligation assays (Fredricksson et al., 
2002).  
As previously mentioned in Chapter 4, it is thought that monomeric Reptin may be 
oncogenic. I have previously shown in Chapter 3 that the binding between Reptin 
and AGR2 is decreased in the presence of ligands. Reptin binding is thought to 
activate AGR2, which in turn inhibits p53. In contrast, the binding between Reptin 
and p53 is increased in the presence of ligands and is thought to activate its tumour 
suppressor abilities. The identification of a specific peptide in Reptin that could be 
responsible for its transition between monomer and oligomer be relevant in a clinical 
setting due to the high incidence of overexpression of Reptin in cancer patients, in 
particular hepatocellular carcinoma (Rousseau et al., 2007, Iizuka et al., 2006), 
colon cancer (Graudens et al., 2006), melanoma (Talantov et al., 2005), bladder 
cancer (Sanchez-Carbayo et al., 2006) and prostate cancer (Kim et al., 2005, Kim et 
al., 2006).  
One possible speculative explanation for the increase in the levels of monomeric 
Reptin could be that if p53 binding helps to stabilise the Reptin oligomer in vivo 
when the increase in the overall expression of Reptin in the cell is not accompanied 
by a similar overexpression of p53, there might be a decrease in oligomer stability 
resulting in a greater proportion of monomeric Reptin. This increased monomeric 
Reptin could then preferentially bind to AGR2, activating it, resulting in increased 
inhibition of the remaining pool of p53 in the cell.  
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To see if this has any clinical relevance, it would be possible to investigate specific 
mutations seen in cancer patients and compare their localisation in both the Reptin 
sequence and the 3D structure of Reptin. Any mutations found at the inter-subunit 
interface or in the rest of the CLICK motif would be of particular importance. 
Here, Reptin is used to develop new approaches to dissect oligomerisation driven 
by ligand binding. This method utilises hydrogen-deuterium exchange to highlight 
sites on the external faces of a protein which are exposed or enclosed on small 
molecule binding. A single binding motif for Reptin was identified using the HDX 
experiments, identifying an important stabilising side chain the Y340 which is 
responsible for holding the homo-hexamer together.  Combining self-peptide motif 
screens and HDX data allowed definition of an inter-subunit bridge formed between 
the same peptide in all monomers. A study looking at both Reptin and Pontin found 
that their oligomerisation and activity can be controlled through binding to Histone 
H3 N-terminal tails (Queval et al., 2014).  This highlights the importance of binding 





7.1 Discovery and testing of Liddean 
Discovery and testing of Liddean In Chapter 3 my work involved the first in vitro 
testing of compound output from the in-silico screening software LIDAEUS (Taylor et 
al., 2008). The software docked a virtual library of 4.4 million conformers. 49,971 
hits identified as binding to the Walker A site of Reptin were re-docked using 
Autodock software (Trott and Olson, 2010). The hits were prioritized using a ‘rank-
by-rank’ protocol and 30 were selected to be tested in protein-protein binding assays 
to assess the effectiveness of the in silico approach. From this 30, a single 
compound, Compound 1 (Chapter 3, figure 3.1C and D) was identified as having the 
greatest inhibitory effect on the binding of Reptin to known protein interactor, AGR2 
(Maslon et al., 2010). Compound 1 was subjected to a structure-activity-relationship 
study (Chapter 3, figure 3.1E). The panel of Compound 1 derivatives was then 
subjected to the same assays resulting in the selection of Liddean for further 
studies. The binding of Liddean to the Walker A site of Reptin was readily detailed 
using hydrogen-deuterium exchange mass spectrometry (Chapter 6, figure 6.5A and 
B).    
This approach allowed me to confirm the effectiveness of the LIDEAUS software to 
identify small molecule ATP mimetics, which bind to the Walker A site of Reptin. To 
extend this study, a larger number of proteins could be tested for changes in protein-
protein interactions induced by small-molecule binding. Candidates would include 
Pontin, the homolog of Reptin, as well as other known binders of Reptin in these 
assays.   
Similar approaches using in-silico screening and in vitro assays could be used in the 




AAA+ proteins for which crystal structures are available. Modelling of other Walker A 
sites and comparing them with the same conformer library could allow for a greater 
understanding of the specificity of these small molecules, perhaps allowing for some 
to be discounted if they were predicted to bind the Walker A sites of several 
proteins.   
In addition to this, alternative assays could be used to look at changes in Reptin 
functional dynamics. For example, Reptin and Pontin are found together in many 
chromatin remodelling complexes. We observed in the proximity ligation assay that  
Reptin-Pontin foci shuttle out of the nucleus into the cytoplasm (Chapter 4, figure 
4.4C). The effects on Reptin-Pontin activity could be investigated further by looking 
specifically at chromatin remodelling (Flaus and Owen-Hughes, 2001). Well 
documented assays that could be used include ATP-dependant nucleosome 
remodelling (Chen et al., 2014), mono/di-nucleosome binding (Owen-Hughes et al., 
1999, Chen et al., 2014), DNA and nucleosome dependant ATPase assays (Chen et 
al., 2014). These assays could be performed in the presence and absence of 
Liddean, using multiple Reptin-containing chromatin remodelling complexes. If 
changes in chromatin remodelling were observed, the next step would be to look for 
changes in gene expression in cells exposed to Liddean for many time points, this 
could be studied using RNAseq. This is computationally complex but could give rise 
to candidate genes (Finotello and Di Camillo, 2015, Rapaport et al., 2013). Those 
candidate genes could then be used to see if they undergo repositioning within the 
nucleus which can also be related to their expression level (Egecioglu and Brickner, 
2011).   
For work in vivo, the specificity of Liddean is of great importance. As much of the 




able to comment on the off-target effects caused by Liddean in vivo. However, some 
off-target effects were likely observed in the experiment looking at changes in the 
electrical impedance of cells on the addition of Liddean (Chapter 3, figure 3.7) which 
were thought to be caused by changes in cell morphology and adherence capability.   
One method to test the specificity of Liddean could be to make a derivative that can 
be chemically bound to beads, incubating the Liddean beads with cell lysates and 
performing mass spectrometry analysis on the bound proteins. This could yield a 
more specific target pool of possible interacting proteins which could be used to 
narrow down the list of off-target effects. To see if the changes in cell morphology 
and adherence a result of changes in the protein-protein interactions of Reptin are 
merely induced by Liddean, Reptin knockdown could be performed followed by 
treatment with Liddean. To enable quick removal of Reptin, the auxin-inducible 
degron (AID) system could be utilised (Nishimura et al., 2009). Here, rapid and 
reversible degradation of target proteins is possible due to the introduction of the 
plant-specific auxin pathway into animal cells, resulting in polyubiquitination of the 
target protein followed by degradation by the proteasome. If the result of this 
experiment was similar to those seen in the cells with normal levels of Reptin, the 
resulting changes in morphology could be attributed to an off-target effect of this 
small molecule. To test if this off-target effect was caused by the binding of Liddean 
to another AAA+ protein, such as dynein (Vale, 2000), a library of AAA+ AID cell 
lines could be made. Such AID cell lines produced could also be used for many of 
the other experiments outlined above.  
7.2 Use of ScFv to identify a Reptin self-binding site  
In Chapter 4 my work involved the use of antibody phage display, to identify 5 
single-chain variable-fragments (ScFv) that bind Reptin. The binding site for ScFv 4 




whereas the sites for ScFv 25 and the multi-ScFv site are seen on the external 
surface (PDB 3UK6). This means that ScFv 4 is unlikely to be able to bind to 
oligomeric Reptin. In the assay looking specifically on the effect of the presence of 
Liddean on ScFv binding, the binding of ScFv 4 was lost (Chapter 4, figure 4.7). This 
was expected as we have seen from the gel filtration that Reptin bound to the ligand 
is an oligomer (Chapter 6, figure 6.9). This further argues that us that this ScFv is 
only able to bind to monomeric Reptin.   
To investigate this further, we could use the mutant proteins expressed for the 
experiments in Chapter 6. If the Y340A mutant is monomeric, the ScFv 4 should be 
able to bind successfully in the presence and absence of ligand. In contrast, D299N 
should have very low, if any, binding of ScFv 4 due to its oligomeric conformation. 
Wildtype Reptin could also be used to test this using the addition of various ligands.   
To help identify the binding site of ScFv 21, which binds Reptin but not the Reptin 
overlapping peptide library we could use the hydrogen-deuterium exchange to map 
the binding site, as we did for Liddean (Chapter 6, figure 6.5). This could confirm 
that ScFv 21 has a structural epitope rather than a linear peptide epitope. This 
technique could also be used to map the binding sites of the other ScFv, giving 
information on the oligomeric state of the proteins that are bound to the specific 
ScFv.   
If it can be confirmed that ScFv 4 is specific for monomeric Reptin then this could be 
used in proximity ligation assays to ascertain the oligomeric state of Reptin when it 
is bound to each of its binding partners. If other of the ScFv were confirmed to bind 




7.3 Use of peptide motif screen to identify Liddean 
dependent motifs  
In Chapter 5, I used peptide phage display to look at changes in the binding 
landscape of Reptin on ligand binding. In the first screen, I identified specific binding 
motifs from the dataset, one of which turned out to be relevant to the interaction of 
Reptin with p53. On further investigation, the motif was found to be present in a 
peptide mapping to the tetramerization domain of p53. The p53 protein is only active 
in its tetrameric form, which binds to DNA with high affinity. The activation of p53 is 
closely linked to its conformation with a regulatory domain next to the 
tetramerization domain at its C-terminus. As Reptin is found in several chaperone 
complexes, such as R2TP, the interaction may help to ensure the correct 
conformation of p53 allowing it to carry out its role as a tumour suppressor. To 
investigate this further, investigations into this complex involving looking at the 
molecular ratio of the two proteins using techniques such as ion-mobility mass 
spectrometry (Kalenius et al., 2018), which gives information on the size and shape 
of a complex, and SEC-MALS (Tarazona and Saiz, 2003), which allows for 
estimation of the size of protein complexes. It would also be interesting to test the 
DNA binding ability of p53 in the presence of Reptin, Pontin, and the two proteins 
together. It would also be possible to locate the binding site on Reptin for p53. This 
could be achieved using the Reptin specific peptide library performing peptide-
protein interaction assays and hydrogen-deuterium exchange using peptide 38 of 
p53 and Reptin.   
As p53 is well characterised for its mutations in cancer, it would be of interest to 
investigate whether any of these mutations are found at the Reptin binding site and 
if, when mutated in bacterially expressed proteins, they abolish the binding between 




could be stimulated by the addition of Liddean, forcing Reptin into its hexameric 
form which appears to have a higher binding affinity for p53.   
The identification of several peptides that can bind to Reptin (Chapter 5, figure 5.6), 
and whose binding is affected by the addition of Liddean, could also lead to other 
lines of further experimentation. Initially, it would be of interest to ask whether those 
peptides which can be seen to have a high affinity for either Reptin, Reptin with 
Liddean or both occur elsewhere in the human proteome, possibility identifying 
novel protein-protein interactions of Reptin. It would also be interesting to see which 
of these peptides can bind to the mutant forms of Reptin Y340A and D299N, and 
how these levels of binding compared to wildtype Reptin. This could also be tested 
in the absence and presence of Liddean and other ligands. Mapping of these 
binding sites could be achieved with the hydrogen-deuterium exchange. If specific 
peptides are seen to bind to oligomeric Reptin, it would be very informative to 
determine if they bind across multiple monomers of Reptin helping to ‘lock’ Reptin 
into its oligomeric form.   
7.4 Fine mapping of Liddean induced changes in 
Reptin  
Hydrogen-deuterium exchange mass spectrometry (HDX-MS) was used to compare 
wildtype Reptin to Reptin bound to Liddean. As discussed earlier I was able to map 
Liddean binding into the ATPase site of Reptin. Comparison of the predicted binding 
of Compound 1 (Chapter 3, figure 3.1D) to the deuterium mapped ATPase site 
(Chapter 6, figure 6.5B) revealed that Liddean is bound in the predicted manner. 
This shows that HDX-MS can be used to effectively map binding sites on a protein 




To analyse the localisation of deuteration on the Reptin monomer, the sites were 
mapped onto the PDB 3UK6 structure of Reptin (Chapter 6, figure 6.7A and B). A 
single peptide -333-345- showed much higher levels of deuteration than the others 
(Chapter 6, figure 6.8). On closer inspection of the contacts of this peptide, I noticed 
tyrosine 340 protruding into a pocked in the same motif on the adjacent monomer 
(Chapter 6, figure 6.7C). I also compared the corresponding peptide in Pontin 
(Chapter 6, figure 6.7E) and noted that this lacked the tyrosine. In its place is 
isoleucine, which forms similar contacts with the adjacent monomer. Modelling the 
conversion of tyrosine 340 to alanine (Chapter 6, figure 6.8D) showed that this 
mutation would likely result in the loss of several contacts between adjacent 
monomers. The bacterial expression vector for Reptin was mutated using site-
directed mutagenesis to give mutant Y340A Reptin. At the same time, I also 
mutated D299N, a mutant of Reptin which was previously characterised as a ‘loss-
of-function’ mutant unable to hydrolyse ATP.   
Several biochemical assays of wildtype Reptin, Y340A and D299N revealed that 
Y340A is unlikely to be able to form a hexamer. The gel filtration experiment was 
carried out 4 times, each time revealing that wildtype Reptin could be visualised as 
two peaks in the presence of ligand but Y340A was only ever able to form a single 
peak. I also used sedimentation assays (performed in duplicate) but could not 
successfully resolve multiple peaks for any form of Reptin. This may be due to the 
high G force and vacuum used in this experiment, resulting in a collapse of the 
oligomeric form or it could be due to Reptin being separated from ligands required to 
form oligomers in the gradient. The sedimentation assay was carried out over 18 
hours in comparison to only 50 minutes for the gel filtration experiment. These 
various factors could explain why it was possible to observe the different oligomeric 




Functional assays were then carried out on Reptin wildtype and mutants revealing 
that the D299N mutant can bind ATP in the absence of Pontin but Y340A and 
wildtype Reptin are not. However, in the presence of Pontin, wildtype Reptin can 
hydrolyse ATP which the Y340A mutant is not. This is likely due to the inability of 
Y340A to form a heterohexamer with Pontin, again reflecting the importance of this 
residue.   
The final experiment was to perform HDX-MS on the Y340A mutant and compare 
the levels of deuteration to wildtype Reptin in the absence and presence of ATP. 
Interestingly no changes of deuteration were detected in the ‘CLICK’ motif (-333345-
) in the Reptin Y340A mutant when exposed to the ligand. The lack of changes on 
the deuteration levels of the ‘CLICK’ docking motif in Reptin Y340A protein is 
consistent with the model that loss of Tyrosine 340 results in the Reptin monomer as 
in the wildtype protein this peptide is seen to increase in deuteration after the 
addition of ligand.  
It may be possible to test if the binding affinity for Liddean is different between the 
different Reptin mutants as they appear to be more stable in their confirmation that 
wildtype Reptin.   
7.5 A new model for the Reptin binding landscape  
Integrating the diverse data gained during this thesis it is possible to postulate a 
model for the binding of Reptin to its various binding partners in the presence of 
different ligands. I have shown that ligand binding stimulates oligomerisation of 
Reptin either alone as a homohexamer or in complex with Pontin as a 
heterododecamer.   
In figure 7.1, monomeric Reptin can bind AGR2, there may also be binding partners 






Figure 7.1 Model for Reptin binding to specific partners in its different 
oligomeric states 








Pontin can form hexameric structures alone in vitro and both have been solved by x-
ray crystallography. It is not known whether the Reptin-Pontin complex can form a 
stable heterohexamer. These two, possible three, oligomeric forms of Reptin and 
Pontin could therefore have their binding partners independent of one another, 
suggested here by the binding of p53 to oligomeric Reptin. The heterododecamer 
formed by Reptin and Pontin is well characterised as having roles in DNA 
remodelling and is known to be part of many protein complexes. This is likely the 
most abundant oligomer for Reptin and Pontin. More investigation into the 
prevalence and interactions of the different oligomeric forms of these two proteins 
would lead to a much better understanding of Reptin and Pontin functions and in 
particular why they are found to be upregulated in various cancers. For example, 
Reptin is overexpressed in hepatocellular carcinoma (Rousseau et al., 2007, Iizuka 
et al., 2006), colon cancer (Graudens et al., 2006), melanoma (Talantov et al., 
2005), bladder cancer (Sanchez-Carbayo et al., 2006) and prostate cancer (Kim et 
al., 2005, Kim et al., 2006). The techniques used here could likely also be applied to 
other AAA+ proteins.  
7.6 Drugging the undruggable  
The term undruggable is used to describe proteins that are currently unable 
to be targeted pharmacologically. Current developments in techniques mean 
progress is being made to target these proteins, many of which are 
oncogenes (Dang et al., 2017). The ability to target these ‘undruggable’ 
proteins would mean greater specificity for therapeutics as it is often these 
proteins which fall at crucial steps in signalling pathways, for example, 
proliferation and apoptosis (Hantschel et al., 2011). A large number of these 




nuclear-factor κB (Baud and Karin, 2009) and many cancers are found to 
have mutations in these proteins. A second group is the RAS family of 
proteins (Cox et al., 2014) who is found to be mutated in around 30% of 
cancers. Protein phosphorylation is another possible target for therapeutics, 
but this can be difficult due to the complex signalling pathways they are 
involved in and single kinases being able to target multiple proteins (Bain et 
al., 2007). The ability to selectively inhibit regulatory subunits could be 
important here as currently, many inhibitors are designed to block 
phosphorylation by the kinase. To target all the ‘undruggable’ proteins it is 
not possible to use the standard methods used for drug development.  
The methodology adopted in this thesis allows observation of available small 
molecules and the ability to then develop them for specificity allowing them to 
be optimised for use with proteins which were not their original target. For 
example, despite many years of research, there have been no approved 
drugs against the protein KRAS. It was recently discovered that there is a 
shallow pocket of the surface of active and inactive KRAS but due to the 
shape it was considered undruggable (Quevedo et al., 2018, Cruz-Migoni et 
al., 2019). The use of LIDAEUS and peptide phage display techniques would 
allow for the creation of specific small molecules or peptides which can bind 
directly to this shallow pocket. A similar project was undertaken in the 
manner of our screen (Healy et al., 2015), where they developed an inhibitor 
of KRAS which blocks downstream signalling and has an antiproliferative 
affect (Kessler et al., 2019). In this study they observed the shape of the 




were able to use a ‘structure activity relationship’ study, as we did, to 
optimise the small molecule and used co-crystalisation to look at binding of 
the small molecule to KRAS. This is an alternative method to our HDX 
experiments giving high resolution data for the binding of the small molecule 
to KRAS (Kessler et al., 2019) which we were not able to obtain.  
The ability to target proteins and protein-protein interactions which before 
were classed as ‘undruggable’ has been achieved with the development of in 
silico screening and with biophysical techniques. The ability to model binding 
pockets and interfaces means that it is now possible to develop molecules 
which are highly specific for the site on a particular protein which they have 
been designed to bind to. This allows sites which would not normally be 
classed as ‘binding pockets’ to be used to create changes in oligomerisation, 
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Abstract: Many regulatory proteins are homo-oligomeric and designing assays that measure self-
assembly will provide novel approaches to study protein allostery and screen for novel small mole-
cule modulators of protein interactions. We present an assay to begin to define the biochemical
determinants that regulate dimerization of the cancer-associated oncoprotein AGR2. A two site-
sandwich microtiter assay (2SMTA) was designed using a DyLight800-labeled monoclonal antibody
that binds to an epitope in AGR2 to screen for synthetic self-peptides that might regulate dimer sta-
bility. Peptides derived from the intrinsically disordered N-terminal region of AGR2 increase in trans
oligomer stability as defined using the 2SMTA assay. A DSS-crosslinking assay that traps the AGR2
dimer through K95-K95 adducts confirmed that D45-AGR2 was a more stable dimer using denaturing
gel electrophoresis. A titration of wt-AGR2, D45-AGR2 (more stable dimer), and monomeric AGR2E60A
revealed that D45-AGR2 was more active in binding to Reptin than either wt-AGR2 or the AGR2E60A
mutant. Our data have defined a functional role for the AGR2 dimer in the binding to its most well
characterized interacting protein, Reptin. The ability to regulate AGR2 oligomerization in trans opens
the possibility for developing small molecules that regulate its’ biochemical activity as potential can-
cer therapeutics. The data also highlight the utility of this oligomerization assay to screen chemical
libraries for ligands that could regulate AGR2 dimer stability and its’ oncogenic potential.
Keywords: oligomerization; allostery; protein interactions; monoclonal antibody
Introduction
The discovery of protein–protein interactions is a
key, fundamental goal in life sciences research and
protein–protein interactions are emerging as compel-
ling landscapes in the drug discovery field.1,2 The
fundamental nature of a protein–protein interaction
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has changed since the realization that intrinsically
unstructured proteins form important components of
a large number of protein–protein interactions.3
This view of a protein-protein interaction provides
approaches for using structural and computational
sciences to develop lead molecules that disrupt a
given protein–protein interaction.4 In addition, the
realization that proteins exist in large oligomeric
signaling complexes provides a relatively large sur-
face area for identifying protein-interaction hotspots
that might be amenable to fragment-based lead
molecule discovery.5,6
Structure-based lead molecule discovery remains
a fundamental mechanism to exploit protein struc-
ture, develop small molecule drug leads, and mani-
pulate allostery in proteins.7 Amongst the many
emerging models in the cancer field, for example,
small molecules exist that stabilize the tetramer–
dimer/monomer conversion of pyruvate kinase that
has potential to regulate metabolism in cancer
cells.8,9 In addition, the structure of porphobilinogen
synthase has led to models on the interconversion of
octomers to hexamers through dimer assembly.10
Small molecules have been developed that
stabilize the hexameric form of the enzyme and
inhibit enzyme activity11 that highlight the ability to
exploit the allosteric regulatory nature of many pro-
teins by developing small molecule tools or drug
leads.
One limitation of structure-based drug discovery
in human disease-associated proteins is that a large
proportion of polypeptide sequence information in
higher eukaryotes is composed of intrinsically disor-
dered regions that make some domains refractory to
structural solutions.12,13 These disordered regions
can acquire structure by an induced-fit mechanism
upon binding to their targets thus providing a speci-
ficity in the protein–protein interaction.14 Proteins
with disordered domains and oligomeric properties
can form prototypes for developing innovative
approaches to measure allostery in protein control.15
The oncoprotein MDM2 has formed such a prototype
model whose full-length properties have been refrac-
tory to structural biology solutions.16–18 We had used
MDM2 as a model to develop a nanoparticle binding
assay using surface-enhanced RAMAN spectroscopy
(SERS) that can measure the oligomerization state of
small amounts of protein when bound to ligand thus
providing a nano-sensing assay to measure protein
allostery.19 Although one methodological advantage
of SERS as a nanoparticle binding assay is its use of
small amounts of protein, a major limitation of SERS
in measuring protein oligomerization is that it
requires the target protein to be complexed to its
ligand.
In this study, we present an alternative to the
ligand-dependent SERS oligomerization assay by
using a fluorescently labeled monoclonal antibody
based microtiter assay that measures oligomerization
of a ligand-free protein. The prototype protein used
was the pro-oncogenic protein Anterior Gradient-2,
that is an emerging cancer drug target in the
endoplasmic-reticulum secretory system.20–22
Anterior-Gradient-2 has an intrinsically disordered
N-terminal region and the protein has recently been
reported to be dimeric.23 This fluorescent-based
microtiter assay measured changes in AGR2 dimer
stability in response to synthetic peptides derived
from its intrinsically disordered domain in trans.
This methodology provides a robust assay that can
be used to screen chemical libraries for molecules
that can alter AGR2 dimer stability and that can in
turn be tested for inhibition of the oncogenic
function of AGR2 in cells. In addition, this methodo-
logical concept is amenable in principle to other oli-
gomeric proteins and can be used to screen for and
isolate chemicals that alter oligomeric protein
stability.
Results
Size exclusion chromatography demonstrates
that AGR2 can exist as a homodimer
Gel-filtration size exclusion chromatography of recombi-
nant mature AGR221–175 was used to define its oligo-
meric structure [Fig. 1(A)]. At highest concentrations
(2.5 mg mL21; 136 mM), the protein eluted with a calcu-
lated molecular mass of 34.843 kDa [Fig. 1(B)], signifi-
cantly greater than the theoretical monomeric molecular
mass of 18252.1 kDa (Expasy Compute pI/MW tool,
http://web.expasy.org/compute_pi/), more closely resem-
bling a dimer structure relative to the theoretical mass
of 36,504 kDa. The elution profiles of globular proteins
used for calibration are summarized in Figure 1(C,E).
By comparison, a prior analysis of AGR221–175 protein
using SEC-MALLS gave a dimeric mass of 30.5 kDa
from a protein with a monomeric mass of 17.8 kDa and
predicted dimeric mass of 32.2 kDa.23
We diluted AGR2 protein from 136 mM down to
13.6, 1.36, and 0.27 mM prior to injection on
the Sephadex-75 column to determine whether
there is a concentration-dependence to dimerization
[Fig. 1(B)]. AGR2 protein injected at a concentra-
tion of 13.6 mM eluted with an estimated mass of
32.429 kDa, protein injected at 1.36 mM exhibited a
slower eluting species with an estimated mass of
29.119 kDa, and injection at a concentration of 0.27
mM displayed a mass of 26.147 kDa, suggesting
that the protein can exist in a dimer-monomer
equilibrium as it approaches predicted monomeric
mass of 18.2 kDa at lower concentrations. The
observed absorbance upon elution after each injec-
tion (214 nm; data not shown) corresponds to the
starting concentration, as after integration of
the peaks of each trace and plotting against
the concentration, the values appear linear with
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R2 5 0.9951 [Fig. 1(D)]. The traces in Figure 1(B)
have been normalized for ease of visual comparison.
These data are consistent with data suggesting
that a stable dimeric species of AGR2 requires an
in vitro concentration of the pure protein in the
low mM range.23
Figure 1. Molecular mass of native AGR221–175 protein. (A) The amino acid sequence of the recombinant “mature” AGR221–175
protein lacking the N-terminal leader sequence, highlighting the: (i) hexa-histidine motif and TEV protease cleavage site in the
tag, (ii) 60-EALYK-64 dimerization motif, (iii) 81-CPHS-84 thioredoxin motif, (iv) K95, (v) 101-AEQFVLLNLVYETTD-115 hydropho-
bic Reptin binding site, and (vi) degenerate 172-KTEL-175 ER retention site. (B) Gel filtration size exclusion chromatography of
AGR221–175 protein, injected at the indicated concentrations, using an analytical Superdex PC 75 column. The data are plotted
as relative absorbance to allow superimposition of the elution profiles. (C and E). Calibration of the Superdex PC 75 column
was performed with the indicated gel filtration markers (GE) in SEC buffer (50 mM Tris pH 7.5, 200 mM NaCl. (D). Displays a
plot of the peak area of the AGR2 peak (from B) as a function of AGR2 protein concentration at the time of injection, to high-
light the linearity between protein absorbance upon elution (at 214 nm) and protein (concentration) injected. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Developing a quantitative microtiter assay to
measure AGR2 oligomerization
It is not known whether the oligomeric (e.g., dimeric)
structure of AGR2 is required for any of its protein-
interaction functions.23 To develop quantitative
assays to measure AGR2 dimerization, we aimed to
first determine whether a quantitative two-site
“sandwich” microtiter assay (2SMTA) could be used to
quantify oligomerization (e.g., dimerization). We had
previously published a panel of monoclonal anti-
bodies generated to the AGR2 orthologue, AGR3.
Like AGR2,24 AGR3 can mediate cisplatin resist-
ance25 in xenografts. Of these monoclonal antibod-
ies,25 one (MAB3.4), cross-reacted with AGR2
[Fig. 2(D)]. The AGR2 epitope recognized by MAB3.4
was fine mapped to a short linear 5 amino acid resi-
due motif of 76-HHLED-80 [Fig. 2(C)];25 that is out
with the dimerization site [Fig. 2(A)] and therefore
the antibody can be used in the 2SMTA. The premise
of the 2SMTA is that the same immobilized MAB can
both capture and detect the target protein only if the
protein was oligomeric; for example, monomers can-
not be detected by this assay [Fig. 2(E)]. Fluorescent
labeling would allow quantitative detection of
oligomers over monomers in real time [Fig. 2(F)]. As
we cannot distinguish a dimer (based on gel filtra-
tion) from an oligomer using the 2SMTA, we prefer to
name the species we observe an oligomer.
Figure 2. Localization of the epitope for MAB3.4 on AGR2 protein. (A) Cartoon of the dimeric structure of AGR2 (PDB;
2LNS;23) highlighting the dimer interface (B) and the MAB3.4 epitope (C). (D) ELISA-based assay analyzing the specific
reactivity a panel of monoclonal antibodies raised against AGR325 toward AGR2. One of the AGR3-targetting monoclonal
antibodies binds to AGR2 (MAB3.4). (E and F) Theory of analyzing and quantifying the oligomeric nature of AGR2 using the
monoclonal antibody 3.4; (E) If AGR2 was monomeric and captured in the solid phase with MAB3.4, then the detection of this
immune complex with the same MAB would not give a signal as there is not a second epitope (red triangle) present in the
monomeric protein. However, a dimeric or oligomeric protein could be captured and detected with a monoclonal antibody that
binds to the same epitope as there would be more than one epitope exposed in the immune complex. Although we can pre-
sume that AGR2 is a dimer in solution (as from Fig. 1 and from Patel et al.,23), this assay cannot distinguish between a dimer
and higher oligomer, so we use oligomer throughout the text. (F) Predicted generic emission of an assay to measure AGR2 oli-
gomerization using the fluorescently tagged MAB3.4. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
Gray et al. PROTEIN SCIENCE VOL 22:1266—1278 1269
Labeling the monoclonal antibody and
optimization of the 2SMTA
To determine whether MAB3.4 can be used to mea-
sure AGR2 oligomerization, it was used to capture
AGR2 and then a DyLight800-(DyL800)-labeled ver-
sion of MAB3.4 was used to detect the captured
AGR2. If AGR2 was only a monomer, then there could
not be any detection of AGR2 protein using DyL800-
MAB3.4 in the solution phase. However, if AGR2
were oligomeric (e.g., dimeric or larger order assem-
blies), the epitope would, in principle, be presented to
DyL800-MAB3.4 in the liquid phase and the extent of
oligomerization would be proportional to the amount
of DyL800-MAB3.4 bound [Fig. 2(E,F)].
To develop this 2SMTA, we needed to first label
the MAB3.4 with a fluorescent probe under conditions
in which the labeled MAB retained functionality.
Labeling of MAB3.4 was done with the far-infrared
fluorophore DyL800. The labeling reaction proceeds
through modification of primary amines and if an
essential lysine in the complimentary determining
region (CDR) was important for AGR2 binding, then
Figure 3. Developing a quantitative microtiter assay to measure AGR2 oligomerization. (A) Evaluation of the bioactivity of fluo-
rescently labeled MAB3.4 in a luminescent-based ELISA. (B) MAB3.4 was left unconjugated or conjugated to DyL800 and after
purification of the latter; the monoclonal antibodies were titrated into reactions containing AGR2 protein on the solid phase. The
binding of MAB3.4 to AGR2 was measured using an anti-mouse IgG secondary antibody conjugated to peroxidase. The bioac-
tivity of the monoclonal antibody (in relative luminescent units) is measured as a function of increasing MAB3.4 concentration.
(C) Evaluation of the bioactivity of fluorescently labeled MAB3.4 in a fluorescence detection assay. (D) MAB3.4 was left unconju-
gated or conjugated to DyL800 and the monoclonal antibodies were titrated into reactions containing AGR2 protein on the solid
phase. The bioactivity of the monoclonal antibody was measured as levels of emission at 800 nm a function of increasing
MAB3.4 concentration. (E) Evaluation of the bioactivity of fluorescently labeled MAB3.4 to detect a potential AGR2 oligomer. (F)
MAB3.4 was coated onto the solid phase and increasing amounts of oligomeric AGR2 were added to allow capture onto the
solid phase. Fixed amounts of DyL800 MAB were added into reactions and the binding of DyL800-MAB3.4. The extent of oligo-
merization was quantified as levels of emission at 800 nm a function of increasing AGR2 protein concentration and is presented
as an average from triplicate titrations. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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labeling might inactive the MAB [Fig. 3(A)]. A
titration of MAB3.4 and DyL800-MAB3.4 reveals
that the labeled antibody produces a binding activ-
ity in RLU 1.8–2.5 lower fold lower than the unla-
beled monoclonal antibody [Fig. 3(B)]. These data
indicate that the DyL800-labeled monoclonal antibody
retains significant affinity for its epitope in AGR2
protein and that binding could be quantified in a
dose-dependent manner. The AGR2 protein-MAB
interaction in Figure 3(B) measured the binding of
the MAB3.4 or DyL800-MAB3.4 using peroxidase-
labeled anti-mouse IgG secondary antibody and
detection using chemiluminescence [Fig. 3(A)]. Fol-
lowing this, we evaluated binding using Licor far-
infrared detection by excitation at 750 nm and fluoro-
phore emission detected at 800 nm [Fig. 3(C)]. The
DyL800-MAB3.4 binding to AGR2 adsorbed on the
solid phase could be detected in a dose-dependent
manner [Fig. 3(D)], relative to the unlabeled MAB3.4
that did not give rise to any signal. The binding reac-
tion appeared more linear using DyL800-MAB3.4 in
the direct excitation-emission assay [Fig. 3(D)] than
in the indirect peroxidase-labeled secondary anti-
body [Fig. 3(B)]. There are two explanations for
this phenomenon. First, the chemiluminescence
assay [in Fig. 3(B)] uses “enhanced” enzymatic con-
version by the antibody-peroxidase conjugate of
substrate to create light that is quantified as a
function of a fixed time. As a result, the data do
not reflect a reaction rate but a final product accu-
mulation. This “enhancement” of the primary signal
may produce results that deviate from linearity. By
contrast, the fluorescently conjugated monoclonal
antibody emits a signal that is detected directly
and the results are presumably more linear. Sec-
ond, the indirect enhanced chemiluminescence
assay incorporates an additional 75 min of incuba-
tion with secondary antibody, washings, and chemi-
luminescence substrate addition and this
incorporates an unquantified effect of antibody off
rate on the signal intensity. By contrast, after incu-
bations with the fluorescently conjugated antibody,
the reaction is washed rapidly, and fluorescence
intensity is read immediately thus minimizing
effects of the antibody off rate on the signal inten-
sity. These data validate the DyL800-MAB3.4 exci-
tation-emission assay as a bioactive probe. As such,
we next evaluated whether DyL800-MAB3.4 could
detect oligomeric forms of AGR2 in assay as a
quantitative assay to measure oligomerization (oli-
gomerization) of AGR2 protein [as outlined in
Fig. 2(E)]. An outline of approach using DyL800-
MAB3.4 to detect an oligomeric (potentially
dimeric) species of AGR2 is outline in Figure 3(E).
Reactions were assembled without or with adsorp-
tion of unlabeled MAB3.4 on the solid phase. Upon
titration of DyL800-MAB3.4, a dose-dependent sig-
nal can be observed [Fig. 3(F)], suggesting that
this assay can indeed measure oligomeric AGR2
protein.
Self-peptides that stabilize or disrupt the
oligomer equilibrium
We next used the 2SMTA to determine whether
AGR2 oligomer stability can be attenuated using
dimer interface peptides or indeed stabilized in trans
by regulatory motifs from the intrinsically disordered
region of the protein [Fig. 4(B)]. The predicted disor-
der of polypeptides regions in AGR2 protein (using
Disprot) are shown in Figure 4(B). The assay
[Fig. 4(A)] included a pre-incubation stage where
AGR2 oligomers were incubated with overlapping
peptides derived from the open reading frame of
AGR2 [Fig. 4(C)]. These overlapping AGR2-derived
peptides (numbered 1–5) are from the N-terminal
leader sequence, disordered region, and the dimeric
interface [Fig. 4(C)]. Peptides 2 and 3 derived from
the disordered region stabilize the AGR2 oligomer in
trans, with peptide 3 inducing the most stabilized
oligomer [Fig. 4(D)]. There is a dose-dependence in
oligomer stabilization with a concentration of peptide
as little as 3 mM increasing stability [Fig. 4(D)]. As
controls, peptides overlapping the dimer interface do
not stabilize the oligomer. Rather, these peptides
4 and 5 reduce the fluorescence [Fig. 4(E)] with
peptide 5 containing the interface sequence
60-EALYK-64 inducing the greatest degree of
oligomer de-stabilization. The ability of peptide 4 to
similarly de-stabilize the oligomer, although to a
lesser extent than peptide 5, suggests other motifs in
AGR2 can be targeted to affect the dimer stability.
The common amino acid sequences of peptides
4 and 5 that attenuate oligomer stability include
51-QLIWT-55 [Fig. 5(A)]. The more bioactive peptide
5 has the additional 56-QTYEEALYK-64 comprising
the dimer interface [Fig. 5(A)], which suggests why
peptide 5 is more active at disrupting the AGR2
oligomer using the 2SMTA. We created a set of
AGR2 mutants to determine whether the 2SMTA can
be used on full-length mutants to observe changes in
oligomer stability. We chose to mutate Y58, since it
protrudes into the adjacent internal b-sheet and
might be required for stabilizing the dimer interface
[Fig. 5(C)]. We also mutated E59 as it protrudes out-
ward into solvent [Fig. 5(C)], whilst E60 forms a salt
bridge with K64 across the adjacent monomer form-
ing an important feature of the dimer interface
[Fig. 5(A)]. The mutant forms of AGR2 created to
determine how these affect oligomer stability,
included Y58A, E59A, E60A, and D45 (deletion
of amino acids 21–45) [Fig. 5(B)]. A titration of
AGR2-E59A revealed its’ oligomer stability is similar
to wt-AGR2 [Fig. 5(B)]. By contrast, AGR2-E60A
was in an apparent monomeric state, as judged by
the absence of a signal in the oligomer assay
[Fig. 5(B)]. The AGR2-Y58A was attenuated as an
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oligomer with a signal in the 2SMTA only seen at
the highest concentration of the protein [Fig. 5(B)].
By contrast to these loss-of-function mutants,
D45-AGR2 was more stable as a dimer [Fig. 5(B)].
The enhanced stability of the oligomer by deletion of
the disordered region is consistent with prior
research showing that deletion of amino acids 21–40
increases dimer stability.23
Mapping the crosslinked AGR2 dimer
We sought to develop an independent assay to vali-
date the stability of the AGR2 dimer through the use
of a DSS crosslinker that can trap a covalent dimeric
species [Fig. 6(A)]. Mapping of this crosslink using
mass spectrometry identified K95 as the dominant
cross-link [Fig. 6(B,C)]. Mutagenesis of K95 to create
AGR2-K95R confirmed that this is the dominant
cross-link site [Fig. 6(D)]. An image of the position
of K95 relative to the dimer interface is depicted
in Figure 6(E). We used this assay to determine
whether the AGR2 mutant panel exhibited altered
dimerization (Fig. 7). A titration of DSS into reactions
containing wt-AGR2, AGR2-E60A, and D45-AGR2
demonstrated that AGR2-E60 is attenuated in
Figure 4. Effects of self-peptides on the extent of AGR2 multimerization. (A) Staging the effects of self-peptides on the oligome-
rization of AGR2. (B) Plot of the predicted disorder of AGR2 as a function of the amino acid sequence (Disprot). (C). Overlapping
peptide sequences from the disordered and dimeric region of AGR2. (D) Effects of the “disordered” peptides 2 and 3 on AGR2
oligomerization. The 2SMTA was set up as in Figure 3(E) except that AGR2 protein (5.5 pmoles) was preincubated with the over-
lapping peptides 2 and 3 at the indicated concentrations from 3 to 50 mM for 1 h. After washing the DyL800-MAB3.4 probe was
added for 1 h and the extent of oligomerization was measured as a function of emission at 800 nm. The data are depicted as
DyL800-MAB binding (emission at 800 nm) as a function of peptide 2 and 3 concentration with subtraction of the inert peptide
control. (E). Effects of the dimer-interface peptides 4 and 5 on AGR2 oligomerization. AGR2 protein (5.5 pmoles) was preincu-
bated with the overlapping peptides 3, 4, and 5 at the indicated concentrations for 1 h. After washing the DyL800-MAB3.4 probe
was added for 1 h and the extent of oligomerization was measured as a function of emission at 800 nm. The data are depicted
as DyL800-MAB binding (emission at 800 nm) as a function of peptide 3, 4, and 5 concentration after subtraction of the inert
peptide control background. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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dimer formation [Fig. 7(B)]. In addition, D45-AGR2
exists in a more stable, spontaneous dimer in the
absence of cross link [Fig. 7(C), lane 1], suggesting
that deletion of the N-terminus can allow it to form a
stable dimer in the presence of the 0.1% SDS buffer.
These data together are consistent with the quantita-
tive 2SMTA that demonstrated D45-AGR2 is a more
stable dimer whilst AGR2-E60A is predominantly
monomeric.
Evaluating the specific activity of the AGR2
oligomer
There is no known biochemical function for the AGR2
dimer. Having created a series of gain-of-function or
loss of function AGR2 mutants, we evaluated the role
of oligomerization in molecular interaction of AGR2
with two of its most well-characterized substrates:
peptides containing the [T/S]-x-I-[YF]-[Y/F] consensus
motif20 and the AAA1 chaperone protein, Reptin.26
The former protein-interaction presumably represents
docking sites in its client proteins (manuscript in prep-
aration). The latter protein interaction is with the
AAA1 protein Reptin, which itself functions as a
molecular machine able to assemble multiprotein com-
plexes. The in vivo impact of AGR2 protein binding on
client proteins containing the [T/S]-x-I-[Y/F]-[Y/F]
motif and on Reptin complex assembly is currently
undefined. Nevertheless, we wanted to determine
whether AGR2 binding to either of these two targets
was influenced by its’ dimer-monomer state. A titra-
tion of wt-AGR2, AGR2-E60A, and D45-AGR2 indi-
cates that all three exhibited relatively similar
activity in binding to this peptide substrate [Fig. 8(A)].
By contrast, the Reptin substrate is substantially sta-
bilized using the gain-of-function more stable dimer
mutant D45-AGR2, whilst AGR2-E60A is attenuated
[Fig. 8(B)]. These data provide the first biochemical
evidence that dimerization of AGR2 protein can play a
role in its affinity for a client protein. As there are
over one dozen binding proteins identified for AGR2
protein using yeast-two hybrid,21 it will be interesting
to see whether this panel of AGR2 oligomerization
mutants can be used to access the role of the AGR2
dimer in these protein-protein interactions.
Discussion
Developing assays that measure oligomerization and
how allosteric effects can be measured in parallel will
provide important tools in the emerging field of drug-
ging protein-protein interactions. We evaluate here
an approach to measure oligomerization and allostery
using Anterior Gradient-2. The mechanism whereby
AGR2 mediates its’ functions is thought to include its
ability to chaperone proteins in the ER27 and to medi-
ate induction of oncogenic signals like EGF or p53
tumor suppressor silencing.28,29 The majority of
AGR2 protein interactions have been identified using
yeast-two hybrid,21 with the only well-validated pro-
tein being the AAA1 pro-metastatic protein Reptin.26
Characterizing these various protein–protein interac-
tions will likely shed light on its mechanism of action.
Toward this aim, we focused on characterizing the
AGR2 oligomer (dimer) as a model, since our initial
biochemical characterizations demonstrated that its
apparent mass was consistent with a homodimeric
quaternary structure (Fig. 1). This is consistent with
a recent report showing that recombinant AGR2
Figure 5. Effects of single point mutations in AGR2 dimer
interface on multimerization using 2SMTA. (A) Sequence of
bioactive peptides (from Fig. 4) derived from the disordered
and dimerization region of AGR2 protein. Highlighted are
minimal motifs predicted to drive stimulation (KDTKD from
peptides 2 and 3) and inhibition (QLIWT from peptides 4 and
5). The dimer interface (from Ref. 23) in peptide 5 is high-
lighted as EALYK. (B). Oligomer stability in AGR2 mutant
panel. Increasing amounts of wild-type and mutant AGR2
proteins (from left, 0, 0.69, 1.38, 2.75, and 5.5 pmoles) were
captured using MAB3.4 as indicated in Figure 3(E). Following
the addition of DyL800-MAB3.4, the extent of oligomerization
was quantified by emission at 800 nm and the data is pre-
sented as an average from triplicate titrations. No protein
background signal is represented on the far left (157 U). The
ratio of dimer to monomer is highlighted above each series:
wt: dimmer>monomer; Y58A: monomer>dimer; E59: as
wild-type; E60A: monomeric; and D45: more stable dimeric
over monomeric. (C). Summary of the positions of Y58, E59,
and E60 across the dimer interface region. [Color figure can
be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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(AGR221–175 or AGR241–175) lacking the N-terminal
leader sequence or disordered region, respectively,
can form homodimers.23 Showing that AGR2 can exist
as a dimer in vitro, we then wanted to determine
whether the dimeric structure was important for
two of the most well-characterized interactions; (i) the
[T/]-x-I-[Y/F]-[Y/F] pentapeptide consensus binding
site; and (ii) the AAA1 protein Reptin. Toward this
aim, we needed to create a set of mutants in AGR2
with altered oligomeric state and we needed robust
assays to define changes in its dimeric structure as a
function of mutation.
The assay designed to measure oligomer stability
was a two-site microtiter assay in which an oligomeric
protein captured in solid phase can be detected in
small volume liquid phase using the same monoclonal
antibody; for example a “sandwich assay” (2SMTA). In
this assay it is not possible for a monomer to give a
signal. The 2SMTA detected attenuation of AGR2 oli-
gomerization using self-peptides derived from the
dimer interface (60-EALYK-64). Amino acids outwith
this motif also attenuated oligomer stability (e.g., pep-
tide 4; Fig. 4) suggesting that the dimer motif
requires the stability of the adjacent peptide chain. In
addition, we also surprisingly identified peptide
motifs that can stimulate AGR2 oligomerization in
trans. These peptides are derived from the intrinsi-
cally disordered region in the N-terminal domain of
AGR2 (Fig. 4) and their ability to act in trans as posi-
tive effectors of oligomerization suggests they disrupt
the function of the natural N-terminal sequences in
cis. There are interesting paradigms where peptides
and mimetics can allosterically stimulate protein–pro-
tein interactions30,31 and it will be interesting to
determine whether these AGR2 stimulatory peptides
can be used as tools to manipulate the activities of the
protein. Using 2SMTA as a rapid screen for oligomeri-
zation capability, we confirmed that AGR2-E60A was
Figure 6. Mapping the sites of DSS dimer crosslinking to Lysine-95. (A) Crosslinking of AGR2 into a homodimeric species using
the covalent crosslinker DSS. (B) Absence of crosslinking of AGR2-K95R mutation into a homodimeric species using the covalent
crosslinker DSS, based on the K95-K95 crosslinks identified in C and D. (C). Mass spectrum of interprotein crosslinked peptides
VFAENKEIQK and KKVFAENKEIQK (the bold K corresponds to the DSS-linked amino-acid), at [M15H]51 5 561.716 m/z units.
(D) The lower panel shows the annotated tandem mass spectrum after coalitional-induced dissociation and subsequent Orbitrap
mass analysis. Crosslinked peptides were identified as indicated in the materials and methods. (E) Cartoon of the interdomain ori-
entation of the K95 amino acid residues with respect to the dimeric interface. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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largely monomeric (Fig. 5) and D45-AGR2 had an
enhanced oligomerization capacity (Fig. 5). This was
confirmed using a DSS crosslinking assay (Fig. 7)
that was mapped to the K95 residue using mass spec-
trometry (Fig. 6).
Having developed a set of well-characterized oli-
gomerization mutants, the effect of subunit structure
on biochemical activity was finally evaluated. The
AGR2 monomeric mutant E60A bound as stably as
wild-type AGR2 or the enhanced dimer mutant
D45-AGR2 to the [T/S]-x-I-[Y/F]-[Y/F] pentapeptide
motif. This data indicates that if the TxIYY docking
site represents a cellular binding interface for AGR2
client proteins, then the monomeric form of AGR2 has
the potential to be equally active. By contrast, the
binding of AGR2 to Reptin was stabilized by creating
an enhanced dimer (D45-AGR2) and attenuated using
the monomeric E60A mutant AGR2. Thus the deter-
minant in AGR2 that interacts with Reptin (primarily
within amino acids 104–111;26) exploit its’ dimeric
subunit structure. Solving the interface of AGR2-
Reptin might facilitate developing biologics that dis-
rupt this protein interaction to determine how it
might contribute to cancer cell growth.
In conclusion, we have developed a microtiter-
based assay that measures in small volumes the oligo-
merization state of AGR2 protein. Such an assay was
used to identify ligands like self-peptides that can
allosterically regulate multimer stability thus form-
ing a proof-of-concept assay for screening for cellular
proteins or drug-leads that might regulate of AGR2
dimer stability in vivo. The use of microtiter assays
like the “sandwich”-type assay (2SMTA) that meas-
ures ligand-free oligomerization provides a robust
small volume methodology that can be adapted to
screen for ligands that regulate the stability of oligo-
meric proteins implicated in human disease.
Experimental
Purification of recombinant AGR2 protein and
analytical gel filtration size-exclusion
chromatography
AGR221–175 was cloned into pEHISTEV and trans-
formed into BL21 (DE3).20,32 Bacteria were grown to
OD600 of 0.6 at 37
C and 1 mM IPTG was added for a
further 3 h, followed by harvesting and resuspending
in 30 mL of lysis buffer (50 mM NaH2PO4 pH 7.5,
400 mM NaCl, 10 mM Imidazole) on ice. Cells were
subjected to high-pressure (25k PSI) followed by cen-
trifugation at 40,000g for 50 min to isolate the soluble
fraction. The supernatant was applied to a Ni-charged
HisTrap FF 5-mL column (GE Life Sciences). The
immobilized protein was subject to a step-elution with
30 mM then 300 mM Imidazole. The eluted protein
was pooled and cleaved with recombinant tobacco etch
virus protease overnight at 20C. The resultant solu-
tion was desalted into protein buffer (50 mM Tris
pH 7.5, 200 mM NaCl) with a HiPrep desalt 26/10
column (GE Life Sciences) before reloading onto the
IMAC to remove protease and uncleaved protein.
Purified protein was analyzed by gel-filtration size
exclusion chromatography on an analytical Superdex
PC 75 3.2/30” column (GE Healthcare) at titrated con-
centrations ranging from 2.5 mg mL21 to 5 mg mL21
(injection volume of 20mL). Detection was by absorp-
tion at 214 nm at a flow rate of 0.5 mL min21. The col-
umn was calibrated using protein standards (GE
Healthcare).
Monoclonal antibody purification and DyLight800
labeling. Monoclonal antibody MAB3.425 was
affinity purified on a Protein G column by elution
using a buffer containing 0.1 M Glycine (pH 2.5)
and then neutralized with 1/10th volume of a 1 M
Tris HCl (pH 8.8) buffer. The IgG was dialyzed
against PBS and was conjugated to DyLight800 fluo-
rophore (excitation at 770 nm and emission at 794
nm) using DyLight800 Microscale Antibody Labeling
Kit (53063; Thermo Scientific). Briefly, 50 lL of
MAB3.4 (1.3 mg mL21) was diluted to 100mL final
volume with 0.67M Borate buffer and the protein as
added a vial of DyLight800 reagent to initiate cou-
pling and the reaction is continued in the dark for
60 min at room temperature. The labeled protein
Figure 7. Effects of DSS on the dimerization of AGR2 mutants.
The indicated proteins; (A) wt-AGR2, (B), AGR2-E60A, or (C)
D45-AGR2, were incubated with increasing concentrations of
DSS and separated by electrophoresis on an SDS gel (contain-
ing 0.1% SDS). AGR2 was detected using MAB3.4 in an immu-
noblot. The positions of monomeric and dimeric proteins are
highlighted.
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was added to a spin column in microfuge format and
the labeled antibody was separated from the label
by collecting the eluate after centrifugation.
Measuring AGR2 oligomerization using a two-
site sandwich microtiter assay (2SMTA). Immu-
noglobulins (100 ng/50 ml per well) were adsorbed
onto 96-well Costar opaque (white) wells, diluted in
100 mM NaHCO3 pH 8.6 and incubated at 4
C, with
agitation, for 14–16 h. Wells were washed 3–53 with
PBS-0.05% Tween-20, prior to blocking with 200 mL of
3% bovine serum albumin in PBS-0.05% Tween-20
per well for 1 h at room temperature. Protein was
titrated in triplicate to the desired concentration in
blocking buffer to 50mL per well and incubated on the
plate for 1 h at room temperature and washed 3–53
with PBS-0.05% Tween-20 prior to antibody detec-
tion. Primary antibody was diluted 1:1000 (1 mg
mL21) and 50-mL per well incubated at room tempera-
ture for 1 h, plates were then washed 3–53 with
PBS-0.05% Tween-20. For ECL, 50 mL secondary anti-
body (rabbit anti-mouse, 1:1000 in 3% BSA-PBST)
was incubated for 1 h, prior to a final 3–53 washes
with PBS-0.05% Tween-20 and relevant detection. To
detect dimerization: (i) enhanced chemiluminescence
was carried out using white 96-well plates and sec-
ondary antibody conjugated to horseradish peroxi-
dase followed by detection on a Fluoroskan Accent FL
(ii) alternatively, a 800 nm near-IR label (DyLight
800, Thermo) was used to label the anti-AGR2
MAB3.4 and, using black walled, clear bottomed 96-
well microtiter plates (Costar), antibody binding was
quantified using Licor Odyssey.
Oligomer disruption assays using 2SMTA
The capture MAB (100 ng per well of MAB3.4)
was diluted in 50mL of NaHCO3 (pH 9.0) buffer
and adsorbed on to the black walled, clear bottomed
96-well microtiter plate overnight at 4C. Plates
were then washed 3–53 with PBS-0.05% Tween-20,
and blocked with 3% BSA in PBS-0.05% Tween-20
for 1 h. Concurrently, 100 ng (up to 5.5 pmoles) of
Figure 8. The effects of AGR2 oligomerization on its protein-interaction activity. The indicated AGR2 proteins (wt-AGR2,
AGR2-E60A, or D45-AGR2) were incubated in reactions containing (A) biotinylated TxIYY containing peptide and (B) Reptin.
AGR2 bound to either peptide or Reptin was detected using MAB3.4 and quantified using anti-secondary IgG coupled to
peroxidase and chemiluminescence. The data are depicted as AGR2 binding activity (in RLU) as a function of increasing
AGR2 protein concentration (in triplicate and presented as an average). [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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purified AGR2 protein was diluted to 50 mL of pro-
tein buffer, and incubated with the indicate amounts
of biotinylated overlapping peptide (in triplicate) for
1 h. The blocking solution was removed from the
plate and replaced by peptide–protein solution and
incubated for 1 h. Nearly 150 ng of DyLight800-
labeled MAB3.4-labeled was then added to each well
and allowed to bind for 1 h. Unbound or weakly
bound antibody was then removed by 53 washes
with PBS-0.05% Tween-20 before directly detected
on the Licor Odyssey with 750 nm laser excitation
and emission at 800 nm. Images were analyzed and
quantified with the Odyssey Sa software.
Site directed mutagenesis of AGR221–175-pEHIS-
TEV to produce Y58A, E59A, and E60A mutants
and cloning for D45 mutant. The indicated pri-
mers (Y58A, E59A, and E60A) were used for mutagen-
esis using GENEART mutagenesis kit (Invitrogen).



















The D45 mutant was amplified by PCR using forward
(CCATGGCTATGAGAGGTTGGGGTGACCAAC) and
reverse (CTCGAGTTACAATTCAGTCTTCAGCAACTT).
The PCR products were cloned into pEHISTEV vector
digested with NcoI and XhoI restriction enzymes to
generate the final vectors.
Measuring mutant AGR2 protein oligomeriza-
tion status using 2SMTA. About 500 mL pellets of
bacteria induced to express wild-type and mutant
AGR2 were resuspended in 10 mL lysis buffer and
subject to 3 3 10 s sonication on ice. Protein mutants
included Y58A, E59A, E60A, and D45-AGR2. The
lysed bacteria were centrifuged to isolate the soluble
fraction. About 10 mL fractions of each mutant crude
lysate was separated by SDS-PAGE, transferred to
nitrocellulose and probed with the DyLight800-
labeled MAB3.4. Using the Licor Odyssey system an
immunoblot was used to quantify and normalize
AGR2 protein concentrations (as in Fig. 5). Nearly
100 ng of MAB3.4 antibody was adsorbed onto a
clear-bottomed 96-well plate and the plate was
washed and blocked as described previously. A titra-
tion of the normalized AGR2 protein (in triplicate)
was applied to the plate in the mobile phase before
washing 53 PBS-0.05% Tween-20 and quantification
using the DyLight800-labeled MAB3.4.
Measuring the AGR2 oligomerization status
using the K95-dependent DSS cross-linking
assay. For protein crosslinking, AGR2 protein was
exposed to DSS (Pierce 21555) and separated by
SDS gel electrophoresis. The DSS crosslinked pro-
tein was dissolved in 50 mM ammonium bicarbonate
and 6 M urea, reduced with 1 mL 50 mM DTE
(dithioerythritol) for 60 min at 37C, and alkylated
by adding 1 mL of 400 mM iodoacetamide for 60 min
at room temperature. The sample was diluted three
times and digested overnight at 37C with 0.1 mg of
sequencing grade trypsin (Promega, Madison, WI).
The remaining methodology for identification of
crosslinked peptides has been described,33–35 includ-
ing the use of an LTQ Orbitrap velos mass spectrom-
eter (Thermo Electron; San Jose, CA) equipped with
a NanoAcquity system (Waters). Mutagenic primers
for K95R mutant generation were as follows: K95R
forward: 50-gtgtttgctgaaaatagagaaatccagaaattg, and
reverse: 50-caatttctggatttctctattttcagcaaacac.
Measuring AGR2 protein–protein interactions.
AGR2-Reptin. Human Reptin expressed in BL21
AI (Invitrogen) E. coli was purified as described.26 To
measure the binding of AGR2 (and mutants), purified
Reptin (100 ng per well) was adsorbed to the well in
carbonate buffer (0.1 M pH 9.0) overnight. Following
blocking with PBS containing 0.05% Tween-20 and
3% BSA, the indicated AGR2 proteins were titrated in
triplicate and incubated for 1 h at room temperature
followed by detection with an AGR2 monoclonal anti-
body (Abnova) and HRP conjugated rabbit anti-mouse
secondary antibody (Dako).
AGR2-TxIYY peptide. The TxIYY containing pep-
tide (Biotin-SGSG-HLPTTIYYGPPG;20) was cap-
tured on streptavidin-coated wells and incubated for
1h, then plates were washed 53 with PBS-0.05%
Tween-20 and blocked. AGR2 protein and the indi-
cated mutants were titrated in triplicate onto the
plates and incubated for 1 h at room temperature
followed by detection using the AGR2 monoclonal
antibody and HRP conjugated rabbit anti-mouse sec-
ondary antibody.
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Discovery of a novel ligand that modulates the
protein–protein interactions of the AAA+
superfamily oncoprotein reptin†
Alan R. Healy,a Douglas R. Houston,*b Lucy Remnant,c Anne-Sophie Huart,c
Veronika Brychtova,d Magda M. Maslon,c Olivia Meers,c Petr Muller,d Adam Krejci,d
Elizabeth A. Blackburn,b Borek Vojtesek,d Lenka Hernychova,d
Malcolm D. Walkinshaw,b Nicholas J. Westwood*a and Ted R. Hupp*c
Developing approaches to discover protein–protein interactions (PPIs) remains a fundamental challenge. A
chemical biology platform is applied here to identify novel PPIs for the AAA+ superfamily oncoprotein
reptin. An in silico screen coupled with chemical optimization provided Liddean, a nucleotide-mimetic
which modulates reptin's oligomerization status, protein-binding activity and global conformation.
Combinatorial peptide phage library screening of Liddean-bound reptin with next generation sequencing
identified interaction motifs including a novel reptin docking site on the p53 tumor suppressor protein.
Proximity ligation assays demonstrated that endogenous reptin forms a predominantly cytoplasmic
complex with its paralog pontin in cancer cells and Liddean promotes a shift of this complex to the
nucleus. An emerging view of PPIs in higher eukaryotes is that they occur through a striking diversity of
linear peptide motifs. The discovery of a compound that alters reptin's protein interaction landscape
potentially leads to novel avenues for therapeutic development.
Introduction
Discovering protein–protein interactions (PPIs) remains a
major challenge.1 However, a detailed understanding of a pro-
tein's PPI network is central to novel biomedical applications.
Rate-limiting protein nodes need to be identied as they can
serve as a focus for novel diagnostic and/or therapeutic
advances. The current view is that drugging PPIs remains an
untapped landscape in the drug discovery eld.
The main approaches used to dene the PPIs of a target
protein include yeast two-hybrid methods2 and mass-spec-
trometry-based sequencing of multi-protein complexes using
tagged-bait proteins.3 Although powerful, their limitations are
that they are done outside an authentic cellular context, require
articial tagging of the bait protein and are unable to capture
weak, or dynamic interactions. One advance in the study of PPIs
is the idea that a large proportion of the polypeptide sequence
information in higher eukaryotes is intrinsically disordered
thus providing a template for “weak” regulatory, combinatorial
and specic PPIs to occur in signal transduction.4 A second
advance is the realization that a number of PPIs occur via a
linear amino acid motif1 that provides opportunities for
sequence based hotspots to be identied. Developing methods
to capture such consensus linear motifs of a target protein
would complement the technology currently used to discover
PPIs.
The AAA+ (ATPase associated with various cellular activities)
superfamily of proteins is present within all kingdoms of life.5
Members of this family exist as oligomers and form compelling
targets in understanding allosteric control of protein function.6
Reptin and pontin represent two highly conserved members
that are now viewed as model systems to dene fundamental
aspects of AAA+ superfamily function in eukaryotes.7 Reptin is
an important regulator of key cellular functions through a range
of PPIs.8–19 The different oligomeric forms of reptin and its
ability to form a range of complexes with different compositions
could underpin its functional diversity.20–22 The composition of
these oligomeric complexes must be tightly regulated and this
has been linked to reptin's bound ligand ATP/ADP.23,24 Devel-
opment of a synthetic ATP/ADP mimetic to probe the intrinsic
oligomerization properties of reptin and its ability to form
diverse PPIs could provide insight into the regulation and
function of reptin and the wider AAA+ family.
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Here, a chemical biology platform is used to deliver a novel
tool to dissect the function of reptin. This approach involves; (i) in
silico screening of virtual libraries to identify novel ATPmimetics;
(ii) optimization of a hit as a PPI and oligomerization modier
giving the novel chemical tool, Liddean; (iii) use of combinatorial-
peptide libraries and next generation sequencing to identify novel
responsive PPIs; and (iv) cell based validation of ligand-activated
PPIs using proximity ligation assays. We also demonstrate that
our chemical tool Liddean (an ATP-mimetic) can be used to
discover and manipulate the PPIs of the AAA+ protein reptin.
Results
In silico screening leading to a prioritized ATP mimetic
An in silico screen was used to identify small molecules that
might bind at the Walker A site on reptin. The rigid-body
Fig. 1 Identification of small molecules targeting reptin using an in silico screening programme. (a) Structure of hit compound 1 was identified
through a reptin–AGR2 peptide interaction assay of the top 30 hits from the in silico screen (see Fig. S1 and S2†) and Liddean, the most active
analog obtained through chemical optimization (see Scheme S1 and Fig. S4 and S5†). (b) The Autodock prediction of the binding mode of 1 is
shown as black sticks. The side chains of residues that comprise the active site are shown as green lines and are labeled. The ADP molecule is
colored white and shown as sticks. The pocket is also shown as a transparent surface representation. In all cases nitrogen is colored blue, oxygen
red, phosphorous orange, and chlorine green. See also Fig. S1 and S3.† (c) Changes in hydrogen–deuterium exchange on reptin peptide motifs
after pepsin proteolysis. Ligand free reptin protein (Fig. S7a†) was digested with pepsin after processing in the absence or presence of Liddean.
Processing of peptides was performed using HPLC-MS/MS with the instrument operated in a data-dependent mode. All identified peptides are
shown as green bars (1 minute) or black bars (five minutes) without or with Liddean (L) and the % change in deuteration as a function of peptide
fragment is highlighted. Shown are representative peptide fragments with increased or decreased deuterium exchange with ligand (*) or without
changes in deuterium exchange with ligand (–). The peptic peptides cover the majority of the sequence of reptin with the numbering shown
below the amino acid sequence. The sequence includes six residual N-terminal amino acids from the “tag” after precision protease cleavage from
glutathione beads, amino acids and includes GPLGST (Fig. S7a and b†). (d) The reptin protein (PDB 3UK6) is displayed as a cartoon in green. The
ADP molecule from reptin is shown as spheres in cyan. Regions with suppressed deuterium exchange are shown in red and regions with
increased deuterium exchange are shown in blue. Key regions which form a dimer interface (R428-S439, arrow 1) and the ATP pocket (T81-G95
(arrow 2) & Y362-C375 (arrow 3)) are highlighted. The most dominant peptide fragments which show alterations in deuterium exchange ((c) and
Table S2†) map either around the ADP binding site or at the dimer interface.
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docking program LIDAEUS25 was used to dock a conformer
virtual library of 4.4 million compounds. The results were
ranked based on the LIDAEUS score and the top 49 971
compounds were redocked using Vina and Autodock (Fig. S1†).
A “rank-by-rank” consensus protocol prioritized hits, culmi-
nating in the selection of 30 compounds for assessment using
an ELISA assay17 with the peptide 104-FVLLNLVY-111 from the
known reptin binding protein AGR217 (Table S1†). Hits from this
assay were dened as compounds that modied (increased or
decreased) signicantly the signal corresponding to reptin
binding to the AGR2-peptide compared to control. Of the 30
compounds tested (Fig. S2†), compound 1 (Fig. 1a) led to the
most dramatic response and was therefore prioritized for study.
Compound 1 contains a biphenyl substituent that is predicted
to sit deep in the Walker A pocket where the adenine of ADP/
ATP binds and a pyridine–oxazolo ring system which is pre-
dicted to extend out of the pocket (Fig. 1b and S3†).
Structure activity relationship and hydrogen–deuterium
exchange studies
The synthesis of 1 (Scheme S1†) provided sufficient material for
hit validation studies. An SAR study was then carried out to
improve the activity of 1. Modied analogs were either
purchased or synthesized (Schemes S1 and S2 and Fig. S4†). The
bromo-analog of 1, now called Liddean (Fig. 1a), was found to
be the most active analog. The results from this SAR study (see
Fig. S5† legend for a more detailed discussion), supported by
hydrogen–deuterium exchange (HDX) studies (Fig. 1c and d),26
were consistent with the proposed binding mode. Importantly,
suppression of HDX by Liddean was most pronounced for
amino acids 362–375 in the Walker A site (Fig. S6†). Interest-
ingly, an increased rate of HDX was observed along the length of
the a-helix (81–95) that contacts to the Walker A site. In addi-
tion, deuterium exchange was suppressed for amino acids 428–
439 which are located at the known protein–protein interface in
reptin homodimers (Fig. 1c and d). It was therefore decided to
assess whether Liddean had an effect on the oligomerization
status of reptin.
Liddean alters reptin's oligomerization status
Oligomerization of reptin is known to increase in the presence
of bound ligands ATP or ADP.24 Reptin was subjected to SDS
denaturing (0.1%) electrophoresis in the presence of varying
amounts of SDS (Fig. 2a and S8a†). The preincubation of reptin
with Liddean induced the formation of a stable oligomeric form
of reptin (MW z 250 kDa, Fig. 2a) as well as additional bands,
corresponding to higher order oligomers (possibly hexamers
based on the apparent mass). These data suggested that
Fig. 2 (a) The effect of Liddean on the oligomerization dynamics of
reptin. (a) Reptin (1 mg) was subjected to denaturing SDS (0.1%) gel
electrophoresis in ADP binding buffer without or with ADP (100 mM) or
Liddean (100 mM), as indicated. After 30 minutes of incubation at room
temperature, gel loading buffer was added (with 1% SDS concentra-
tion), and electrophoresis was then carried out. Reptin protein was
visualized by silver staining. See Fig. S8† for additional data. (b) The
effect of Liddean on the interaction of reptin with the molecular
chaperone HSP90. SBP-tagged HSP90 was captured on streptavidin
coated wells and reptin (100 ng) was added in the ligand free and
ligand bound states (100 mM where indicated). After washing the
amount of reptin bound was quantified using an anti-reptin polyclonal
antibody and peroxidase conjugated-anti rabbit IgG. The data are
plotted as relative reptin activity (in RLU) as a function of the ligand
bound state of reptin. CON ¼ control.
Fig. 3 Discovery of new Liddean-dependent interaction motifs for
reptin. Next generation sequencing of peptide-phage pool obtained
from a reptin screen in the apo and ligand bound state. Reptin was
captured onto the solid phase without or with ligands ADP or Liddean.
After selection of the peptide library on reptin protein, elution and
propagation in bacteria, the phage DNA was amplified using PCR
primer sets that capture the sequences flanking the peptide insert (as
in Fig. S9†). Pooling of all phage into deep sequencing reactions can be
done with subsequent deconvolution using the “bar code” whose
position in the primer is indicated. (a) Parameters from the sequencing
reactions from a representative screen are summarized. These
include: (i) the sequencing reads before filtering non-specific binding
peptides; (ii) the number of sequencing reads in apo or ligand bound
protein; (iii) and the number of peptides that are shared in a number of
apo or ligand bound screens. (b and c) Representative peptides that are
enriched in the ligand bound state or suppressed in the ligand bound
state are indicated to highlight a representative set of raw sequencing
reads. (d) An example ciliopathy protein present in the list of human
proteins which contain consensus sites identified by our Liddean-
bound reptin screen. Processing the top 500 peptides from the apo
and Liddean bound reptin usingMEME to identify the top 10 consensus
motifs (http://meme.nbcr.net/meme/cgi-bin/meme.cgi) highlights
the distinct sets of motifs acquired in the apo and ligand bound form.
The motifs were processed using MAST or blastp to identify targets in
the human proteome that have matches to these motifs, some of
which are listed as potential ciliopathy targets.
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 3109–3116 | 3111
























































































Liddean was able to modify reptin's oligomerization dynamics
with reptin being present in a more stable oligomeric state in
the presence of Liddean. Liddean was also more effective at
stabilizing reptin than ADP (Fig. 2a) with as little as 2 mM Lid-
dean inducing stable oligomers (Fig. S8b,† lane 2). An attempt
to correlate Liddean's ability to induce reptin homo-oligomeri-
zation and its stimulation of reptin's binding to the AGR2
peptide proved successful (Fig. S8†).
The link between nucleotide-induced changes in oligomer-
ization status and function is a key feature of AAA+ proteins
including reptin. To assess whether our Liddean-induced
change in oligomerization status led to a modication of rep-
tin's PPIs, we initially evaluated the effect of Liddean on rep-
tin's known PPI with the molecular chaperone HSP90.
Streptavidin-mimetic tagged (SBP) HSP90 was captured on
solid phase followed by the addition of either apo-, ADP- or
Liddean-bound reptin. Liddean (and to a lesser extent ADP)
increased the stability of the reptin–HSP90 complex (Fig. 2b).
Encouraged by the fact that clear changes could be observed in
the presence of Liddean, we next used it as a tool to examine
Liddean-induced changes on the global peptide-binding space
of reptin.
Discovering new Liddean-stimulated peptide docking motifs
on reptin using next generation sequencing of a phage-
peptide combinatorial library
A combinatorial peptide-based selection assay exploiting next-
generation “deep” DNA sequencing of peptide-phage pools was
carried out using reptin in its ligand-free, ADP- or Liddean-
bound form. Peptides were processed through 3 rounds of
biopanning using a 12-mer peptide library, and peptide pools
were sequenced (Fig. 3a, S9 and Table S3†). Comparison of the
peptides identied using apo-reptin with those obtained when
Liddean-bound reptin was used showed that, as expected, the
binding of some peptides to reptin were suppressed (for
representative raw peptide reads see Fig. 3b) or elevated by
Liddean (Fig. 3c). Recent data has shown that reptin has an
important interaction with the cytosolic cilia machinery.27,28
This is a new cellular interactome for reptin distinct from its
known links to the chaperone and transcription systems. It is
interesting to note that several ciliopathy proteins are present in
Fig. 4 Identification and validation of p53 as a novel reptin interacting
protein. (a) 1000 peptides that were enriched in the ligand bound state
(including those shown) were processed using MEME to identify
consensus motifs (http://meme.nbcr.net/meme/cgi-bin/meme.cgi).
(b) The panel represents data from a 12-mer peptide screen where the
core motif identified is highlighted as fRERf or LRER[L/G]. (c) A blast
motif screen using theMEME derived peptide consensus sites gave rise
to a peptide derived from the tumor suppressor protein p53. (d)
GST-tagged reptin and AGR2 proteins were assayed for their ability to
bind to full length p53 using ELISA. p53 protein was absorbed onto the
solid phase, and the indicated proteins were titrated in solution phase.
The binding was detected using GST antibodies, followed by peroxi-
dase conjugated secondary antibodies and processing using chem-
iluminescence. The data is plotted as binding activity as a function of
protein amount (in RLU). (e) The effect of Liddean on the stability of the
reptin–AGR2 and reptin–p53 protein interactions was evaluated.
Either p53 or AGR2 were absorbed onto the solid phase and reptin
(200 ng) was added in 50 ml of buffer containing increasing amounts of
the indicated ligand. After 60minutes incubation at room temperature,
reptin protein bound to its target was quantified as indicated in the
methods (in RLU).
Fig. 5 Fine mapping of the dominant linear peptide docking site of
reptin on p53. (a) The domain structure of p53 including the sites
bound by MDM2 (in green), proline rich motif (blue), the specific
DNA-binding domain (pink); tetramerization domain (yellow); and the
C-terminal regulatory domain (in red). The arrows highlight the two
binding sites mapped for reptin (in panels below). (b) An overlapping
series of synthetic biotinylated peptides derived from the open reading
frame of p53 were captured on streptavidin coated solid phase and
reptin binding wasmeasured as indicated in themethods. Two domain
regions from p53 bound to reptin and mapped to the BOX-V domain
(RNS.GRD) and to the tetramerization domain (YFT.EMF). The latter
peptide contain two repeats of the fRERf or LRER[L/G] motifs iden-
tified from the ligand responsive peptides using MEME (Fig. 4). (c)
Alanine scan mutagenesis of peptide 38 identifies important amino
acids for reptin binding to p53; in the core sequence IRGRERFEMF,
mutating IRGR or the overlapping RERF motif abrogates reptin binding
to p53. This functional alanine mutagenesis is consistent with the
MEME derived peptide motif from the deep sequencing.
3112 | Chem. Sci., 2015, 6, 3109–3116 This journal is © The Royal Society of Chemistry 2015
























































































the list of human proteins which contain consensus sites
identied by our Liddean-bound reptin screen (Fig. 3d for one
example, and Fig. S10†). Whilst the identied binding sites have
yet to be validated, these data are entirely consistent with this
approach being able to deliver a molecular peptide-binding
“ngerprint” for reptin. In addition, the change in binding
motifs identied in the presence of Liddean, linked with this
ligand's observed effect on the oligomerization of reptin,
provides indirect evidence for a substantial allosteric effect on
the peptide-binding prole of reptin.
During these studies, several consensus peptide motifs were
identied that were enriched in both ADP and Liddean bound
forms. Our attention was drawn to the enrichment of motifs
containing a fRERf sequence by ADP and/or Liddean (Fig. 4a
and b). When this motif was compared with the human pro-
teome, a motif was identied in the tetramerization domain of
the p53 tumor suppressor (Fig. 4c). An ELISA assay demon-
strated that the reptin protein was able to bind to puried
human p53 whereas GST and AGR2 did not (Fig. 4d). Liddean
was shown to stabilize the p53–reptin complex, consistent with
the results from peptide-phage display (Fig. 4e).
In order to ne map the reptin binding site on p53, over-
lapping biotinylated peptides from human p53 (Fig. 5a and b)
were probed with reptin to evaluate binding. Two dominant
peptides (Fig. 5b), one which overlapped with the knownMDM2
binding site in the central domain of p53 (peptide 31) and one
with a motif in the tetramerization domain of p53 (peptide 38)
bound to reptin. This provides at least two docking sites
for reptin on p53. Alanine scanning mutagenesis of peptide
38 revealed that the key amino acid contacts required for effi-
cient reptin binding to p53 form the core fRERfmotif (Fig. 5c).
These data further conrmed that our peptide combinatorial
screen linked with next-generation sequencing can identify
dominant docking sites for reptin on substrates and that Lid-
dean can induce changes in reptin binding activity to important
proteins such as AGR2, HSP90, ciliary proteins and p53.
Evaluation of the effects of Liddean on reptin–pontin
interactions in a cell-based assay
In the nal part of this study we assessed whether Liddean
could be used to study reptin function in cells. To do this rep-
tin's interaction with its most dominant paralog, pontin was
observed using proximity ligation assays29 in HCT116 cells. The
complex between reptin and pontin was found to be largely
cytoplasmic in the absence of Liddean (Fig. 6a; DMSO only). By
contrast, Liddean (used at up to 2 mM) led to a substantial
reduction in the cytoplasmic reptin–pontin foci and a change
from clear punctate nuclear foci to aggregated reptin–pontin
foci (Fig. 6b, c and S11†). Similar results were observed in p53-
null cells (Fig. S12a–c†). Reptin and pontin expression levels
were found to be equivalent with or without Liddean with the
majority of both proteins being in the cytoplasmic fractions,
relative to the mitochondrial and nuclear fractions using
chemical fractionation (Fig. 6d). However, since the nucleus can
be leaky in such chemical fractionation experiments, we also
evaluated reptin and pontin proteins using immunouores-
cence (IF; Fig. S12d–g†). The total amounts of reptin or pontin
proteins also remained relatively unchanged in the absence or
presence of Liddean (Fig. S12d–g†) and as dened by immu-
noblotting using urea lysis buffer (Fig. S12h and i†). Although
the IF demonstrates a largely cytosolic reptin pool (Fig. S12d
and f†), pontin does indeed show mixed cytosolic and nuclear
pools (Fig. S12e and g†) suggesting the chemical fractionation
does induce a leaching of pontin into the cytosol. These data
together indicate that Liddean does not induce global changes
in reptin or pontin protein levels or localization, but instead
stimulates the production of reptin–pontin complexes in the
nucleus. Together with the previous experiments, these data
validate Liddean as a novel chemical tool with which to probe
both in vitro and in vivo changes in the functions of the AAA+
protein reptin.
Discussion
The AAA+ proteins, including reptin, are known for their
nucleotide binding sites, oligomeric propensity, and wide range
of functions.5 Here we built on the observation that nucleotide
binding is known to regulate the oligomerization status of
reptin. In particular, we were interested in exploring whether by
modifying reptin's oligomeric state we would change the
proteins it interacts with.30 A number of assays could have been
used to screen for novel reptin ligands, including helicase
activity, ATPase activity, fragment based drug discovery, and/or
high throughput competitive binding with nucleotide ligands.31
Indeed, a recent approach has identied small molecule
Fig. 6 The effects of Liddean on reptin–pontin interactions in cell
models using the proximity ligation assay. HCT116 cells were pro-
cessed using the proximity ligation method to identify whether reptin
forms a PPI in cells and the images are superimposed using DAPI to
highlight the nuclear (blue) or cytosolic foci location. The data high-
light the foci of: (a) reptin–pontin in DMSO treated cells; (b) reptin–
pontin foci in cells treated with 2 mM Liddean. (c) Number of cytoplasm
(black bar) and nuclear (white bar) foci in the absence of presence of
Liddean (1 mM and 2 mM). See Fig. S11† for the image of HCT116 cells in
the presence of 1 mM Liddean; (d) immunoblots that show the amount
of reptin or pontin after chemical fractionation into cytoplasmic,
mitochondrial, and nuclear fractions.
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inhibitors of the ATPase activity of the reptin paralog, pontin.32
Instead we used an in silico screen to predict small molecules
that would target the deep nucleotide binding pocket (Walker A
site) that is a characteristic feature of oligomeric AAA+ proteins.
The identied hit (compound 1) was subjected to SAR analysis
guided by an ELISA based PPI assay to generate the chemical
tool, Liddean. The SAR data and results from hydrogen–deute-
rium (H–D) exchange experiments supported our proposal that
Liddean binds in the Walker A site of reptin. In addition, Lid-
dean stabilised higher order oligomers of reptin as evidenced by
(i) the estimated mass using a denaturing gel electrophoretic
screen and (ii) the use of HDX experiments that revealed
suppression of deuterium incorporation at the previously
reported dimer interface.
Reptin is known to interact with a variety of chromatin and
chaperonin signalling proteins and is oen considered impor-
tant in oncogenesis.33 More recently, based on genetic screens,
reptin has been linked to the assembly of cilia structures on the
plasma membrane.27,28 With Liddean in hand, we decided to
assess whether it could be used to nd and provide details
about reptin PPIs. As a proof of principle we conrmed that
Liddean-bound reptin modied reptin's known interaction with
HSP90. Next we decided to use the stabilized, oligomeric state of
Liddean-bound reptin in vitro to search for “consensus peptide
motifs” using a combination of next generation deep-
sequencing and a combinatorial peptide-phage library. Whilst a
very information rich dataset was obtained, our focus turned to
a novel reptin-interacting motif in the p53 tumor suppressor
protein. Independent screens veried that indeed reptin can
bind to p53-derived peptides mainly through a peptide motif
that is located in the p53 tetramerization domain (Fig. 4 and 5).
As a further demonstration of the utility of our approach, it was
also noted that peptide motifs in proteins of the cytosolic cilia
machinery were identied. On-going studies will probe the
details of these proposed interactions.
Whilst Liddean had proved a very useful tool in vitro, we
wanted to assess whether it could also be used in cells. A
proximity ligation assays29 was therefore used to assess the
effect of Liddean on the interaction of reptin with its dominant
partner, pontin, in cells. This technique enabled us to observe
directly the reptin–pontin complex in the cytoplasm of cancer
cells. Interestingly, reptin formed signicantly more nuclear
foci with pontin on addition of Liddean. Whilst an explanation
for this observed redistribution remains challenging, dramatic
changes in protein expression levels or localization have been
ruled out.
Conclusions
In discovering and subsequently using Liddean, our chemical
biology platform has provided novel insights into the PPIs
associated with the important human protein reptin. Ulti-
mately, identifying reptin's complete PPI network and explain-
ing how the network is controlled is central to understanding its
role in normal and disease processes. An important concept
relating to PPIs is that small linear peptide motifs can form
dynamic and specic docking sites for a protein.34–36 Small
molecule stabilization/destabilization of thesemotifs provides a
promising approach towards overall modulation of protein
function.1 Indeed, there are PPI drug leads emerging that are
being applied in the clinic; the most notable of which targets
the linear peptide motif-binding groove of the MDM2 onco-
protein.37 As dynamic linear peptide-motif based PPIs form a
vast untapped landscape in biology and medicine,38 approaches
that facilitate the discovery of such interactions will provide new
avenues to impact on drug discovery programs.39 We believe
that the approach we have outlined in this report is applicable
to other members of the AAA+ superfamily.
Materials and methods
Protein–protein interaction assays of reptin
The expression and purication of reptin protein was carried
out as previously described17 and as discussed in Fig. S13† with
the following exceptions. The cells were initially put into a
buffer containing 50 mMHEPES pH 8.0 and 10% sucrose before
being snap frozen, the rest of the components of the lysis buffer
were then added with the exception of Triton X-100 which was
added at a 0.1% concentration rather than 0.5%. The lysate was
incubated with glutathione beads for 150 minutes at 4 C with
rotation before the washes were carried out. The protease used
to cleave the reptin from the beads was HRV 3C. Biotinylated
AGR2 derived peptides (or p53 where indicated) were coated
overnight onto streptavidin coated wells and reptin binding was
measured in buffers as described previously.17 All biotinylated
peptides were obtained from Chiron Mimotopes (Australia).
When small molecules were evaluated to the indicated nal
concentrations (balanced with DMSO carrier), reptin was added
immediately to the reaction well to allow binding competition
to take place in the presence of the AGR2 (or p53) peptide. The
wells were washed17 and bound reptin was detected using a
reptin antibody coupled to anti-rabbit secondary antibody and
chemiluminescence. Binding activity was quantied by chem-
iluminescence using a Fluoroskan Ascent FL Labsystems. For
measuring the effects of ligands on the SDS-resistant oligo-
merization state of reptin using SDS gel electrophoresis, reptin
protein (1 mg) was added to buffer B (25 mM HEPES, pH 8.0;
10% glycerol, 10 mM KCl, 1 mM DTT) with the indicated
amounts of ADP or Liddean. Following incubation at room
temperature for 60 minutes, samples were processed for elec-
trophoresis as indicated in the Fig. S8† legend.
Hydrogen–deuterium exchange mass spectrometry
Deuteration of the reptin either free or in complex with Liddean
was initiated by a sequential dilution into deuterated water with
0.1% DMSO nal concentration. The molar ratio between reptin
and Liddean was 1 : 5 (as summarised in Fig. S7†). The
exchange was done at 21 C and was quenched by the addition
of 1 M HCl in 1 M glycine at 1 min and 5 minutes followed by
rapid freezing in liquid nitrogen. Each sample was quickly
thawed and injected onto an immobilized pepsin column (15 ml
bed volume, ow rate 20 ml min1, 0.1% formic acid in water).
Peptides were trapped and desalted on-line on a peptide
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microtrap (Michrom Bioresources, Auburn, CA) for 1 minute at
a ow rate 20 ml min1. The peptides were eluted onto an
analytical column (Jupiter C18, 1.0  50 mm, 5 mm, 300 Å,
Phenomenex, CA) and separated by a linear gradient. The
injection, switching valves, immobilized pepsin column, trap
cartridge, and the analytical column was kept at 1 C in a cool
box (within the robotics system). Mass spectrometric analysis
was done on an Orbitrap Elite mass spectrometer (Thermo
Fisher Scientic) with ESI ionization on line connected with a
robotic system based on a HTS-XT platform (CTC Analytics
company). The instrument was operated in a data-dependent
mode for peptide mapping (HPLC-MS/MS). Each MS scan was
followed by MS/MS scans of the top three most intensive ions
from both CID and HCD fragmentation spectra. Tandem mass
spectra were searched using SequestHT against the cRap
protein database (p://p.thegpm.org/fasta/cRAP) containing
sequence of reptin protein. Sequence coverage was visualized
with Proteome Discoverer 1.4 soware (Thermo Fisher Scien-
tic). Analysis of deuterated samples was done in HPLC-MS
mode with ion detection in the orbital ion trap and data were
processed in HDX Workbench. Graphs showing deuteration
kinetics were plotted by DrawHDXPlot (MSTools).
Combinatorial peptide phage screen
Peptide phage was carried out using the 12-mer Ph.D.™ Phage
display library (New England Biolabs). The surface panning
procedure (direct target coating) was carried out as instructed
by the manufacturer's protocol with an additional protein
capture step. Themicro titer wells were coated as directed with a
rabbit anti-reptin polyclonal antibody overnight. The wells were
then washed three times with tris buffered saline with 0.1%
Tween-20 (TBST). The wells were then blocked with 3% bovine
serum albumin in TBS for 1 hour. Washes were once again
carried out before the addition of reptin with and without
ligand (either ADP or Liddean at 100 mM) and incubated for one
hour at RT. Washes were then carried out 6 times with TBST,
containing ligand in the ligand treated wells. The phage pool
was then added, again containing ligand if required, and
incubated for 1 hour. Non-binding phage was removed and the
wells were washed 10 times with PBST prior to the elution of the
phage as directed by the manufacturer. Amplication and
titering of the phage was also carried out with each round of
panning as per the manufacturer's instructions. Titering was
carried out to ensure that the phage pool being panned was not
greater than that of the original pool once it had been amplied
and to check for white-type lytic phage contamination. Poly-
merase chain reaction (PCR) and deep sequencing of phage was
carried out in the following stages; (i) PCR was used to amplify
phage DNA from each round of screening using the primer bar
codes in table code (Table S3†) that have an Illumina adaptor
sequence and a 3 letter bar code; (ii) equal amounts of DNA was
gel puried on a 2% agarose gel to create a pool (5 mg) that was
sequenced by Otogenetics (USA). Fastq les were then captured
using a custom tool programmed in Java language (script
available upon request) that was used to extract amino acid
sequences from raw NGS reads. Only forward reads were
processed (as reverse reads do not capture the bar code). Bar-
code and mimotope DNA sequences were extracted from reads
that passed quality control based on exact match search for
bordering sequences. All sequences having nonsense (not in
list) bar code were ltered out. Mimotope sequences having
inappropriate length or containing nonsense codons (stop
codons as well as some other “forbidden” codons that should
not be present according to New England BioLabs phage library
manual) were ltered out. Sequences passing these lters were
translated, grouped by resulting peptide sequence and sorted as
indicated in the tables.
Duo-link proximity ligation assay
Cells were grown on coverslips until they reached around 30%
conuency upon which the small molecule Liddean was trans-
fected into cell and incubated for 24 hours (transfection was
performed using 1 or 2 mM molecule with DMSO control
balanced in 100 ml of DMEM containing attractene carrier).
Cells were xed with 4% paraformaldehyde dissolved in PBS
and permeabilized using 0.25% Triton X-100 in PBS. Duolink II
(green) assay from Olink Bioscience was carried out following
manufactures instructions. Briey, unspecic antibody binding
was blocked by the addition of 3% BSA (w/v) in PBS for
30 minutes at room temperature. Primary antibodies were
diluted in 3% BSA (w/v) in PBS and added to the cells overnight
at 4 C. Negative controls include no primary or no secondary
antibodies which gave rise to no foci in subsequent assay pro-
cessing (data not shown). PLA probes were added to cells and
incubated to 1 hour at 37 C. Ligation mix was added for
30 minute at 37 C followed by the polymerase amplication
mix for 2 hours at 37 C. Coverslips were mounted in S3023
Mounting medium (Dako). Results were visualized using a BX51
(Olympus) uorescent microscope. Antibodies and PLA probes
include; anti-reptin/TIP49B/RUVB2 rabbit antibody ab36569
(abcam) (1 : 250 dilution); monoclonal anti-pontin 5G3-11
(Sigma) (1 : 250 dilution); Duolink II PLA probe anti rabbit PLUS
(Olink) (1 : 10 dilution); and Duolink II PLA probe anti mouse
MINUS (Olink) (1 : 10 dilution).
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A B S T R A C T
Reptin is a member of the AAA+ superfamily whose members can exist in equilibrium between monomeric apo forms and ligand bound hexamers. Inter-subunit
protein-protein interfaces that stabilize Reptin in its oligomeric state are not well-defined. A self-peptide binding assay identified a protein-peptide interface mapping
to an inter-subunit “rim” of the hexamer bridged by Tyrosine-340. A Y340A mutation reduced ADP-dependent oligomer formation using a gel filtration assay,
suggesting that Y340 forms a dominant oligomer stabilizing side chain. The monomeric ReptinY340A mutant protein exhibited increased activity to its partner protein
AGR2 in an ELISA assay, further suggesting that hexamer formation can preclude certain protein interactions. Hydrogen-deuterium exchange mass spectrometry
(HDX-MS) demonstrated that the Y340A mutation attenuated deuterium suppression of Reptin in this motif in the presence of ligand. By contrast, the tyrosine motif
of Reptin interacts with a shallower pocket in the hetero-oligomeric structure containing Pontin and HDX-MS revealed no obvious role of the Y340 side chain in
stabilizing the Reptin-Pontin oligomer. Molecular dynamic simulations (MDS) rationalized how the Y340A mutation impacts upon a normally stabilizing inter-
subunit amino acid contact. MDS also revealed how the D299N mutation can, by contrast, remove oligomer de-stabilizing contacts. These data suggest that the Reptin
interactome can be regulated by a ligand dependent equilibrium between monomeric and hexameric forms through a hydrophobic inter-subunit protein-protein
interaction motif bridged by Tyrosine-340.
Significance: Discovering dynamic protein-protein interactions is a fundamental aim of research in the life sciences. An emerging view of protein-protein interactions
in higher eukaryotes is that they are driven by small linear polypeptide sequences; the linear motif. We report on the use of linear-peptide motif screens to discover a
relatively high affinity peptide-protein interaction for the AAA+ and pro-oncogenic protein Reptin. This peptide interaction site was shown to form a ‘hot-spot’
protein-protein interaction site, and validated to be important for ligand-induced oligomerization of the Reptin protein. These biochemical data provide a foundation
to understand how single point mutations in Reptin can impact on its oligomerization and protein-protein interaction landscape.
1. Introduction
The AAA+ superfamily contains a group of ATP-regulated hex-
americ proteins that are highly conserved in evolution [1]. Their dy-
namic oligomeric properties provide a model system to understand al-
losteric regulation of polypeptide assembly and function [2]. The
RuvBl1/2 orthologues, also named Reptin and Pontin, represent two
representative AAA+ protein members. Structural studies have defined
the properties of complexes of homo-oligomeric Pontin [3], hetero-
dodecameric Pontin and Reptin [4] and homo-hexameric Reptin [5].
There are two ATP-binding motifs in such AAA+ proteins: the Walker A
and Walker B ATP-binding motifs that mediate ATP binding and hy-
drolysis respectively.
Reptin's key evolutionarily conserved activity, from yeast to verte-
brates, regulates chromatin-modifying machinery, including Ino80
[6,7], and SCRAP [8]. Additional protein-protein interactions from
studies in human cancer include those with ATF2 [9], Myc [10], tran-
scription associated protein β-catenin [11], tumor suppressor ARF [12],
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and the oncogenic protein AGR2 [13]. Reptin and Pontin are also
regulators of all PIKK (phosphatidylinositol 3-kinase-related protein
kinase) members [14] that in turn mediate the DNA damage response
and nonsense-mediated mRNA decay (NMD). Reptin and Pontin also
regulate the assembly of the telomerase holoenzyme through interac-
tions with TERT and dyskerin [15]. A major paradigm in Reptin
structure and function was identified using yeast models where it forms
a multi-subunit chaperonin complex with HSP90 [16].
Reptin is a potential drug target in cancer due to its oncogenic
nature and large ATP-binding pocket that might make it suitable for
drug-discovery programmes [17]. As such, we had previously per-
formed in silico screening of a large chemical library to identify several
lead molecules that can interact with the Walker A ATP-binding site
[18]. The screen resulted in the small molecule Liddean which: (i) mi-
micked ATP or ADP in the stimulation of the oligomerization of Reptin
protein; (ii) regulated Reptin's heterologous protein-protein interac-
tions; and (iii) stimulated Reptin assembly with Pontin in cell-based
systems. Together these observations suggested that occupation of the
ATP-pocket of Reptin by a small molecule ATP-mimetic like Liddean can
stimulate its oligomerization. In this report, we focus on understanding
the role of ligand binding in promoting key protein-protein contacts at
the oligomerization interface of Reptin during its self-oligomerization.
We identified an inter-subunit hotspot in the ‘rim’ of the hexamer at
Tyrosine-340 that plays an important role in ligand-induced oligomer-
ization that promotes hexamer stability and regulates Reptin's specific
activity.
2. Experimental procedures
2.1. Site directed mutagenesis of Reptin at D299N and at Y340A
All chemicals were obtained from Sigma unless otherwise indicated.
Human Reptin was cloned into Gateway Entry clone (Invitrogen) for
subsequent use. The human Reptin sequence for cloning into a new E.
coli expression system was amplified using the following primers: for-
ward primer 5′-GGGACAAGTTTGTACAA AAAAGCAGGCTTCCTGGAA
GTTCTGTTCCAGGGGCCC ATGGCAACCGTTACAGCCACAACC-3′ and
reverse primer 5′-GGGGACCACTTTGTACAAGAAAGCTGGGTCCAGGA
GGTGTCCATGGTCTCG-3′. The forward primer had a PreScission pro-
tease cleavage site inserted. Following amplification, the polymerase
chain reaction (PCR) product was first inserted into pDONR201 and
then into pDEST-15 using Gateway technology (Invitrogen) to generate
GST-tagged Reptin. Point mutations in the above mentioned plasmids
were introduced using the following primers: for the Reptin D299N
mutant, forward primer 5′-GAGTGCTGTTCATCAACGAGGTCCACA
TGC-3′ and reverse primer 5′-GCATGTGGACCTCGTTGATGAACAGCA
CTC-3′; and for the Reptin Y340A mutant, forward 5′- GAATCCGGGG
CACCAGCGCCCAGAGCCCTCACGGCA-3′ and reverse 5′- GCCGTGAGG
GCTCTGGGCGCTGGTGCCCCGGATTC-3″.
2.2. Expression and purification of proteins
2.2.1. Reptin WT and mutant production
Reptin proteins were expressed as indicated previously [13]. Briefly,
plasmids encoding the indicated Reptin proteins were transformed into
BL21-AI (Thermo Fischer Scientific). The cells were grown in LB
medium (1 L) at 37 °C up to an A600 of 0.5. Induction of gene expression
was achieved by adding arabinose to the culture (final concentration
0.2%). The bacterial culture was grown at room temperature (21 °C) for
another 3 h and then pelleted by centrifugation. The lower temperature
of induction (rather than 30 °C or 37 °C) gave rise to reproducible re-
cover of Reptin protein. Cells were lysed with 30ml of a buffer con-
taining 10% sucrose, 50mM HEPES, pH 8.0, 400mM NaCl, 0.1% Triton
X-100, 1mM DTT, 1mM benzamidine, 0.5 mg/ml lysozyme, and pro-
tease inhibitors for 30min on ice and then sonicated for 3× 5 s bursts
to reduce the viscosity. The clarified bacterial lysate was obtained by
centrifugation for 15min at 15,000 g. The lysate was incubated with
glutathione beads (0.5 ml) (GE Healthcare) for 150min at 4 °C with
rotation in a 50ml conical tube. The beads were thoroughly washed
three times by mixing the beads with 10 bead-volumes of a high salt
buffer (20mM HEPES, pH 7.5, 1M NaCl, 1 mM DTT, and 1mM ben-
zamidine) to remove non-specifically bound proteins. The beads were
then washed three times with 10 bead-volumes of a low salt buffer
(20mM HEPES, pH 7.5, 0.05M NaCl, 1 mM DTT, and 1mM benzami-
dine). The beads were finally washed three times with 10 bead-volumes
of PreScission buffer (GE Healthcare, Uppsala, Sweden) and then re-
suspended in 1 bead volume (0.5ml) of PreScission buffer. GST-tagged
PreScission protease (GE Healthcare; 5 units) was added to the slurry
and incubated overnight rotating in the cold room. The beads were
sedimented at 2340 g for one minute and the supernatant containing
cleaved Reptin protein was recovered. The purity of Reptin was con-
firmed using SDS-gel electrophoresis as described previously [13]. The
beads were washed with an additional column volume of PreScission
buffer to collect additional, but more diluted protein. The first fraction
from the elution, which is more concentrated than the second fraction,
was invariably used. The Reptin protein cleaved off the column using
PreScission protease (GE Healthcare) was stored at 4 °C at concentra-
tions from 0.5mg/ml to 1mg/ml. The protein was stable in this con-
dition for at least 6months.
2.2.2. AGR2 purification
His-tagged AGR2 (from [19]) was expressed in BL21-AI and purified
using Ni2+-nitrilotriacetic acid-agarose (Qiagen). according to the
manufacturer's instructions. In detail, the cells were grown in LB
medium (0.5 L) at 37 °C up to an A600 of 1.0 and protein was induced by
adding arabinose to the culture (0.2%). The culture was grown at 30 °C
for 3 h and then pelleted by centrifugation. The pellets were lysed with
40ml of a buffer containing 20mM Tris–HCl, pH 8.0, 150mM NaCl,
10mM MgCl2, 0.05% Tween 20, 10% glycerol, 20mM imidazole,
pH 8.0, and 0.5 mg/ml lysozyme for 30min on ice. The lysate was then
sonicated for 3× 5 s bursts to reduce the viscosity. The clarified bac-
terial lysate was obtained by centrifugation for 15min at 15,000 g. The
lysate was incubated with Ni-agarose on rotary shaker at 4 °C for 1 h to
capture the AGR2 protein. The beads were washed two times in lysis
buffer and three times in lysis buffer with 40mM imidazole, and then
the AGR2 protein was eluted with lysis buffer containing 150mM
imidazole. Purity was confirmed using SDS-gel electrophoresis as de-
scribed [19]. AGR2 protein eluted from the column was stored at
−70 °C at concentrations from 1 to 3mg/ml. The protein was stable in
this condition for at least 2 years.
2.2.3. HSP90 purification
The coding sequence of the human HSP90AA1 gene (Hsp90α,
NM_001017963.2) was cloned into a pDEST17 vector containing an N-
terminal His 6×-tag cleavable by TEV protease. All cloned genes were
expressed in BL21(DE3) RIPL cells. The cells were grown in LB medium
at 37 °C up to an A600 of 0.5. Induction of gene expression was achieved
by adding isopropyl β-D-thiogalactopyranoside to the culture (final
concentration 1mM). The bacterial culture was grown at 30 °C for an-
other 3–4 h and then pelleted by centrifugation for 15min at 6000 g.
The cells were resuspended in His binding buffer II (50mM Tris, pH 8.0,
0.2 M NaCl, 2 mM MgCl2, 10% glycerol). Cell suspensions were en-
riched with lysozyme (1mg/ml) and PMSF (1mM) and then sonicated.
Bacterial lysates were obtained by centrifugation for 30min at
12,000 g. His 6 -tagged Hsp90α was purified using a HisTrap column,
and the His 6 x-tag was cleaved by overnight incubation with TEV
protease. The protein was subsequently exchanged into His binding
buffer II and then subjected to a second immobilized metal affinity
chromatograph to remove His 6 x-tag and His 6-TEV. The flow-through
fractions were concentrated and further processed by gel filtration
using a HiPrep 16/60 Sephacryl S-200 HR column (GE Healthcare). The
purity of all isolated proteins was confirmed by SDS-PAGE/Coomassie
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staining [20]. All proteins were finally exchanged into final assay
buffers using 7-kDa molecular mass cutoff Zeba spin desalting column
(Thermo Fischer).
2.2.4. Reptin ELISA protein-peptide interaction assays
Overlapping biotinylated peptides were obtained from Chiron
Mimotopes (Australia). Peptides derived from Reptin are displayed in
the Fig. 1 legend. Reptin protein binding to biotinylated protein was
measured using ELISA. Fifteen-mer peptides with a 5-mer overlap
(Fig. 1A) and containing a N-terminal biotin followed by a SGSG spacer
were purchased from Chiron Mimotopes. Peptides were dissolved at
5mg/ml in DMSO. In peptide binding assays, ELISA plates were coated
with streptavidin (AnaSpec) overnight at 37 °C and washed with PBS-
Tween-20 (0.1% Tween-20). The biotinylated peptides diluted in water
(1 μg per well) were added for 1 h followed by blocking with BSA 3% in
PBS 1×. Reptin diluted in blocking buffer was then added to the plate
and incubated for a further 1 h. When ligands such as ADP or Liddean
were used, the chemicals were added to buffer containing Reptin for
30min prior to addition of the reactions to the ELISA wells to allow
sufficient oligomerization of the protein induced by the ligands.
Blocking buffer and DMSO only controls were included. After further
washes, wells were incubated with the Reptin primary antibody and
Fig. 1. Structure of Reptin (RUVBL2). (A) ELISA assay measuring the binding of wt-Reptin to self-peptides. The bottom right diagram highlights the order of addition
in the Reptin binding reaction, including; (i) coating the ELISA wells with Streptavidin (S); (ii) adding the biotinylated peptide containing a SGSG space; (iii) the
addition of Reptin protein; and (iv) the addition of the primary anti-reptin antibody (Y shape; in grey) that is detected using HRP conjugated secondary antibody. The
top panel summarized the overlapping, biotinylated peptides derived from the Reptin open reading frame (from the N-terminus (peptide 1) through the C-terminus
(peptide 40) were coated onto streptavidin ELISA wells. After washing, Reptin was added and binding measured using anti-Reptin antibody in conjunction with HRP
labeled secondary antibody. Reactions were monitored via chemiluminescence. Binding data is represented by RLU (relative light units) as a function of peptide
number. (B) X-ray crystal structure of the Reptin hexamer (PDB id: 3UK6) with the subunits shown in different colors (red, magenta, blue). An inter-subunit interface
(428–439) is colored green and the oligomerization site (333–345) is colored aqua. (C) Details of the oligomerization site (aqua) between two Reptin monomers (blue
and magenta). The side chain of the Tyrosine finger (Y340) is located in the oligomerization pocket of the second Reptin. (D). Reptin structure. A linear rod structure
of Reptin domain organization. Domain DI (in purple) containing highly conserved motifs of AAA+ proteins such as the Walker A, the Walker B, the Sensor I, the Arg
finger and the “Click” (inter-subunit stabilizing) motif described in this article. Domain DIII (in red) contains the conserved motif of AAA+ protein region named
Sensor II. The insertion domain DIII is also highlighted. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
D. Coufalova, et al. Journal of Proteomics 199 (2019) 89–101
91
then horseradish peroxidase conjugated secondary antibody for 1 h
each at room temperature followed by further washing and ECL addi-
tion and the luminescence produced was measured. The data are pre-
sented as Relative Light Units and represent triplicates graphed as a
mean with error bars representing the deviations from the mean.
2.2.5. Gel filtration
Reptin and the indicated mutants (Y340A and D299N; 25 μg) were
incubated without ligand or with ligand (1mM ADP) in 100 μl of
HEPES buffer (pH 7.6) containing PBS. Samples were injected onto a
25ml Superose-12 gel filtration column in the same buffer and fractions
were collected at a flow rate of 0.5 ml/min. In the ligand bound state,
the column was pre-incubated in the same buffer but including 1mM
ADP. Gel filtration markers were used to calibrate the column and to
demonstrate ADP did not alter the elution of marker proteins (data not
shown). Samples eluting from the column (50 μl) of each fraction were
absorbed onto ELISA wells overnight in a cold room and wells were
incubated with PBS with BSA (3%) to block reactive interaction sites.
The wells were washed with PBS (containing 0.1% Tween-20) (0.1%)
followed by incubation with the anti-Reptin antibody (1:1000; Abcam)
in PBS-tween-20 (0.1%) including BSA (3%). Reactions were processed
with HRP-conjugated secondary antibodies (DAKO; 1:1000) to define
the elution profile of Reptin (in RLU, chemiluminescence). The elution
profiles are highlighted in Fig. 3. Molecular mass markers (GE
Healthcare) that calibrated the column were injected (100 μl) at 10 mg/
ml concentrations (in deionized water) and elution peak volumes were
defined by absorbance (max280 nm).
2.3. Experimental design and statistical rationale for hydrogen-deuterium
exchange mass spectrometry
2.3.1. Sample preparation of Reptin proteins
Reptin, either wt or mutant (5 μM), was incubated with 1mM ATP
for 1 h at 21 °C prior to the exchange. The exchange was initiated by a
sequential dilution into deuterated buffer (50mM Tris-HCl pD 7.1,
150mM NaCl, 1 mM EDTA, 2mM MgCl2 and 1mM DTT) to a final
concentration of 2 μM. The sequential dilution took approximately 25 s.
Counting of the incubation time was initiated after addition of the first
aliquot of deuterated buffer. For sample with ATP the deuterated buffer
was enriched with 1mM ATP. The exchange was carried out at room
temperature and was quenched by the addition of 1M HCl in 1M
glycine at 5min followed by rapid freezing in liquid nitrogen.
2.3.2. Digestion and HPLC separation
Each sample was thawed and injected onto an immobilized pepsin
column (15 μl bed volume, flow rate 20 μl/min, 2% acetonitrile/0.05%
trifluoroacetic acid). Peptides were trapped and desalted on-line on a
peptide microtrap (Michrom Bioresources, Auburn, CA) for 2min at
flow rate 20 μl/min. Next, the peptides were eluted onto an analytical
column (Jupiter C18, 1.0× 50mm, 5 μm, 300 Å, Phenomenex, CA) and
separated using a 2min linear gradient elution of 10%–40% B buffer in
A buffer, followed by 31min isocratic elution at 40% B. Solvents used
were: A buffer – 0.1% formic acid in water, B buffer – 80% acetonitrile/
0.08% formic acid. The immobilized pepsin column, trap cartridge and
the analytical column were kept at 1 °C.
2.3.3. Mass spectrometry and data analysis
Mass spectrometric analysis was carried out using an Orbitrap Elite
mass spectrometer (Thermo Fisher Scientific) with ESI ionization on-
line connected with a robotic system based on the HTS-XT platform
(CTC Analytics, Zwingen, Switzerland). The instrument was operated in
a data-dependent mode for peptide mapping (HPLC-MS/MS). Each MS
scan was followed by MS/MS scans of the top three most intensive ions
from both CID and HCD fragmentation spectra. Tandem mass spectra
were searched using SequestHT against the cRap protein database
(ftp://ftp.thegpm.org/fasta/cRAP) containing the sequence of the
Reptin protein with the following search settings: mass tolerance for
precursor ions of 10 ppm, mass tolerance for fragment ions of 0.6 Da, no
enzyme specificity, two maximum missed cleavage sites and no-fixed or
variable modifications were applied. The false discovery rate at peptide
identification level was set to 1%. Sequence coverage was analyzed
with Proteome Discoverer software version 1.4 (Thermo Fisher
Scientific) and graphically visualized with MS Tools application [21].
Totally 94% of Reptin sequence was covered by 249 identified peptides
(Supplementary Fig. 1). Analysis of deuterated samples was done in
HPLC-MS mode with ion detection in the orbital ion trap. The MS raw
files together with the list of peptides (peptide pool) identified with
high confidence characterized by requested parameters (retention time,
XCorr, and charge) were processed using HDExaminer version 2.2
(Sierra Analytics, Modesto, CA). The software analyzed protein and
peptides behavior, created the uptake plots that showed peptide deu-
teration over time with calculated confidence level (high, medium
confidence are accepted, low confidence is rejected). The HDX data in
Figs. 5 and 7 are representative of data obtained in at least three in-
dependent experiments. The results from peptide pools (Supplementary
Tables 1-3) were displayed as butterfly comparison plots (Supplemen-
tary Figs. 2-4) that showed the deuteration percentage as a function of
peptide index calculated for different protein states. This function in-
cludes other useful information about how well the peptide pool covers
protein (number of peptides, percentage of coverage protein sequence,
standard deviation, average redundancy etc., Supplementary Figs. S2-
S4). Other graphs showing the evolution of deuteration at individual
parts of the protein at the same time and different protein states were
plotted using the GraphPad Prism version 5.03 for Windows (GraphPad
Software, San Diego, CA, USA). The bimodal isotopic envelopes were
analyzed by HX-Express 2 [22]. Molecular structures were rendered
using PyMOL [23]. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE re-
pository with the dataset identifier “PXD008226”; Username:
reviewer05996@ebi.ac.uk, Password: I7pjGxG1.
2.4. Modeling and molecular dynamics (MD) simulations
MD simulations of apo and ADP bound monomeric and hexameric
Reptin in its wt, Y340A and D299N mutant forms were carried out with
the pemed.CUDA module of the program Amber14 [24]. The structures
of the mutants (Y340A, D299N) were generated by substituting Tyr340
with Ala and Asp299 with Asn in the wild-type protein [5]. All atom
versions of the Amber 14SB force field (ff14SB) [25] and the general-
ized Amber force field (GAFF) [26] were used to represent the protein
and ADP respectively. The Xleapmodule was used to prepare the system
for the MD simulations. Each structure was solvated in an octahedral
box with TIP3P [27] water molecules, leaving at least 10 Å between the
solute atoms and the borders of the box. All the simulation systems
were neutralized with appropriate numbers of counterions. MD simu-
lations were carried out in explicit solvent at 300 K. During the simu-
lations, the long-range electrostatic interactions were treated with the
particle mesh Ewald [28] method using a real space cutoff distance of
9 Å. The Settle [29] algorithm was used to constrain bond vibrations
involving hydrogen atoms, which allowed a time step of 2 fseconds
during the simulations. Solvent molecules and counterions were in-
itially relaxed using energy minimization with restraints on the protein
and inhibitor atoms. This was followed by unrestrained energy mini-
mization to remove any steric clashes. Subsequently the system was
gradually heated from 0 to 300 K using MD simulations with positional
restraints (force constant: 50 kcal mol−1 Å−2) on protein and inhibitors
over a period of 0.25 nseconds allowing water molecules and ions to
move freely. During an additional 0.25 nseconds, the positional re-
straints were gradually reduced followed by a 2 nseconds unrestrained
MD simulation to equilibrate all the atoms. For each system, three in-
dependent MD simulations (assigning different initial velocities) were
carried out for 250 nseconds with conformations saved every 10
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pseconds. Figures were drawn using PyMOL [23].
3. Results
3.1. Defining hotspot Reptin interaction sites using an overlapping
biotinylated Reptin self-peptide library array
Reptin forms multiple inter-subunit protein-protein interaction
contacts. However, the dominating, functional interaction sites or “hot-
spots” that stabilize inter-subunit protein-protein interactions [30] in-
volved in Reptin homo-oligomer assembly are not well-defined. The
emerging view of protein interactions in higher eukaryotes highlights
the concept that the large portion of protein-protein interactions are
driven by linear peptide motifs that encompass hotspots for stabilizing
domain-domain interactions [31]. We used this concept as an approach
to determine whether Reptin exhibits self-binding activity towards
linear peptide motifs derived from the Reptin amino acid sequence. We
set up an overlapping biotinylated peptide scan assay using sequences
derived from Reptin (Fig. 1A) to identify self-peptides that might in-
teract stably with the protein. Identification of such linear peptides
could point out high affinity, functional, “hotspots” in inter-subunit
protein-protein docking site.
Synthetic biotinylated peptides contained a SGSG amino acid spacer
followed by the appropriate overlapping Reptin amino acid sequence
are listed in Fig. 1A. The biotinylated peptides were captured on
streptavidin coated ELISA wells and unbound peptides was washed
away. Monomeric Reptin was added to measure binding activity. There
was only one major, dominating self-peptide binding activity that was
mapped to peptide 28 (Fig. 1A; Biotin-SGSG-GITRIRGTSYQSPHG)
which resides at an inter-subunit region of the Reptin oligomer
(Fig. 1B). This peptide forms a tyrosine finger which embeds into each
adjacent subunit in the hexameric structure (Fig. 1C). We name this
tyrosine-containing peptide a click motif. Interestingly, deuterium ex-
change mass spectrometry was used previously to demonstrate that the
Reptin ligand and ADP-mimetic named Liddean suppressed deuteration
at this site within the ring structure formed between all six subunits
[18]. These data are consistent with a model that oligomerization in-
duced by Liddean might suppress deuteration at this buried inter-sub-
unit interface motif.
3.2. Ligands that induce Reptin oligomerization suppress its interaction with
the click interface peptide 28
We next set up assays that measure the impact of a ligand that can
induce Reptin oligomerization on its binding to peptide 28. A titration
of Reptin protein (up to 320 ng) into ELISA wells coated with either
peptide 27, peptide 28, or peptide 29 (Fig. 1A) confirmed that the
protein exhibits a high preference for peptide 28 (Fig. 2A). This peptide
contains the amino acid sequence with the bridging Tyrosine 340 amino
acid side chain (Fig. 1C). Using this assay, we next determined whether
Reptin binding to peptide 28 can be affected by ligands that induce its
oligomerization. Using fixed amount of Reptin (500 ng), increasing
concentrations of ADP from 1 μM to 200 μM resulted in a reduction in
its binding to peptide 28 (Fig. 2B). Similarly, increasing the con-
centrations of Liddean from 1 μM to 200 μM resulted in suppression of
Reptin binding to peptide 28 (Fig. 2B). As a control, the weak binding
activity of Reptin observed to peptide 27 was also reduced by in-
creasing the concentrations of either ADP or Liddean (Fig. 2B). These
data are consistent with the hypothesis that Reptin homo-oligomer
formation stabilized through the inter-subunit docking of the peptide
28 click motif to the adjacent subunit (as in Fig. 1B and C) would
sterically preclude the self-peptide 28 binding in trans.
We next also evaluated previously identified Reptin interacting
proteins, as controls, to determine how ligand-induced oligomerization
impacts on Reptin binding activity. Liddean was used as an ATP mimetic
ligand that binds to the Walker-A ATP binding domain [18]. ADP was
also used to eliminate the contribution of ATPase activity of Reptin
from the Walker B ATP-interaction site to its dynamic oligomerization.
AGR2 is a previously published Reptin binding protein whose binding
to Reptin has been fine-mapped [18]. As expected, we observed that
both Liddean and ADP reduced Reptin binding to AGR2 (Fig. 2C).
Reptin is part of the R2TP complex and can interact with certain
molecular chaperones, including HSP90 [32]. A titration of Reptin
alone resulted in relatively low levels of binding to the HSP90 cha-
perone (Fig. 2C). The pre-incubation of Reptin with either Liddean or
ADP (500 μM) increased the binding activity of Reptin (Fig. 2D). Lid-
dean was more potent than ADP in stimulating the HSP90-Reptin
complex (Fig. 2D). This is consistent with the increased potency of
Liddean to induce SDS-stable oligomerization of Reptin [18]. These data
suggest that the ligand bound form of Reptin (presumably oligomeric)
or the ligand-free form of Reptin (presumably monomeric) have dif-
ferent affinities for partner proteins (summarized in Fig. 4).
3.3. Mutation of tyrosine-340 within the click peptide motif reduces ligand-
stimulated oligomerization of Reptin
These data can be used to predict that if we mutate the Y340-pep-
tide oligomerization interface (Fig. 1C) we might alter Reptin oligo-
merization. In addition, we might also impact on the affinity of Reptin
for these proteins whose binding is regulated by Reptin oligomerization
states (as in Fig. 2). In order to determine whether the Y340A mutation
can impact on Reptin oligomerization states, we evaluated the relative
mass of the wild-type and mutant Reptin by quantifying their elution
profiles using gel filtration.
Two mutant forms of Reptin were purified and characterized com-
pared to the wild-type protein. We chose to mutate Tyrosine 340 to
Alanine (ReptinY340A), since the Tyrosine side-chain forms a possible
key hydrophobic stabilizing interaction between monomers (Fig. 1C).
We then asked how the loss of this apparently stabilizing tyrosine
amino acid contact (Fig. 1C) can impact on ligand-dependent oligo-
merization. We also chose to mutate Aspartate 299 to Asparagine
(ReptinD299N). This mutation resides within the Walker B ATP binding
domain and is implicated as a gain-of-function inhibitor of Reptin in
cell growth since it has enhanced ATP-binding activity [13] because of
a defective ATPase activity [33]. However, to our knowledge, despite
significant functional cell based data on the biochemical characteristics
of this D299N mutant, there has been no analysis of its oligomerization
status in the absence and presence of ligand. As such, we included this
mutant as another control to evaluate how the oligomerization of
Reptin might be affected in comparison to the Y340A mutation.
An ELISA assay was used to measure the elution of Reptin from a
Superose-12 gel filtration column and then to define its relative oligo-
merization state in the ligand-free and ligand bound forms. Following
elution from the gel filtration column, aliquots of the fractions were
absorbed onto 250 μl ELISA wells. Protein was detected using im-
munochemical detection as indicated in the Experimental Procedures.
We would predict at the outset that wild-type Reptin would exhibit an
increase in its oligomerization status in the presence of ligand. We
would predict that the ReptinY340A mutant would presumably be less
oligomeric if our hypothesis is accurate that the Y340 side chain forms a
stabilizing hotspot interaction with the adjacent subunit. We did not
know at the outset how the ReptinD299N mutant would elute in the
absence and presence of ligand.
We processed the samples without ADP or with ADP in the gel fil-
tration buffer (1 mM), rather than ATP, as the use of ADP removes the
contribution of ATP hydrolysis to the dynamic oligomerization state of
the protein over the course of the gel filtration elution (90min).
Relative to molecular mass markers, wt-Reptin elutes as an apparent
monomer on S12-sepharose (Fig. 3A). The preincubation of Reptin with
ADP, and including ADP in the gel filtration buffer, results in an in-
crease in a pool of the protein at a larger mass range suggesting the
elution of a stable oligomer (a hexamer based on crystal structure data).
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We found that a reproducible proportion of the Reptin did not shift into
the fully oligomeric (presumably hexameric) position, as highlighted by
the presence of two peaks in the gel filtration elution profile (Fig. 3A).
These data suggest there might be two distinct conformational pools of
the recombinant Reptin purified from bacterial host (as suggested by
bimodal hydrogen deuterium exchange data, see below). Alternatively,
the gel filtration methodologies might dilute Reptin during the chro-
matography, reducing its concentration sufficiently below its associa-
tion constant in the presence of ligand.
Elution of ReptinY340A protein resulted in a protein that mimicked
wild-type Reptin profile in the absence of ligand but the inclusion of
ADP in the buffer did not result in a shift it into a larger oligomeric state
(Fig. 3B). These data suggest that the Y340 does provide a hotspot
stabilization interaction between the subunits as its mutation precludes
stable oligomer formation in the presence of the ligand. This is con-
sistent with the ability of peptide-28 (containing the tyrosine 340 re-
sidue) to bind with a relatively high affinity to Reptin (Fig. 1A). As the
unknown control, to our surprise, the ATP-binding gain-of-function
mutant ReptinD299N resulted in a profile (in the absence of ligand) that
mimics wt-Reptin bound to ADP (Fig. 3C). These latter data suggest that
the D299N mutant traps Reptin in an oligomeric state without ligand.
These data are rationalized using molecular dynamic simulations
(below) and we include this D299N mutant in our discussion on oli-
gomer fluctuation as a comparison to the Y340A and wt forms of Reptin
(Fig. 4). The data also suggest, although the D299N mutation has been
defined as ‘inactive’ in cells due to its low ATPase activity, with respect
to oligomerization, the D299N mutation induces a ‘gain-of-function’
property to the protein. However, since the protein is ATP hydrolysis
inactive, it would presumably be not only gain-of-function with respect
to oligomerization but dominant negative in its activity in cells.
Having established that the panel of wild-type and mutant proteins
exhibit different oligomerization properties in the presence or absence
of ligand, we next tested all in a range of biochemical assays to correlate
oligomerization potential to its specific activity. This panel of Reptin
proteins (wt-Reptin, ReptinY340A, ReptinS342A, and ReptinD299N) was
next tested for binding to one of its most well-characterized binding
proteins; the oncogenic AGR2 protein [13]. The binding of either wild-
type Reptin or ReptinS342A to AGR2 are relatively similar (Fig. 3D)
suggesting that the Serine 342 site chain does not form a hot spot sta-
bilizing interaction. Interestingly, ReptinD299N exhibited a much lower
specific activity in this AGR2 binding assay (Fig. 3D). Since ReptinD299N
exhibits enhanced oligomerization without ligand (Fig. 3C), these data
are consistent with the prior data showing that that the ligand-bound
form of Reptin has reduced AGR2 binding activity (Fig. 2D). By con-
trast, the ReptinY340A exhibited a much higher specific activity that
wild-type Reptin in this AGR2 binding assay (Fig. 3D). These data are
also consistent with the concept that Reptin can exist in dynamic oli-
gomeric states. The monomeric state of the Y340A mutant (as suggested
Fig. 2. Impact of ligands on the protein-binding function of Reptin. (A). ELISA wells pre-coated with streptavidin were incubated with the indicated peptides (27, 28,
and 29) representing the motif surrounding the self-binding peptide (28; Fig. 1). Reptin was titrated to measure relative binding. Anti-Reptin and HRP-conjugated
secondary antibodies were used to measure the extent of Reptin binding (in RLU, chemiluminescence). (B). ELISA wells pre-coated with streptavidin were incubated
with the indicated peptides (27 and 28). Reptin (500 ng) was preincubated with or without increasing concentrations of the indicated ligand (DMSO), Liddean, or
ADP) in buffer (50 μl). Anti-Reptin and HRP-conjugated secondary antibodies were used to measure the extent of Reptin binding (in RLU, chemiluminescence). (C).
The previously published Reptin binding proteins (AGR2) was coated onto ELISA wells. Reptin was titrated with or without the indicated ligand (DMSO, ADP
(100 μM), or Liddean (100 μM)). Anti-Reptin and HRP-conjugated secondary antibodies were used to measure the extent of Reptin binding (in RLU, chemilumi-
nescence). (D). The previously identified Reptin interacting protein, HSP90, was coated onto ELISA wells. Reptin was titrated with or without the indicated ligand
(DMSO, ADP (500 μM), or Liddean (500 μM)). Anti-Reptin and HRP-conjugated secondary antibodies were used to measure the extent of Reptin binding (in RLU,
chemiluminescence).
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by Fig. 3B) can increase its binding to some proteins such as AGR2
(Fig. 3D and Fig. 4).
3.4. Use of Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to
measure Reptin oligomerization dynamics
HDX-MS was used to measure the effect of ATP on the conformation
of Reptin and the impact of the Y340A mutation on these properties.
Fig. 3. The impact of mutation on Reptin quaternary structure and specific activity. (A). Wild-type Reptin, ReptinY340A, and ReptinD299N were incubated with 1mM
ADP or without ligand and loaded onto a superose-12 gel filtration column (25ml). Fractions of samples eluting from the column were absorbed onto ELISA wells.
Anti-Reptin and HRP-conjugated secondary antibodies were used to measure the extent of Reptin elution and binding (in RLU, chemiluminescence). The arrows
highlight the elution of molecular mass markers in kDa (440, Ferritin; 158, Aldolase; 43, Ovalbumin; 13, RNase A) in parallel processed in the absence of ADP. (B).
Wild-type Reptin and the indicated mutants were analyzed in AGR2 protein binding assays. AGR2 (1 μg) was pre-coated onto ELISA wells. Reptin was titrated, and
anti-Reptin and HRP-conjugated secondary antibodies were used to measure the extent of Reptin binding (in RLU, chemiluminescence). The diagram on the right
interprets the data in the ELISA; mutations that drive Reptin into the monomeric state (Y340A) have a higher specific activity for AGR2, whilst mutations that
stabilize Reptin in its oligomeric state (D299N) have a lower specific activity for AGR2 protein. These data are consistent with the attenuation of wild-type Reptin
binding to AGR2 protein in the presence of oligomerization-promoting ligands, Liddean or ADP (Fig. 2).
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Fig. 4. A model describing the specific activity of
Reptin as a function of its oligomeric state. Reptin is
presented as existing in distinct dynamic oligomeric
states. Mutations or ligands can impact on this flux.
The reason for developing a staged model is, firstly;
there is one stable inter-subunit protein-protein in-
terface that can be detected as suppressed by HDX-
MS in Reptin in the presence of ATP (Supplementary
Fig. 5C and Fig. 6A). The wild-type Reptin and
Y340A mutant form of Reptin exhibit similar sup-
pression of deuteration at this inter-subunit protein-
protein (Fig. 6A and B). These data suggest that the
Y340A mutation has little impact on oligomer as-
sembly at this site. By contrast, the Y340A mutation
can attenuate full oligomerization at the ‘rim’
(Fig. 3B and Fig. 6B). By contrast to the Y340A mutation that attenuates oligomer formation, the D299N mutation stabilizes the hexameric state in the absence of
ligand (Fig. 3C). The stabilization effect of the D299N mutation is rationalized in Figs. 7-9. In contrast to mutations, oligomerization (hexamerization) can be
stimulated by ligands such as ATP, ADP, or Liddean. Oligomerization stimulation of Reptin can increase or decrease its binding to client proteins (Fig. 2). This is
similar to a study on the assembly of Reptin and Pontin by Histone-3; where proteins that bind to the Reptin-Pontin system depend on the monomer to oligomer status
of the two proteins [43].
Fig. 5. Hydrogen-Deuterium exchange
mass spectrometry of Reptin in dif-
fering conformational states. (A) wild-
type Reptin; (B) Y340A mutant form of
Reptin; (C) wild-type Reptin with
Pontin. Reptin in all three conforma-
tional states (apo) was preincubated
with or without ligand (ATP) and sub-
jected to deuteration and pepsiniza-
tion. The reaction products were sub-
jected to mass spectrometry as
indicated in the Experimental
Procedures. The graphs highlight the
change in the number of deuterons as a
function of ligand from each isoform
(See Supplementary Table 4). In addi-
tion, the average deuteration (%) of
peptic peptides, as a function of pri-
mary amino acid sequence, of ligand-
bound and ligand-free Reptin at the
300 s time point calculated as de-
scribed [37] is summarized in Supple-
mentary Fig. 6.
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We have previously used HDX-MS methodology to define conforma-
tional changes induced upon mutation or ligand binding in proteins
including MDM2 [34], CHIP [35], EpCAM [36], and HSP70 [37]. We
first compared deuteration of wild-type Reptin with deuteration of
wild-type Reptin pre-incubated with 1mM ATP (Fig. 5 and Fig. 6A).
Peptic peptide segments that exhibited different deuterium exchange
rates at 300 s post-dilution with deuterated buffer as result of ATP
binding are highlighted in Fig. 5 (in red). The data reflect changes in
deuteron number as a function of the indicated peptic peptide frag-
ments. These peptides are located in all three Reptin functional do-
mains (Fig. 6A). In domain I (Fig. 1D and Fig. 6A), these segments
contain amino acids 63–109 that comprise the ATP-binding Walker A
motif (Supplementary Fig. 5; in white). This is consistent with ATP
occupying the nucleotide binding pocket of Reptin under these condi-
tions and serves as a positive control that the ATP-binding reaction was
active under the deuteration dilution conditions. In addition, domain I
containing amino acids 298–318, comprising the Walker B motif, also
exhibited attenuated deuteration (Supplementary Fig. 5; in blue). This
is also consistent with ligand interaction at this site leading to sup-
pression of deuteration. A third motif in domain I includes amino acids
340–351 (Fig. 6A, in red) that contains the Tyrosine-340 residue and
comprises the so-called “click” motif that is proposed to be an im-
portant stabilizing amino acid involved in inter-subunit stability
(Fig. 1C). These latter data are consistent with the model that ligand
binding results in hexamer formation and that this leads to lowered
solvent accessibility and/or structural fluctuations of the “click” motif
containing Tyrosine-340.
In domain II, also known as the insertion domain, deuterium sup-
pression induced by ATP includes segments containing amino acids
179–194 and 275–282 (Fig. 6A; and (Supplementary Fig. 5B; in white).
This domain is proposed to bind DNA and/or RNA. In domain III, which
is also part of the ATP pocket, we were unable to map peptides to al-
most half of the domain using pepsin digestion (see grey regions in
Fig. 6A). However, in the remaining part of domain III, deuteration
suppression was observed in segments comprising amino acids 355–371
and 412–433 (Fig. 6A and (Supplementary Fig. 5B; in blue)). Other
previously dissected functional domains of Reptin were also examined.
The Arg finger (R353) was not covered by peptic peptides. The sensor I
region (amino acids M326 - N329) exhibited no changes in deuteration
and the sensor II region (amino acids T397 - A402) was also not covered
by peptic peptides. An inter-subunit protein-protein interface (amino
acids 428–439) were suppressed by ligand (Supplementary Fig. 5C; in
white).
Next, we compared the deuteration of ReptinY340A and ReptinY340A
with 1mM ATP to determine the effects of reduced oligomerization
(Fig. 3B) using deuteration as an assay (Fig. 5 and Fig. 6B). The pre-
sence of ATP induced structural changes in ReptinY340A which are si-
milar to that observed with wild-type Reptin (Figs. 4 and 6; A vs B).
Peptic segments that exhibited slower deuterium exchange as a result of
ATP binding are highlighted in Fig. 6B (in red). In contrast to wild-type
Reptin, there are two segments located in domain I and domain II
(amino acids 114–123 and amino acids 275–282 respectively; high-
lighted in Fig. 6B, in blue colour) that exhibited increase in deuteration
after incubation with ATP. These data suggest that this region in Rep-
tinY340A becomes more exposed to solvent after ATP binding and is
suggestive of a lower rate of hexamer formation. Decreases in deu-
teration were detected similarly as in wild-type Reptin in domain I
(segments 51–74 and 90–109) and domain III (segments 355–399 and
411–433).
Interestingly no changes of deuteration were detected in the Y340
peptide docking motif (Y340) in the ReptinY340A mutant but decreases
in deuteration was observed after the amino acid at position 355
(Fig. 5B and Fig. 6B). The neutral effects of ligand on the deuteration of
the Y340 peptide docking motif in ReptinY340A protein are consistent
with the model that loss of Tyrosine 340 precludes full “hexameriza-
tion” of the Reptin monomer.
Finally, as a control, we compared the deuteration of the Reptin-
Pontin complex and Reptin-Pontin complex with 1mM ATP (Fig. 5 and
Fig. 6C). Deuterium incorporation was reduced by ATP in two segments
of Reptin (Fig. 5). Peptides protected by ATP in the HDX-MS analysis
are highlighted on the structure of Reptin (Fig. 5). The first protected
segment with reduced deuteration includes amino acids 63–109 and
comprise the Walker A motif. This result is similar to that for wt Reptin
and is in accordance with ATP binding to the ATP pocket. The second
segment which showed reduced deuterium uptake (amino acids
355–433) belongs to domain III. As seen for ReptinY340A, the decrease of
deuteration caused by ATP was observed in the region following the
Y340 peptide docking motif. This suggests that the Y340 peptide
docking motif does not participate in the formation of the Reptin-Pontin
complex. By contrast, the Reptin-Pontin complex incubated with ligand,
Fig. 6. Localization of deuteration flux superimposed on the three-dimensional
structure of Reptin. (A and B; wild-type Reptin and the Y340A mutant form of
Reptin, respectively). The crystal structures of the Reptin containing one or two
subunits were extracted from the hexamer crystallized as PDB code 3UK6 and
the image contains regions highlighted by colors according to changes in
deuteration. Red regions indicate areas of decreased deuterium exchange larger
than 5% in the presence of ATP and blue regions indicate areas of increased
exchange larger than 5%, whilst green indicates no significant change and grey
indicates regions with no peptic peptides detected by HDX-MS. (A) The
Tyrosine finger (Y340) is indicated by an arrow. (B) The Tyrosine finger (Y340)
mutated to alanine is indicted by an arrow. (C). Crystal structures of the
monomeric Reptin and the Reptin-Pontin complex (PDB code 2XSZ) with re-
gions highlighted by colors according to changes in deuteration. Red regions
indicate areas of decreased exchange larger than 5% in the presence of ATP,
while green indicates no significant change and grey indicates regions with no
peptides detected by HDX-MS. The Tyrosine finger (Y340) is indicated by
arrow. The Pontin is colored light pink. The image was created in PyMOL [23].
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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no changes of deuteration were detected in domain II (Fig. 5).
3.5. Bimodal distribution in MS spectra
A summary of Reptin oligomer dynamics is reviewed in Fig. 4. The
oligomer dynamics in the presence of ligand can also change as a
function of the absolute concentration of Reptin. The concentration of
Reptin decreases upon dilution with D2O. We might predict, therefore,
that the HDX methodology can give rise to transient, distinct popula-
tions of Reptin as the monomer begins to assemble in the presence of
ligand. When analyzing the HDX-MS data, we observed bimodal dis-
tributions of several wild-type Reptin peptides in samples with ATP that
were not present in the ReptinY340A mutant. An illustration of bimodal
spectra is in Fig. 7. These peptides were located in the ATP pocket,
specifically around the walker A motif in domain I and around the Y340
peptide docking motif in domain III. Notably, the bimodal isotopic
envelops occurred only in peptides that exhibited conformational
changes upon ligand binding. The Reptin-Pontin complex also exhibited
bimodal distributions in the presence of ligand (Fig. 7). A bimodal
distribution could result from EX1 HDX kinetics in which the rate of
conformational change of the corresponding peptide is slower than the
HDX rate. The other possible explanation of bimodal distribution is the
presence of two different protein isoforms, and here it may arise from
the distribution of monomeric and oligomeric forms of Reptin. This is
supported by the fact that no bimodal distribution was detected in
ReptinY340A (data not shown) and further, that the change in the pattern
of deuteration appeared after the binding of ATP, which is known to
initiate Reptin oligomerization. Moreover, the location of peptides with
bimodal isotopic patterns also supports this interpretation, because the
ATP pocket is located in between two Reptin molecules in the Reptin
oligomer.
A complication of these data interpretation is that HDX-MS provides
only an average of the deuteration of a given peptide length and does
not necessarily provide fine-resolution mapping of a protein-protein
interface. For example, our prior study discussed, using AGR2 as a
model protein [36], that higher levels of deuterium suppression in a
small stretch of the polypeptide are compensated by elevated deutera-
tion in adjacent regions (due to conformational changes) so that the net
deuteration in larger peptides is different than the smaller peptide.
Thus, it is possible that this methodological limitation impacts on the
number of deuterons measured in a given peptic fragment (as in Fig. 5).
This limitation did not preclude the identification of regions whose
deuteration can be altered through mutation of Y340. In addition, oli-
gomeric proteins present a different problem which might relate to
bimodal distributions (Fig. 7). When Reptin assembles into an oligomer,
we do not know which monomer a given peptide originates from within
the hexamer. A solution to this might be isotopic labelling of a Reptin
pool so that upon mixing with normal isotopic Reptin, inter-subunit
interactions might be revealed in the mixed olgiomer.
3.6. Use of molecular dynamic (MD) simulations to measure Reptin
oligomerization dynamics
We carried out MD simulations to probe the above interpretations
(Fig. 4). It is evident that the Y340 sidechain remains embedded in the
adjacent subunit (Fig. 8A and C; Fig. 9C), stabilized by a hydrogen bond
with the sidechain of Thr333 and also by packing interactions with the
sidechains of Arg330 and Arg336 (all 3 residues belonging to the
neighboring chain); this is seen in the MD simulations of both wild-type
Reptin and in the D299N Reptin mutant (Supplementary Movie 1 and
Supplementary Movie 3). In contrast, in the Y340A Reptin mutant
(Fig. 8B; Fig. 9D), the sidechain Ala has no polar groups to form the
hydrogen bond, resulting in the loop containing Y340 moving away by
about 5 Å. The buried surface areas between the monomers (Fig. 9A in
the wild-type Reptin and the D299N mutant) remain similar in their
liganded states while the apo form of wild-type Reptin samples two
states – one that resembles the packed liganded states and the other
more open state which is similar to that sampled by the Y340A mutant
Fig. 7. Bimodal isotopic envelopes. Bimodal isotopic patterns were detected in several peptides. Shown are mass spectra of the peptide containing AAs 355–371.
Spectra are shown for all three samples (Reptin wt, Reptin Y340A, and Reptin-Pontin) and for these conditions: undeuterated, sample without ligand and sample with
1mM ATP. Clear bimodal patterns were detected in Reptin wt after incubation with ATP and in Reptin-Pontin regardless of ATP. On the other hand, Reptin Y340A
did not show clear bimodal distributions in any peptides. This is consistent with the data showing that mutation of tyrosine 340 alters Reptin oligomerization. All
these findings support our interpretation that bimodal patterns are caused by presence of monomeric/oligomeric state of Reptin rather than EX1 kinetics.
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which loses key interactions that stabilize the hexamer (Supplementary
Movie 2).
As a control, D299N Reptin is very stable because the interface near
the sidechain of D299 is anionic with several negatively charged groups
(arising from the sidechains of E107, E300 and the phosphate of the
ligand in the same chain as D299 and the sidechains of D349 and D352
from the neighboring chain, all within 8–9 Å of D299). The loss of the
anionic sidechain of D299 in the D299N mutation results in the at-
tenuation of the repulsions; in addition, the N299 sidechain is further
stabilized by a water mediated interaction with D349 from the neigh-
boring chain (Fig. 9A and B). This is also apparent in snapshots from the
MD simulations (Supplementary Movies 1-3).
4. Discussion
Reptin forms a model AAA+ superfamily member with which to
develop new approaches for dissecting stages in ligand-mediated oli-
gomer assembly. In the past thirty years, the dominant tools used by
proteomics approaches to discovery protein-interactions have been; (i)
the yeast two hybrid; and (ii) immuno-precipitations. It is also now
known that the vast diversity of protein interaction dynamics in higher
eukaryotes appear to be regulated by small linear peptide motifs (27).
Linear motifs in peptides can form ‘hotspots’ that play dominant role in
driving protein-protein interactions and might form key target for
drugging protein-protein interactions [38,39]. A classic example is the
oncogenic protein MDM2; which can form a high affinity interaction
with a small synthetic peptide derived from the p53 tumor suppressor
[40] and which has been the basis for drug that target the linear peptide
binding pocket of MDM2 [41].
Thus, a methodological approach for identifying hotspot protein-
peptide interaction sites is using either synthetic peptides or phage-
combinatorial peptide libraries [42]. Overlapping synthetic peptide
scan assays using peptides derived from the open reading frame of
Reptin were used to determine whether self-peptides that interact
stably with Reptin itself, could be identified. This approach revealed a
relatively high affinity, self-assembly interface that stabilizes the Reptin
hexamer (dominating by Tyrosine 340). Only one self-binding motif for
Reptin was identified (peptide 28; Fig. 1). For example, peptides de-
rived from the an inter-subunit interface region of Reptin (amino acids
~420–440) did not bind Reptin in this assay. This highlights a limita-
tion of this assay; it can not necessarily identify any protein-protein
contact dominated by linear peptide motifs. However, peptides that do
bind in such assays form compelling models to dissect out mechanisms
of linear-peptide-protein docking.
The single dominating self-peptide maps to the Reptin hexameric
“rim” (Fig. 1B), with a Tyrosine residue (Y340) forming an inter-sub-
unit stabilizing anchor (Figs. 8-9). The subunit that interacts with the
tyrosine-containing donor peptide forms a small acceptor pocket
(Fig. 9). Size exclusion chromatography affirmed that ligand-induced
oligomerization of mutant Y340A Reptin is attenuated (Fig. 3B).
There is presumably combinatorial diversity in this Y340 donor-
acceptor docking reaction. Although the Y340 side chain forms an
important stabilizing contact in a Reptin-Reptin homo-oligomer, it
might not be as important in a Reptin-Pontin hetero-oligomer (Fig. 6C).
Further, whether the ‘rim’ of a Pontin-Pontin oligomer also forms a
hotspot stabilizing contact in this vicinity requires additional functional
studies. An unexpected result from our studies, that complements the
identification of Y340 as an important driver of Reptin assembly, was
the impact of the D299N mutation on oligomerization.
The D299N version of Reptin, lacks ATPase activity and has clas-
sically been used as a ‘loss-of-function’ mutant [33]. However, this
mutant has an elevated ATP-binding activity [13]. In our current study,
we can interpret the data that the D299N mutant produces a sponta-
neous oligomer in the absence of ligand (Fig. 3C). Molecular Dynamics
simulations show that the ability of Y340A Reptin to form stable oli-
gomers is attenuated because of the loss of the hydrogen bond and
packing afforded by the sidechain of Y340 against neighboring mono-
mers (Fig. 8-9). However, in the D299N Reptin mutant, destabilizing,
negatively charged inter-subunit contacts are removed, resulting in the
stabilization of the hexamer in the absence of ligand (Fig. 9; Movie 3).
This gives a more complex interpretation to cell based studies using the
D299N mutant of Reptin. Its inhibitory effect on growth could be be-
cause of (i) defects in ATPase function; (ii) elevated ATP-binding; or
(iii) elevated spontaneous oligomerization (this study). In the latter
case, since Reptin's specific activity in protein-binding assays is regu-
lated by its monomer and oligomerization status (Fig. 4), then in cells
the ReptinD299N mutant could be inhibitory for cell growth because of
alterations in its interactome.
In conclusion, our pipeline approach for dissecting ‘hotspot’ inter-
actions in one AAA+ family member provides a blueprint to produce
functional mutants based on self-assembly peptide motif scans. Our
data highlight a novel linear motif in Reptin that forms an inter-subunit
Fig. 8. MD simulation guided modeling of Reptin oligomerization. A snapshot
is depicted from the MD simulations of (A). wild-type Reptin, (B). the Y340A
mutant form of Reptin and (C). the D299N mutant form of Reptin, as hexamers.
Although the Y340A mutant form of reptin may not exist as a hexamer, the
structural changes during the MD simulations, which were initiated from the
hexameric wild type structure, show that the mutation results in loss of key
stabilizing interactions, which would likely result in the dissociation of the
hexamer (this dissociation would require very long simulation times). Each
monomer unit is colored differently with the Tyrosine finger (Y340) highlighted
in blue colour. The data can be visualized in Supplementary movies 1-3. (For
interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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bridge that appears to play a role in hexamer stability. Such mutant
forms of Reptin (Y340A) can be used in the future in cell systems to
dissect the interactome of Reptin as a function of monomer to oligomer
states (Fig. 4). There is a precedent for the ability of small peptides to
interact with dynamic forms of Reptin; a recent biochemical study
evaluated the impact of histones on Reptin and Pontin transcriptional
regulation [43]. The authors identified histone-3 peptides that not only
regulate the monomer-oligomer transition of Reptin and Pontin but
showed that endogenous proteins immuno precipitated by monomeric
Reptin are distinct from proteins that interact with oligomers. These
data highlight the functional importance of Reptin oligomerization in
controlling its interactome (as in Fig. 4 and [43]).
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jprot.2019.02.012.
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